<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7407150</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics12070688</article-id><article-id pub-id-type="publisher-id">pharmaceutics-12-00688</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Surface Active Agents and Their Health-Promoting Properties: Molecules of Multifunctional Significance</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2052-8470</contrib-id><name><surname>Anestopoulos</surname><given-names>Ioannis</given-names></name><xref ref-type="aff" rid="af1-pharmaceutics-12-00688">1</xref></contrib><contrib contrib-type="author"><name><surname>Kiousi</surname><given-names>Despoina Eugenia</given-names></name><xref ref-type="aff" rid="af1-pharmaceutics-12-00688">1</xref></contrib><contrib contrib-type="author"><name><surname>Klavaris</surname><given-names>Ariel</given-names></name><xref ref-type="aff" rid="af2-pharmaceutics-12-00688">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9991-3173</contrib-id><name><surname>Galanis</surname><given-names>Alex</given-names></name><xref ref-type="aff" rid="af1-pharmaceutics-12-00688">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4837-7109</contrib-id><name><surname>Salek</surname><given-names>Karina</given-names></name><xref ref-type="aff" rid="af3-pharmaceutics-12-00688">3</xref></contrib><contrib contrib-type="author"><name><surname>Euston</surname><given-names>Stephen R.</given-names></name><xref ref-type="aff" rid="af3-pharmaceutics-12-00688">3</xref></contrib><contrib contrib-type="author"><name><surname>Pappa</surname><given-names>Aglaia</given-names></name><xref ref-type="aff" rid="af1-pharmaceutics-12-00688">1</xref><xref rid="c1-pharmaceutics-12-00688" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1450-3552</contrib-id><name><surname>Panayiotidis</surname><given-names>Mihalis I.</given-names></name><xref ref-type="aff" rid="af4-pharmaceutics-12-00688">4</xref><xref ref-type="aff" rid="af5-pharmaceutics-12-00688">5</xref><xref ref-type="aff" rid="af6-pharmaceutics-12-00688">6</xref><xref rid="c1-pharmaceutics-12-00688" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-pharmaceutics-12-00688"><label>1</label>Department of Molecular Biology &#x00026; Genetics, Democritus University of Thrace, 68100 Alexandroupolis, Greece; <email>ianestop@mbg.duth.gr</email> (I.A.); <email>dkiousi@mbg.duth.com</email> (D.E.K.); <email>agalanis@mbg.duth.gr</email> (A.G.)</aff><aff id="af2-pharmaceutics-12-00688"><label>2</label>Department of Biological Sciences, University of Cyprus, 2109 Nicosia, Cyprus; <email>klavaris.ariel@ucy.ac.cy</email></aff><aff id="af3-pharmaceutics-12-00688"><label>3</label>Institute of Mechanical, Process &#x00026; Energy Engineering, Heriot Watt University, Edinburgh EH14 4AS, UK; <email>k.salek@hw.ac.uk</email> (K.S.); <email>s.r.euston@hw.ac.uk</email> (S.R.E.)</aff><aff id="af4-pharmaceutics-12-00688"><label>4</label>Department of Applied Sciences, Northumbria University, Newcastle Upon Tyne NE1 8ST, UK</aff><aff id="af5-pharmaceutics-12-00688"><label>5</label>Department of Electron Microscopy &#x00026; Molecular Pathology, The Cyprus Institute of Neurology &#x00026; Genetics, 2371 Nicosia, Cyprus</aff><aff id="af6-pharmaceutics-12-00688"><label>6</label>The Cyprus School of Molecular Medicine, P.O. Box 23462, 1683 Nicosia, Cyprus</aff><author-notes><corresp id="c1-pharmaceutics-12-00688"><label>*</label>Correspondence: <email>apappa@mbg.duth.gr</email> (A.P.); <email>mihalisp@cing.ac.cy</email> (M.I.P.)</corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>7</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2020</year></pub-date><volume>12</volume><issue>7</issue><elocation-id>688</elocation-id><history><date date-type="received"><day>30</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>17</day><month>7</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Surface active agents (SAAs) are molecules with the capacity to adsorb to solid surfaces and/or fluid interfaces, a property that allows them to act as multifunctional ingredients (e.g., wetting and dispersion agents, emulsifiers, foaming and anti-foaming agents, lubricants, etc.) in a widerange of the consumer products of various industrial sectors (e.g., pharmaceuticals, cosmetics, personal care, detergents, food, etc.). Given their widespread utilization, there is a continuously growing interest to explore their role in consumer products (relevant to promoting human health) and how such information can be utilized in order to synthesize better chemical derivatives. In this review article, weaimed to provide updated information on synthetic and biological (biosurfactants) SAAs and their health-promoting properties (e.g., anti-microbial, anti-oxidant, anti-viral, anti-inflammatory, anti-cancer and anti-aging) in an attempt to better define some of the underlying mechanism(s) by which they exert such properties.</p></abstract><kwd-group><kwd>surface active agents</kwd><kwd>surfactants</kwd><kwd>health promotion</kwd><kwd>anti-microbial</kwd><kwd>anti-oxidant</kwd><kwd>anti-viral</kwd><kwd>anti-inflammatory</kwd><kwd>anti-cancer</kwd><kwd>anti-aging</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-12-00688"><title>1. Introduction</title><p>Surfactants are amphiphilic molecules characterized by a hydrophilic (ionic or non-ionic) head group and a hydrophobic tail. Biosurfactants are simply surfactants produced by living organisms. Surfactants are classified based on their head group polarity into non-ionic (uncharged), anionic (negatively charged), cationic (positively charged) and zwitterionic (capable of possessing both positive and negative charge). This complexity of head group leads to a range of adsorption and solution behaviors that facilitates their use across a broad range of industrial sectors. The classic application of surfactants is as surface-active agents (SAAs) which exploits their ability to adsorb to solid surfaces and fluid interfaces by partitioning the hydrophilic part in the aqueous phase and the hydrophobic part in/or at the second phase. This allows SAAs to act as wetting and dispersion agents, emulsifiers, foaming and anti-foaming agents and lubricants in a wide range of consumer and other industrial products such as detergents and soaps, foods, pharmaceuticals, cosmetics and personal care products, herbicides, insecticides and sanitizers [<xref rid="B1-pharmaceutics-12-00688" ref-type="bibr">1</xref>]. It has also been realized that their rich and diverse chemistry imparts a range of bioactive properties including anti-microbial, anti-oxidant, anti-viral, anti-inflammatory, anti-cancer and anti-aging. This is important for surfactant manufacturers as it extends the market for SAAs and allows them to be branded as multi-functional ingredients. Similarly, consumer product manufacturers can make additional bioactive claims against products containing surfactants, which enhance the appeal and benefits to consumers and increases sales and market share. As importantly, multi-functional ingredients can lead to potential cost savings for the manufacturers of consumer formulations. For example, SAAs are used as emulsifiers in many foods, as well as cosmetic and pharmaceutical formulations. Having both the surface active as well as the anti-microbial properties of SAAs being exploited, this would remove (or reduce) the need for additional preservatives to be added to the final consumer product(s), with a concomitant decrease in formulation costs.</p><p>The origin of these bioactive properties most likely arises from the ability of SAAs to interact with proteins and lipid membranes. The propensity for SAAs to bind either to specific binding sites or non-specifically to proteins (including enzymes) is wellknown [<xref rid="B2-pharmaceutics-12-00688" ref-type="bibr">2</xref>], and they have been exploited as protein denaturants, for many years, in sodium dodecyl sulfate&#x02013;polyacrylamide gel electrophoresis (SDS-PAGE) assays. Thus, there is certainly the possibility that SAAs can and will disrupt critical microbial and cellular metabolic processes in addition to interacting with membranes [<xref rid="B3-pharmaceutics-12-00688" ref-type="bibr">3</xref>]. The amphiphilic structure of SAAs allows them to penetrate the phospholipid leaflet of a membrane, modifying the membrane structure and fluidity, thus increasing the permeability and disrupting cellular metabolic processes.</p><p>Biosurfactants are receiving increasing attention mainly due to the perception that they are natural ingredients, a selling point appealing to both manufacturers of products and consumers. It has also become apparent that biosurfactants have other appealing properties that differentiate them from their synthetic counterparts, such as higher biodegradability and lower toxicity and ecotoxicity, thus further enhancing their green, natural credentials [<xref rid="B4-pharmaceutics-12-00688" ref-type="bibr">4</xref>].</p><p>In this review, the veracity of the scientific evidence for the bioactive properties of a range of biological and synthetic surfactants is considered, with an emphasis on the mechanism(s) of action and their potential use as the components of industrial and consumer product applications. The discussion on biosurfactants will be confined to those that are produced by microorganisms (bacteria, fungi, yeast) and in particular the glycolipids (rhamnolipids, sophorolipids and mannosityl erithritol lipids (MELs)).</p></sec><sec id="sec2-pharmaceutics-12-00688"><title>2. Structure of Synthetic and BioSurfactants</title><p>Synthetic and biosurfactants are amphiphiles, which have both hydrophilic and lipophilic regions that allow them to adsorb to interfaces, including biological membranes. Their structures, however, can differ markedly, particularly in terms of their hydrophilic regions. Synthetic surfactants often contain an alkyl chain attached to a polar or compact charged hydrophilic head group [<xref rid="B5-pharmaceutics-12-00688" ref-type="bibr">5</xref>]. Glycolipid biosurfactants, on the other hand, have one or two sugar rings as amore bulky polar head group (typically rhamnose, sophorose, galactose, mannosylerithritol, trehalose) [<xref rid="B4-pharmaceutics-12-00688" ref-type="bibr">4</xref>] which can differentiate their properties from their synthetic counterparts. <xref ref-type="fig" rid="pharmaceutics-12-00688-f001">Figure 1</xref> gives a comparison of typical non-ionic, anionic, cationic, zwitterionic and glycolipid surfactants.</p></sec><sec id="sec3-pharmaceutics-12-00688"><title>3. Anti-Microbial Properties</title><p>The discovery and production of anti-microbial agents at the industrial scale has significantly contributed to the world-wide increase in life-expectancy and to the improvement of life quality. Antibacterial and antifungal factors can eliminate the viability and growth of microbial populations by: (i) disrupting their extracellular membranes and/or their cell wall (e.g., penicillin), (ii) inhibiting gene expression (e.g., aminoglucosides), (iii) inflicting DNA damages (e.g., metronidazole) or (iv) manipulating important metabolic pathways (e.g., sulfonamides). However, in recent decades, the severity of antibiotic resistance has dramatically increased, while the discovery of novel safe antibiotics has plummeted. A meta-analysis conducted in 2014 has shown that antibiotic abuse in hospital and community settings is the main factor leading to resistance [<xref rid="B6-pharmaceutics-12-00688" ref-type="bibr">6</xref>]. Today, the most resistant bacteria associated with severe hospital-acquired infections (HAI) are <italic>Enterococcus faecalis, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa</italic> and <italic>Enterobacter</italic> sp. which can often result in fatal outcomes. In addition, some of the aforementioned bacteria as well as fungi (e.g., <italic>Candida albicans</italic>) can organize into compact structures (i.e., biofilms) that attach to abiotic or biotic surfaces. Biofilms are comprised of microorganisms with an altered metabolic activity that are enclosed in a calyx of exopolysaccharides, DNA and proteins. Neither the host&#x02019;s immune cells nor antibiotics can penetrate these structures, thus leading to chronic infections [<xref rid="B7-pharmaceutics-12-00688" ref-type="bibr">7</xref>]. Biofilms can cause serious implications in the recipients of prosthetics and patients with chronic wounds, as the bacteria can be dislodged from the structure, travel through the bloodstream and possibly establish bacteremia and systemic infections. Today, antibiotic use, infection control and the development of novel disinfectants and vaccines are the main challenges for the scientific community. To these ends, compounds with surface-active properties are considered promising antibiotic/disinfectant agents, as well as antibiotic-delivery vehicles due to their physicochemical properties. Most of these molecules disrupt the outer and inner membranes of pathogens by exploiting their charge and hydrophobicity. The advantages of using SAAs as anti-microbials include their broad-spectrum bactericidal action and the lack of resistance mechanisms from the pathogens. Nonetheless, a major setback for the medical administration of these agents is their potential hemolytic activity, due to the lack of specificity of action. </p><p>The largest category of synthetic surfactants with anti-microbial actions is cationic surfactants, which exhibit a broad spectrum of biostatic and biocidal activities against planktonic pathogens. They exert their actions by electrostatically binding onto the negatively charged molecules of bacterial surface and disrupting the membrane continuity as well as the metabolic processes that take place on the bacterial inner membrane. However, these surfactants are mainly effective against Gram-positive bacteria and fungi, while most Gram-negative bacteria are resistant. Some examples of such compounds are: (i) a hexameric surfactant with amide moieties shown to be effective against <italic>E. coli</italic> [<xref rid="B8-pharmaceutics-12-00688" ref-type="bibr">8</xref>], (ii) an amide gemini cationic surfactant 12 (AGS12) with incorporated silver nanoparticles shown to limit the growth of <italic>Bacillus subtilis, Staphylococcus aureus, E. coli, P. aeruginosa, C. albicans</italic> and <italic>Aspergillus niger</italic> [<xref rid="B9-pharmaceutics-12-00688" ref-type="bibr">9</xref>], (iii) V-16 and VBP-16 (two dicationic surfactants containing viologen, vinylbipyridinium moieties and hexadecyl chains) exhibiting inhibitory properties against <italic>S. aureus</italic> 209P, <italic>B. cereus</italic> 8052 and <italic>C. albicans</italic> 855-653 [<xref rid="B10-pharmaceutics-12-00688" ref-type="bibr">10</xref>] and (iv) lysine-derived mono-catenary or gemini surfactants with anti-<italic>S. aureus, Staphylococcus epidermidis</italic> and <italic>B. subtilis</italic> activity [<xref rid="B11-pharmaceutics-12-00688" ref-type="bibr">11</xref>]. Other surfactants and surfactant emulsions rely on their hydrophobic moieties for their anti-microbial activity. These compounds are usually more efficient in combating Gram-negative bacteria than cationic surfactants. For example, benzalkonium chloride (BAC) analogues with hydrophobic chains of varying length exhibited anti-microbial activity against (i) Gram-positive bacteria <italic>S. aureus</italic> and <italic>E. faecalis</italic>, (ii) Gram-negative bacteria <italic>E. coli</italic> and <italic>P. aeruginosa</italic> and (iii) fungus <italic>C. albicans</italic> [<xref rid="B12-pharmaceutics-12-00688" ref-type="bibr">12</xref>] while other nonionic, micelle-forming silicon polyether surfactants (with short hydrophilic chains that form micelles) were shown to be effective against <italic>E. coli</italic> B21 [<xref rid="B13-pharmaceutics-12-00688" ref-type="bibr">13</xref>]. Similarly, <italic>N<sup>a</sup></italic>-lauroyl-arginine methyl ester-derived cationic double-chain surfactants (with arginine heads) rely on their lipophilic moietiesfor their anti-microbial activity. Indeed, the most lipophilic analogue, LANHC<sub>X</sub>, exhibited profound inhibitory activity against <italic>Micrococcus luteus</italic> ATCC 9341, <italic>S. aureus</italic> ATCC 29213 and <italic>S. epidermidis</italic> ATCC 12228 and a weaker one against <italic>P. aeruginosa</italic> ATCC 27853, <italic>C. albicans</italic> ATCC 10321 and <italic>E. coli</italic> ATCC 25922 [<xref rid="B14-pharmaceutics-12-00688" ref-type="bibr">14</xref>]. Lastly, gemini lipopeptide surfactants (with aliphatic chains and Lys residue(s) at the Y- and/or Z-position) exhibited anti-microbial activity against <italic>E. coli</italic> (K12 and W3110), <italic>Salmonella typhimurium</italic> LT2, <italic>B. subtilis</italic> 168 and <italic>S. aureus</italic> FDA 209P. Importantly, these surfactants can, specifically, target the bacterial membranes and do not cause hemolysis to rabbit red blood cells [<xref rid="B15-pharmaceutics-12-00688" ref-type="bibr">15</xref>].</p><p>With glycolipid biosurfactants, there is evidence that the mechanism of antimicrobial activity depends on the glycolipid type, evidenced by the rhamnolipids inhibiting bacterial growth in the exponential phase whilst sophorolipids inhibit growth between the exponential and stationary phases [<xref rid="B16-pharmaceutics-12-00688" ref-type="bibr">16</xref>]. Diaz de Renzo et al. [<xref rid="B16-pharmaceutics-12-00688" ref-type="bibr">16</xref>] suggest that this may be due to the way the two biosurfactants interact with the cell membrane, with rhamnolipids having a greater ability to insert their acyl chains into thus disrupting the membrane [<xref rid="B17-pharmaceutics-12-00688" ref-type="bibr">17</xref>], whilst the mechanism of action of sophorolipids is closer to that of antibiotic drugs. There is also evidence that rhamnolipids and sophorolipids have differing activity against Gram-positive and Gram-negative bacteria, with any activity being strongly pH dependent. <italic>Salmonella enteric</italic> and <italic>Escherichia coli</italic> (both Gram-negative) are resistant to rhamnolipids at all pH [<xref rid="B18-pharmaceutics-12-00688" ref-type="bibr">18</xref>]. In a separate study, the Gram-negative opportunistic pathogen Pseudomonas aeruginosa PAO1 was also shown to be unaffected by rhamnolipid [<xref rid="B16-pharmaceutics-12-00688" ref-type="bibr">16</xref>]. On the other hand, the Gram-positive <italic>Listeria monocytogenes</italic>, <italic>Bacillu cereus</italic> and <italic>Staphylococcus aureus</italic> all show susceptibility to rhamnolipid, with <italic>B. cereus</italic> the most sensitive and <italic>S. aureus</italic> more sensitive at a low pH [<xref rid="B16-pharmaceutics-12-00688" ref-type="bibr">16</xref>,<xref rid="B18-pharmaceutics-12-00688" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-12-00688" ref-type="bibr">19</xref>]. Oral pathogens of the genus Streptococcus (<italic>S. mutans, S. oralis, S. sanguinis</italic>), <italic>Actinomyces naeslundii</italic> and <italic>Neisseria mucosa</italic> are also sensitive to rhamnolipids in both the planktonic and biofilm state [<xref rid="B20-pharmaceutics-12-00688" ref-type="bibr">20</xref>].</p><p>Sophorolipids have been found to have a bactericidal effect towards Gram-positive and Gram-negative strains [<xref rid="B21-pharmaceutics-12-00688" ref-type="bibr">21</xref>]. Diaz De Rienzo et al. [<xref rid="B22-pharmaceutics-12-00688" ref-type="bibr">22</xref>] presented an inhibitory effect of sophorolipids (SLs) on the growth of Gram-positive <italic>Bacillus subtilis</italic> BBK006 and Gram-negative <italic>Cupriavidus necator</italic> ATCC 17699, as well as the biofilm-disruption properties on the biofilms of single and mixed cultures of <italic>B. subtilis</italic> BBK006 and <italic>Staphylococcus aureus</italic> ATCC 9144. In the latest study by Ceresa et al. [<xref rid="B23-pharmaceutics-12-00688" ref-type="bibr">23</xref>], the antimicrobial properties of SL in medical-grade silicone discs were evaluated against <italic>Staphylococcus aureus</italic> ATCC 6538, <italic>Pseudomonas aeruginosa</italic> ATCC 10145 and <italic>Candida albicans</italic> IHEM 2894. SLs were found to significantly decrease a biofilm formation by both Gram-positive strains and significantly reduce the attachment of the yeast <italic>C. albicans</italic> on the silicone-coated discs. Sophorolipids adsorbed onto gold surfaces showed a compelling reduction in the viability of some significant Gram-positive (<italic>Enterococcus faecalis</italic>, <italic>Staphylococcus epidermidis</italic>, <italic>Streptococcus pyogenes</italic>) and Gram-negative (<italic>Escherichia coli</italic>, <italic>Pseudomonas aeruginosa</italic> and <italic>Salmonella typhymurium</italic>) pathogens, as reported by Valotteau et al. [<xref rid="B24-pharmaceutics-12-00688" ref-type="bibr">24</xref>]. These reports feed into a potential application of SLs in antiadhesion therapy, which is proposed as an alternative to the use of antibiotics and antifungal drugs for treating biofilm-associated infections [<xref rid="B25-pharmaceutics-12-00688" ref-type="bibr">25</xref>]. According to the authors, SLs exhibited strong and versatile antiadhesion properties against two well known nosocomial pathogens, <italic>Staphylococcus aureus</italic> and <italic>Escherichia coli</italic>, making these surfactants promising candidates for the design and production of anti-infective biomaterials.</p><p>The antibacterial activity of MELs against Gram-positive sporing bacterium <italic>Bacillus cereus</italic> was reported by Shu et al. [<xref rid="B26-pharmaceutics-12-00688" ref-type="bibr">26</xref>]. <italic>B. cereus</italic>, which is a food-borne pathogen, is able to produce spores resistant to high temperatures, UV and chemicals; therefore, the authors targeted both the vegetative cells as well as the spores for treatment with MELs. Their findings show that MELs had a significant effect on the spores&#x02019; germination and also successfully reduced the viability of vegetative cells. Their findings show a high potential of MELs as a natural preservative in the food industry. One of the recent studies by Ceresa et al. [<xref rid="B27-pharmaceutics-12-00688" ref-type="bibr">27</xref>] presented an excellent activity of MELs against a wellknown pathogen <italic>Staphylococcus aureus</italic> ATCC 6538. The surfactants were efficient at disrupting the <italic>S. aureus</italic> biomass, reducing the metabolic activity of the biofilm and also showed bacteriostatic and bactericidal properties against the pathogen. The biofilm experiments were performed on silicone-coated discs. </p><p>Janek et al. [<xref rid="B28-pharmaceutics-12-00688" ref-type="bibr">28</xref>] examined the antimicrobial and antiadhesive properties of trehalose lipids (TLs) against a number of pathogens. The authors concluded that TLs indicated the highest antimicrobial activity against <italic>Vibrio harveyi</italic> and <italic>Proteus vulgaris</italic>, as well as inhibited the growth of the yeast <italic>Candida albicans</italic> by 30%. Moreover, the authors observed a strong antiadhesive property, especially against <italic>C. albicans</italic> and <italic>Escherichia coli</italic> on polystyrene surfaces and silicone urethral catheters. According to the authors, their findings show that TLs could be successfully used as surface-coating agents.</p><p>Surfactants could be effective anti-biofilm agents due to their physicochemical properties that allow them to penetrate and disrupt hydrophobic structures. For instance, (i) sodium hypochlorite (SHY) effectively disrupted <italic>Listeria monocytogenes</italic> biofilms and killed its planktonic cells [<xref rid="B29-pharmaceutics-12-00688" ref-type="bibr">29</xref>], (ii) cetylpyridinium chloride exerted bactericidal effects against planktonic cells and the biofilms of clinically relevant cariogenic <italic>Streptococcus</italic> species [<xref rid="B30-pharmaceutics-12-00688" ref-type="bibr">30</xref>], whereas (iii) cetylpyridium chloride nano-emulsion limited the attachment of other cariogenic strains like <italic>Streptococcus mutans</italic>, <italic>Lactobacillus casei</italic>, <italic>Actinomyces viscosus</italic> and <italic>C. albicans</italic> [<xref rid="B31-pharmaceutics-12-00688" ref-type="bibr">31</xref>]. In the same manner, novel synthesized ionic liquid nanoparticles [(IL)-incorporated 1-butyl-3-methylimidazolium hexafluorophosphate-incorporated, chitosan-modified, submicron-sized poly (DL-lactide-co-glycolide; PLGA)] together with surfactants Tween-20 or Poloxamer-188, managed to eliminate <italic>S. epidermidis</italic> biofilms. The underlined mechanism involved the degradation of the biofilms&#x02019; polysaccharides (EPS) content, thereby exposing the underlying bacteria to the action of the surfactants, consequently inducing the destruction of the cell wall and the cytoplasmic membrane as well [<xref rid="B32-pharmaceutics-12-00688" ref-type="bibr">32</xref>]. Additionally, the synthetic surfactants could act in synergy with other surfactants and/or antibiotics in order to maximize their beneficial outcomes. To this end, a 8:1 mixture of arginine-based surfactants [N&#x003b1;N&#x003c9;-bis (N&#x003b1;caproylarginine)] &#x003b1;, &#x003c9;-propyldiamide [C<sub>3</sub>(CA)<sub>2</sub>]] together with an anionic lipopeptide (lichenysin), synergistically limited the growth of entero-pathogens <italic>Yersinia enterocolotica</italic>, <italic>E. coli</italic> O157:H7, <italic>B. subtilis</italic> and <italic>C. albicans</italic>, due to their ability to interact with bacterial phospholipids and to activate signaling cascades resulting in a viable, but not culturable, state [<xref rid="B33-pharmaceutics-12-00688" ref-type="bibr">33</xref>]. Moreover, the gemini quarter ammonium bromides [10 (TMPAL-10 Br) and 12 (TMBEAL-12 Br)] were shown to act synergistically with azoles (itraconazole and fluconazole) or polyenes (nystatin and amphotericin), two classes of antifungal agents, resulting in a two-fold increase in the surfactant&#x02019;s inhibitory activity against the pathogens <italic>C. albicans</italic> and <italic>S. cerevisiae</italic>. In addition, both TMPAL-10 Br and TMBEAL-12 Br exerted an antiadhesive action, while only TMEAL-12 Br could dislodge pre-formed <italic>C. albicans</italic> biofilms in a dose-dependent manner. Finally, TMPAL-10 completely stopped filament formation in <italic>C. albicans</italic>, a key early process for biofilm formation [<xref rid="B34-pharmaceutics-12-00688" ref-type="bibr">34</xref>].</p><p>Biosurfactants are also the potent disruptors of biofilms for human bacterial and yeast pathogens. Rhamnolipids were able to remove up to 88.9% of the <italic>S. aureus</italic> biofilm in skim milk or 35% in nutrient broth, both deposited onto polystyrene [<xref rid="B35-pharmaceutics-12-00688" ref-type="bibr">35</xref>]. Similarly, Aleksic et al. extracted dirhamnolipids (with two C10 acyl chains, C10C12 and C8C10 acyl chains) from Lysinibacillus sp. BV152.1 fermentations, and showed that they could prevent biofilm formation by <italic>P. aeruginosa</italic> PAO1, <italic>S. aureus</italic>, and <italic>Serratia marcescens</italic> [<xref rid="B36-pharmaceutics-12-00688" ref-type="bibr">36</xref>]. The semi-synthetic morpholine amide derivative of these rhamnolipids showed an increased biofilm disruption activity (80% against 50% for the unreacted rhamnolipids) with <italic>P. aeruginosa</italic> PAO1. Rhamnolipid congener type also affects biofilm disruption with C10C10 mono-rhamnolipids produced by <italic>P. aeruginosa</italic> having a lower effect than C14C14 di-rhamnolipids from <italic>Burkholderia thailandensis</italic> E264 on biofilm formation by <italic>Bacillus subtilis</italic> BBK006 [<xref rid="B37-pharmaceutics-12-00688" ref-type="bibr">37</xref>]. Bisurfactants also appear to be less effective at preventing or removing biofilm in mixed bacterial cultures compared to single strains. Rhamnolipids at 0.25% were able to remove 24% of the biofilm from a mixed culture of <italic>S. aureus</italic>, <italic>L. monocytogenes</italic> and <italic>S.Enteritidis</italic>, compared to 58.5% for <italic>S. aureus</italic>, 26.5% for <italic>L. monocytogenes</italic>, and 23.0% for <italic>S.Enteritidis</italic> on their own [<xref rid="B38-pharmaceutics-12-00688" ref-type="bibr">38</xref>]. The biofilm-disrupting ability of rhamnolipids extends to pathogenic fungi. Rhamnolipids at 0.16mg/L reduced the adhesion of <italic>C. albicans</italic> to polystyrene by 50%, increasing to 90% at 5mg/L [<xref rid="B39-pharmaceutics-12-00688" ref-type="bibr">39</xref>]. With <italic>Yarrowia lipolytica</italic>, rhamnolipid is more efficient than CTAB or SDS at reducing biofilm formation (up to 50%) [<xref rid="B40-pharmaceutics-12-00688" ref-type="bibr">40</xref>].</p><p>Importantly, surfactants and emulsions can be incorporated into chronic wound care either as direct anti-microbial agents, or due to their ability to produce gels and foams for topical application. Chronic wounds usually attract biofilm-forming microorganisms that decelerate wound healing and often lead to systemic disorders. In this context, a non-propellant based foam (NPF; loaded with the antibiotics sulfadiazine and pectin-capped green nano-silver), applied onto second degree thermal wounds inflicted onto Swiss Albino mice, was shown to protect the wound from microbial insults while promoted skin regeneration [<xref rid="B41-pharmaceutics-12-00688" ref-type="bibr">41</xref>]. In the same line, two non-ionic surfactants (e.g., PluroGel<sup>&#x000ae;</sup> and Wound Dressing and the anti-microbial PluroGel<sup>&#x000ae;</sup> PSSD) eradicated the pre-formed <italic>P. aeruginosa, Enterococcus</italic> sp., <italic>S. epidermidis, S. aureus</italic> and methicillin-resistant <italic>S. aureus</italic> (MRSA) biofilms on several experimental models, by entrapping and killing the dispersed microorganisms from the biofilm [<xref rid="B42-pharmaceutics-12-00688" ref-type="bibr">42</xref>]. Similarly, a concentrated gel [loaded with anti-microbial 1% silver sulfadiazine (SSD)] was able to kill pre-formed <italic>S. aureus</italic>, <italic>S. epidermidis</italic>, <italic>MRSA</italic>, <italic>P. aeruginosa</italic> and <italic>E. faecalis</italic> biofilm, eliminate their planktonic cells and prevent intrusion by environmental pathogens, as documented in various in vitro models [<xref rid="B43-pharmaceutics-12-00688" ref-type="bibr">43</xref>]. In 2016, SSD was tested in a multi-center clinical study, where 70% of the participants experienced positive outcomes (wound closure, reduction of inflammation and odor) with 56% of whom achieved wound closure in less than 11 weeks [<xref rid="B44-pharmaceutics-12-00688" ref-type="bibr">44</xref>]. Lastly, the sterilization of the consumables used in wound care is also significant. To this end, cotton fibers [coated with nano-structured zinc oxide (ZnO NP) stabilized by the surfactants sodium dodecyl sulfate (SDS) or alkyl hydroxy-ethyl dimethyl ammonium chloride (HY)] were shown to exert strong anti-microbial activity against <italic>E. coli, S. aureus, C. albicans</italic> and <italic>Microsporumcanis</italic>, while they were provento be non-irritable for the skin [<xref rid="B45-pharmaceutics-12-00688" ref-type="bibr">45</xref>].</p><p>Synthetic surfactants and emulsions can also be used as anti-biofilm agents on the surfaces of prosthetic medical devices and health care disposables (e.g., cotton buds and respiratory protective devices). More specifically, nystatin admixed with the surfactant sodium deoxycholate (at a ratio of 1:0.8) induced an over 40% inhibition of <italic>C. albicans</italic> biofilm formation on endotracheal tubes, an effect attributed to the fact that the surfactant enhanced the nystatin penetration into the prosthetics [<xref rid="B46-pharmaceutics-12-00688" ref-type="bibr">46</xref>]. Regarding the safety of health professionals, engineered respiratory protective devices (with non-woven reusable fabrics and embedded hexamethylene-1,6-bis (N,N-dimethyl-N-dodecyl ammonium bromide; GS-12-6-12 crystals onto halloysite nanocrystals) exerted an anti-microbial action in the presence of water (i.e., humidity from exhaled air) against <italic>E. coli</italic>, <italic>Pseudomonas fluorescens</italic> as well as <italic>Penicillumchrysogenum</italic> and <italic>A. niger</italic> [<xref rid="B47-pharmaceutics-12-00688" ref-type="bibr">47</xref>]. Lastly, the safety of water in the clinical setting is a very important issue as well. To this end, an anti-microbial and algae-static nanofilm (containing silica-modified quaternary ammonium compounds) was synthesized in an effort to replace chlorine-based water disinfection methods. This nanofilm effectively limited the viability and adhesion of <italic>E. coli</italic> and <italic>Microcystis aeruginosa</italic>, respectively [<xref rid="B48-pharmaceutics-12-00688" ref-type="bibr">48</xref>].</p><p>Emulsions could improve antibiotic efficacy against pathogens without necessarily exerting an antibiotic action, but rather by supporting drug delivery and accumulation. For instance, dipalmitoyl phosphatidyl choline (DPPC) liposomes loaded with the anti-tubercular drugs isioniazid, ethambutol and rifampicin in a ratio of 1:1 (the drug-by-weight ratio was 1:3:2) prolonged the release and alveolar deposition of the antibiotics in mice. Importantly, no hemolytic activity was reported in the human blood samples exposed to the liposomes. Moreover, the mixture remained stable and active after a month-long storage at 4 &#x000b0;C, permitting its use in clinical settings [<xref rid="B49-pharmaceutics-12-00688" ref-type="bibr">49</xref>]. In this line, ciprofloxacin-loaded polyethylene glycol (PEG)ylated phosphatidylcholine (PC)-rich nanovesicles (phosphatiosomes) coated with soyaethyl morphonium ethosulfate (SME), facilitated the antibiotic release and accumulation of ciprofloxacin in the lungs of a rat model of MRSA lung infection, thus resulting in lower lung bacterial counts compared to the animals that were treated with free ciprofloxacin [<xref rid="B50-pharmaceutics-12-00688" ref-type="bibr">50</xref>]. In another recent study, a new nano-emulsion (comprised of oils, surfactants and co-surfactants that increased the solubilization of the broad-spectrum antifungal factor sulconazole (SCZ) was synthesized and when tested in SD male rats, showing a higher skin penetration capacity and stronger inhibitory activity against <italic>C. albicans</italic> and <italic>Trichophyton rubrum</italic> compared to the commercial miconazole cream [<xref rid="B51-pharmaceutics-12-00688" ref-type="bibr">51</xref>]. Likewise, such approaches have been tested for the ocular delivery of anti-microbials as well. A nano-emulsion made from Tween-80, Soluphor<sup>&#x000ae;</sup> P, ethyl-olate and deionized water was used as a vehicle for the ocular delivery of the antibiotic moxifloxacin, in the irritated eyes of Albino rats. Although the nano-emulsion did not affect the anti-microbial activity of moxifloxacin, it did prolong the contact time and release of the antibiotic in the eye, accelerating the recovery process [<xref rid="B52-pharmaceutics-12-00688" ref-type="bibr">52</xref>]. In the same manner, nanoparticles carrying ofloxacin (with PEGylated lipids and chitosan) enhanced the drug-mucoadhesion strength that could be linked to better therapeutic outcomes [<xref rid="B53-pharmaceutics-12-00688" ref-type="bibr">53</xref>]. <xref rid="pharmaceutics-12-00688-t001" ref-type="table">Table 1</xref> summarizes the anti-microbial effects of surfactants against common pathogens: </p></sec><sec id="sec4-pharmaceutics-12-00688"><title>4. Anti-Oxidant Properties</title><p>Reactive oxygen species (ROS) are the metabolic by-products of both endogenous and exogenous stimuli [<xref rid="B54-pharmaceutics-12-00688" ref-type="bibr">54</xref>,<xref rid="B55-pharmaceutics-12-00688" ref-type="bibr">55</xref>] in addition to being important factors of cellular homeostasis through the regulation of signal transduction pathways [<xref rid="B56-pharmaceutics-12-00688" ref-type="bibr">56</xref>,<xref rid="B57-pharmaceutics-12-00688" ref-type="bibr">57</xref>]. Under physiological conditions, ROS production and antioxidant defense systems are in balance, but when such production is overwhelming, then it leads to the excessive accumulation of ROS (i.e., oxidative stress) [<xref rid="B58-pharmaceutics-12-00688" ref-type="bibr">58</xref>,<xref rid="B59-pharmaceutics-12-00688" ref-type="bibr">59</xref>]. During oxidative stress, ROS can interact with DNA, proteins and lipids, thus contributing to the pathophysiology of various disease mechanisms involved in cancer, aging, diabetes as well as cardiovascular and neurodegenerative disorders [<xref rid="B60-pharmaceutics-12-00688" ref-type="bibr">60</xref>,<xref rid="B61-pharmaceutics-12-00688" ref-type="bibr">61</xref>,<xref rid="B62-pharmaceutics-12-00688" ref-type="bibr">62</xref>]. </p><p>Food products are also susceptible to oxidation, mainly affecting their lipid, protein and carbohydrate content. Specifically, lipid oxidation in emulsion-based food products is considered as the main mechanism causing the deterioration of food quality (e.g., reduced nutrition value), short shelflife, undesirable rancidity, color, texture, etc.). Moreover, the subsequent formation of toxic by-products is often associated with the incidence of pathological conditions including neurodegenerative diseases and cancer [<xref rid="B63-pharmaceutics-12-00688" ref-type="bibr">63</xref>,<xref rid="B64-pharmaceutics-12-00688" ref-type="bibr">64</xref>]. To this end, the amelioration of oxidatively-induced damage through the utilization of synthetic and/or naturally-occurring antioxidant compounds, both in humans and in food products, has been extensively reported. In most cases, synthetic antioxidants appear to be more efficient at lower concentrations, while naturally-derived ones usually require higher concentrations. In this context, the utilization of SAAs as novel-antioxidant compounds has attracted scientific interest in recent years [<xref rid="B65-pharmaceutics-12-00688" ref-type="bibr">65</xref>,<xref rid="B66-pharmaceutics-12-00688" ref-type="bibr">66</xref>,<xref rid="B67-pharmaceutics-12-00688" ref-type="bibr">67</xref>]. In general, lipid oxidation in emulsion-based products including those of the food, cosmetic and pharmaceutical industries, is a major health concern for consumers [<xref rid="B68-pharmaceutics-12-00688" ref-type="bibr">68</xref>]. Specifically, the lipid oxidation of emulsion-based foods, rich in fatty/oils, can deteriorate the food&#x02019;s nutritional and sensory quality (during processing and storage) in terms of undesirable color, texture and rancidity while the formation of toxic by-products could potentially relate to serious health problems [<xref rid="B69-pharmaceutics-12-00688" ref-type="bibr">69</xref>]. In general, oil-in-water (O/W) emulsions are used as an emulsion-based model, in food products, consisting of emulsifier-surrounding lipid droplets dispersed in an aqueous continuous phase [<xref rid="B70-pharmaceutics-12-00688" ref-type="bibr">70</xref>]. Lipid oxidation takes place at the interface between the aqueous and oil phase and it is the net effect of the activity of various enzymes, transition metals and photo-sensitizers, all of which can promote lipid oxidation [<xref rid="B71-pharmaceutics-12-00688" ref-type="bibr">71</xref>]. Therefore, it is evident that the composition and characteristics of the interfacial layer and the surrounding microenvironment are critical factors, influencing lipid oxidation rates and oxidation stability in O/W systems [<xref rid="B72-pharmaceutics-12-00688" ref-type="bibr">72</xref>,<xref rid="B73-pharmaceutics-12-00688" ref-type="bibr">73</xref>,<xref rid="B74-pharmaceutics-12-00688" ref-type="bibr">74</xref>]. Consequently, the use of interfacial agents able to manipulate interfacial characteristics, has attracted significant attention, especially towards their application in commercial food products. Indeed, several synthetic compounds that possess both surface active and antioxidant potential have been evaluated for their use as antioxidant emulsifiers in O/W emulsions [<xref rid="B75-pharmaceutics-12-00688" ref-type="bibr">75</xref>]. However, different molecular aspects including the charge [<xref rid="B76-pharmaceutics-12-00688" ref-type="bibr">76</xref>], length of polar head [<xref rid="B77-pharmaceutics-12-00688" ref-type="bibr">77</xref>] and the length of the hydrocarbon tail [<xref rid="B78-pharmaceutics-12-00688" ref-type="bibr">78</xref>] reflect the extent of their antioxidant capacity. </p><p>The visible light irradiation of photosensitizers such as riboflavin (hydrophilic) [<xref rid="B74-pharmaceutics-12-00688" ref-type="bibr">74</xref>] and chlorophyll (lipophilic) [<xref rid="B79-pharmaceutics-12-00688" ref-type="bibr">79</xref>], appear to represent a key mechanism of promoting lipid oxidation in food products [<xref rid="B80-pharmaceutics-12-00688" ref-type="bibr">80</xref>,<xref rid="B81-pharmaceutics-12-00688" ref-type="bibr">81</xref>]. In a recent study, anionic sodium dodecyl sulfate (SDS) and neutral Tween-20 coated oil droplets, were shown to be more stable compared to those coated with cetyl trimethyl ammonium bromide (CTAB) in riboflavin-photosensitized O/W emulsions [<xref rid="B71-pharmaceutics-12-00688" ref-type="bibr">71</xref>], although contradictory results were reported in another study [<xref rid="B82-pharmaceutics-12-00688" ref-type="bibr">82</xref>]. Moreover, lipid oxidation appeared less rapidly in droplets coated with the anionic surfactant SDS, compared to those coated with the non-ionic surfactant Tween-80 [<xref rid="B83-pharmaceutics-12-00688" ref-type="bibr">83</xref>]. Finally, a study that evaluated the influence of the structure&#x02019;s interface on the oxidative stability of the surfactant-stabilized O/W emulsions indicated that the metal-initiated lipid oxidation and the formation of volatile compounds occurred more rapidly in the emulsions stabilized by a mixture of non-ionic Tween-20 and Span-20 surfactants, when compared to those stabilized by a single Tween-20 [<xref rid="B84-pharmaceutics-12-00688" ref-type="bibr">84</xref>].</p><p>Non-ionic surfactants (e.g., polysorbates; Tween group) have been widely used in preclinical and clinical practice due to their amphiphilic nature as emulsifiers. Specifically, Tween-20/80 non-ionic surfactants have been used as pharmaceutical surfactants in various drug delivery systems (oral/parenteral) with poor solubility and consequently, their intravenous use has been approved by the European Medicines Agency and US Food and Drug Administration [<xref rid="B85-pharmaceutics-12-00688" ref-type="bibr">85</xref>]. However, although Tween-20/80 surfactants are generally characterized by a safe profile, extensive knowledge of their antioxidant potential is rather limited. In a recent report, the antioxidant capacity of Tween-20/80 was evaluated by several in vitro assays at concentrations commonly used in laboratory tests [<xref rid="B86-pharmaceutics-12-00688" ref-type="bibr">86</xref>]. According to the results, both surfactants possessed a low scavenging capacity against (2,2-diphenyl-1-picryl-hydrazyl-hydrate; DPPH) radical formation. However, Tween-20 and -80 significantly inhibited the generation of ROS (by means of phorbol 12-myristate 13-acetate (PMA) or the H<sub>2</sub>O<sub>2</sub>-induced activation of human neutrophils), while Tween-20 exhibited the strongest reductive activity. Specifically, Tween-20 showed a greater inhibitory effect against ROS formation in PMA-induced human leucocytes compared to the H<sub>2</sub>O<sub>2</sub>-treatedcells, while the antioxidant capacity of Tween-80 was similar in both cases. According to the authors of this study, the results indicate that the anti-oxidant potential of both polysorbates (i.e., in terms of decreased ROS production) cannot be assigned to their free radical scavenging ability, but rather to their undefined biological interaction-based mechanism(s) [<xref rid="B86-pharmaceutics-12-00688" ref-type="bibr">86</xref>]. </p><p>Another type of non-ionic synthetic surfactant [formed by the esterification of Vitamin E in a reaction catalyzed by polyethylene glycol (PEG) 100], is D-&#x003b1;-Tocopheryl polyethylene glycol 1000 succinate (TPGS/Vitamin E TPGS), a water-soluble derivative of natural Vitamin E [<xref rid="B87-pharmaceutics-12-00688" ref-type="bibr">87</xref>,<xref rid="B88-pharmaceutics-12-00688" ref-type="bibr">88</xref>]. Being readily miscible with oils as well as an important solubilizer of water-soluble and -insoluble agents, TPGS surfactants have been extensively used in drug delivery systems (DDSs) [<xref rid="B89-pharmaceutics-12-00688" ref-type="bibr">89</xref>]. Specifically, it has been reported that TPGS surfactants possess a variety of functions as (i) the enhancers of drug solubility [<xref rid="B90-pharmaceutics-12-00688" ref-type="bibr">90</xref>], (ii) the excipients for multidrug resistance (MDR) and drug absorption [<xref rid="B91-pharmaceutics-12-00688" ref-type="bibr">91</xref>], (iii) the enhancers of drug cytotoxicity [<xref rid="B92-pharmaceutics-12-00688" ref-type="bibr">92</xref>] and (iv) anti-tumor agents synergistically acting with other anticancer drugs [<xref rid="B93-pharmaceutics-12-00688" ref-type="bibr">93</xref>]. Furthermore, these molecules were able to prevent the cyclosporin A (CsA, an immunosuppressive drug)-induced production of ROS and inhibit the loss of protein-bound sulfhydryl groups [<xref rid="B94-pharmaceutics-12-00688" ref-type="bibr">94</xref>]. </p><p>On the other hand, tyrosol, a biophenol with notable anti-oxidant potential [<xref rid="B95-pharmaceutics-12-00688" ref-type="bibr">95</xref>], was utilized for the formation of alkyl-succinylatedtyrosol synthetic amphiphilic lipids (catalyzed by lipase succinylation of tyrosol with different alkyl chain lengths of alkyl succinic anhydrides) [<xref rid="B96-pharmaceutics-12-00688" ref-type="bibr">96</xref>]. According to the characterization profile of tyrosol-based-derived synthetic lipids, all four derivatives exhibited surface active and anti-oxidant abilities to a variable extent. Specifically, among them, the 2-dodecen-1-yl succinylated compound exhibited greater activity against DPPH radical formation when compared to free tyrosol, as well as to the rest of the synthetic lipids. At an emulsion state, both 2-octen-1-ylsuccinylated and 2-dodecen-1-ylsuccinylatedtyrosol-based emulsions inhibited lipid oxidation to a greater extent, as opposed to that of free tyrosol emulsions. </p><p>In another report, erythorbyl laurate (6-O-lauroyl-erythorbic acid), a synthetic product derived from the enzymatic esterification between erythorbic acid (a stereoisomer of L-ascorbic acid widely used as an anti-oxidant in a variety of processed foods) and lauric acid (a medium-chain fatty acid with a strong anti-microbial activity against food-related pathogens) was documented to act as a surface active agent with significant foaming ability [<xref rid="B97-pharmaceutics-12-00688" ref-type="bibr">97</xref>,<xref rid="B98-pharmaceutics-12-00688" ref-type="bibr">98</xref>]. Such property was related to its high concentration at the O/W interface and consequently resulted in the significant inhibition of lipid peroxides, particularly in soybean oil emulsions. The observed emulsifying and anti-oxidant properties indicate its potential use as a promising solubilizer/stabilizer of hydrophobic functional food ingredients in emulsified food systems [<xref rid="B99-pharmaceutics-12-00688" ref-type="bibr">99</xref>].</p><p>Chitosan (CS), a semi-synthetic derivative of the polysaccharide chitin (produced through alkaline deacetylation), has exhibited considerable anti-microbial, wound-healing and anti-oxidant activities, among others [<xref rid="B100-pharmaceutics-12-00688" ref-type="bibr">100</xref>]. However, the low degree of water-solubility is a major disadvantage regarding the efficacy of the compound [<xref rid="B101-pharmaceutics-12-00688" ref-type="bibr">101</xref>]. To this end, synthetic single N-quaternized (QCS) and double N-diquaternized (DQCS) chitosan derivatives were shown to exhibit water solubility. Moreover, both QCS and DQCS derivatives exhibited higher anti-oxidant capacity when compared to single CS. Specifically, the anti-oxidant potential of all the tested compounds followed the order of DQCS &#x0003e; QCS &#x0003e; CS, as evidenced by various anti-oxidant assays [<xref rid="B102-pharmaceutics-12-00688" ref-type="bibr">102</xref>]. These results suggest that the DQCS synthetic derivatives of chitosan could be used in pharmaceutical and food areas as promising anti-oxidant agents. On another note, the synthesized derivatives of glucosyl- and glucuronosyl alkyl gallates demonstrated better surfactant and anti-oxidant activities when compared to those of alkyl galates. However, their ROSscavenging capacity appeared to be lower when compared to that of alkyl esters [<xref rid="B103-pharmaceutics-12-00688" ref-type="bibr">103</xref>]. </p><p>Native as well as the synthetic derivatives of carrageenans have all been shown to associate with significant anti-oxidant potential, such as in the case of &#x003ba;-carrageenan oligosaccharides as well as some of their over-sulfated (SD), low-, high-acetylated (LAD and HAD, respectively) and phosphorylated (PD) derivatives. According to the results, all the types were shown to limit ROS production, to a variable extent, thereby suggesting that chemical modification(s) could enhance their anti-oxidant potential, in vitro, in a manner following the pattern of PD &#x0003e; SD &#x0003e; LAD &#x0003e; HAD. This observation, in turn, highlights the significant role of the sulfated content in exerting an anti-oxidant response [<xref rid="B104-pharmaceutics-12-00688" ref-type="bibr">104</xref>]. </p><p>Moreover, a newly synthesized collagen peptide (CP)-&#x003ba;-carrageenan oligosaccharide complex &#x003ba;-ca3000 + CP, was evaluated for its potential free radical scavenging activity. To this end, the complex [consisting of &#x003ba;-carrageenan conjugated with bioactive tilapia skin collagen peptides (CP), rich in hydroxyl and carboxyl groups, and with noted anti-oxidant and photo-protective properties] was effective against UV-induced cell death in HaCaT and MEF cells more efficiently than each compound alone. Finally, this effect was mediated by: (i) the inhibition of apoptotic cell death (HaCaT), (ii) the induced production of collagen I and reduced matrix metalloproteinase-1 (MMP-1) expression levels (MEF), accompanied by (iii) the inhibition of mitogen-activated protein kinases (MAPKs) pathway activation and ROS production as well. According to the authors, the complex &#x003ba;-ca3000/CP exerts significant photo-protective and anti-oxidant activities, thereby indicating its potential use in cosmetic and pharmaceutical industries [<xref rid="B105-pharmaceutics-12-00688" ref-type="bibr">105</xref>]. </p><p>Rhamnolipid glycolipids have been shown to have significant antioxidant properties, with a mixed mono and di-rhamnolipid from <italic>Marinobacter litoralis</italic> MB15 showing about a 10% lower DPPH scavenging ability (72.6%) at 5mg/mL than ascorbic acid at the same concentration [<xref rid="B106-pharmaceutics-12-00688" ref-type="bibr">106</xref>]. Similarly, rhamnolipids were also reported as having significant antioxidant ability by Abdollahi et al., although this was lower than for the artificial food antioxidant butylated hydroxyanisole (BHA) [<xref rid="B107-pharmaceutics-12-00688" ref-type="bibr">107</xref>]. In a more direct demonstration of the potential of rhamnolipids as antioxidants, Liu et al. [<xref rid="B108-pharmaceutics-12-00688" ref-type="bibr">108</xref>] compared the ability of rhamnolipids, saponins (a plant derived biosurfactant) and Tween 80 to protect &#x003c9;-3-fatty acids in polyunsaturated marine oil emulsions. They found that the order of decreasing oxidative stability was rhamnolipids &#x0003e; saponins &#x0003e; Tween 80, highlighting the potential of the biosurfactants. The antioxidant properties of sophorolipids are reported to be weak [<xref rid="B109-pharmaceutics-12-00688" ref-type="bibr">109</xref>], which may explain the lack of reports on their antioxidant ability. Takahashi et al. 2012 [<xref rid="B110-pharmaceutics-12-00688" ref-type="bibr">110</xref>] report that all common MEL derivatives (e.g.,MEL A, MEL B and MEL C) have a lower antioxidant ability in DPPH in vitro tests than arbutin, a common positive control known to have strong radical scavenging properties. However, when tested for protection against H<sub>2</sub>O<sub>2</sub>-induced oxidative stress on human skin fibroblasts (NB1RGB cell lines), MEL C surprisingly had a greater protective effect than arbutin. The different responses of glycolipids to different antioxidant tests may also partly explain the dearth of reported antioxidant properties.</p><p><xref rid="pharmaceutics-12-00688-t002" ref-type="table">Table 2</xref> summarizes the known polymers with documented anti-oxidant activity and the suggested mechanism(s) of action:</p></sec><sec id="sec5-pharmaceutics-12-00688"><title>5. Anti-Viral Properties</title><p>Re-emerging and emerging viral infections lacking effective therapeutic and preventive measures constitute a global threat. Vulnerable populations (immune-deficient and/or immunocompromised individuals and groups at the extremes of age) are more prone to developing severe disease manifestations and rare complications, often leading to chronic disorders and death. Currently available anti-virals comprise of: (i) directly-acting (DAAs) and (ii) host-acting (HAAs) anti-virals, which can either directly target the virion or alter thegene expression and enhance host anti-viral responses, respectively [<xref rid="B111-pharmaceutics-12-00688" ref-type="bibr">111</xref>]. SAAs are interesting candidates for anti-viral DAA or HAA drug discovery, due to their chemical and physical properties. </p><p>One of the first reported applications of synthetic surface-active compounds with anti-viral potential, was their incorporation in topically-applied gels for the management of sexually-transmitted infections. Nonoxynol-9 was the first non-ionic surfactant with established spermicidal activity, which was tested as a potential virucidal against enveloped viruses, including those of human immunodeficiency virus (HIV). Clinical trials that investigated the use of nonoxynol-9 against HIV infection in female sex workers led to controversial results regarding the efficacy and safety of a such approach [<xref rid="B112-pharmaceutics-12-00688" ref-type="bibr">112</xref>,<xref rid="B113-pharmaceutics-12-00688" ref-type="bibr">113</xref>]. Although nonoxynol-9 appeared as a non-appropriate candidate for a topical virucidal use, it did set the stage for the research of synthetic SAAs with virucidal potential [<xref rid="B114-pharmaceutics-12-00688" ref-type="bibr">114</xref>,<xref rid="B115-pharmaceutics-12-00688" ref-type="bibr">115</xref>]. Of note, the poly-anionic SDS was found to be effective against HIV-1, HSV-2 and the non-enveloped human papilloma virus (HPV), due to its surface-active and denaturing properties [<xref rid="B116-pharmaceutics-12-00688" ref-type="bibr">116</xref>]. In an earlier study, sodium lauryl sulfate (SLS; an anionic surfactant with protein denaturing potency, otherwise called SDS) was shown to be effective against the same targets. Furthermore, a gel formulation containing SLS was potent against herpes simplex virus type-2 (HSV-2)-induced vaginal and epidermal lesions in rabbits and mice [<xref rid="B117-pharmaceutics-12-00688" ref-type="bibr">117</xref>]. Anti-herpetic activity was also exhibited by chlorhexidine, a very potent surface-active agent, that acted by destabilizing the viral lipid outer layer [<xref rid="B118-pharmaceutics-12-00688" ref-type="bibr">118</xref>]. On another note, soaps and sanitizers could also be as readily available for topical virucidal action after viral exposure. For instance, commercial South African soap bars diluted in water demonstrated virucidal action against cell-free HIV-1 virions and cytotoxic effects against HIV-1-infected lymphocytes. These effects were reported after a very short incubation period, ranging from 30 secs to 2 min [<xref rid="B119-pharmaceutics-12-00688" ref-type="bibr">119</xref>]. Accordingly, a microemulsion formulated from different fractions of Tween-80, Span-20, ethanol, oil, isopropyl myristate (IPM), and distilled water, dramatically limited the infectivity of HSV-2 in vitro [<xref rid="B120-pharmaceutics-12-00688" ref-type="bibr">120</xref>]. </p><p>The research on the virucidal properties of SAAs, also targets non-sexually transmitted viruses that are related to significant mortality rates in vulnerable groups. For instance, the Ebola virus (EBV) is a serious life threat, causing re-emerging epidemics as there is no specific medication available yet. In the early 2000s, following the African epidemic of the late 1990s, the findings of a study proposed that the nano-emulsion ATB could decrease the Ebola virus strain Zaire concentration by over 4.0 logs in a cell culture medium and surfaces in 20 min. Such a significant decrease in the viral population could potentially lead to its complete eradication [<xref rid="B121-pharmaceutics-12-00688" ref-type="bibr">121</xref>]. Another serious seasonal epidemic is influenza infections. The efficacy of current anti-viral agents against influenza is doubted, underlining the urgent need for more effective preventive and treatment strategies [<xref rid="B122-pharmaceutics-12-00688" ref-type="bibr">122</xref>]. Surface sanitization is a crucial factor in limiting influenza spread. Household cleaning disinfectants, branded anti-viral wipes and surfactant-coated silica nanoparticles (SNPs) reportedly limited influenza virus strain H1N1 viability [<xref rid="B123-pharmaceutics-12-00688" ref-type="bibr">123</xref>]. In particular, SNPs coated with didodecyl dimethyl ammonium bromide (DDAB; a quaternary ammonium cationic surfactant) were effective against the H1N1 influenza strain, in suspension or when immobilized into surfaces, indicating its potential role as an attractive coating factor for large surfaces and prosthetics [<xref rid="B124-pharmaceutics-12-00688" ref-type="bibr">124</xref>]. Lastly, two nano-emulsions made from soybean oil, tributyl phosphate and Triton X-100, namely 8N8 and 20N10, exhibited prophylactic properties against influenza infection, in both in vitro and in vivo models.Specifically, CD-1 mice that received these mixtures prior to the viral exposure exhibited significantly elevated survival rates compared to mock-treated animals [<xref rid="B125-pharmaceutics-12-00688" ref-type="bibr">125</xref>]. The emergence of the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) almost six months ago in Wuhan, China, and the consequent coronavirus disease of 2019 (COVID-19) pandemic, has fast-tracked many studies on preventative and therapeutic means. Despite the global efforts, currently, there are no specific drugs and/or vaccines available. Therefore, the public relies on disinfection and sanitization methods to limit the viral spread. Very recent studies showed that SARS-CoV-2 can remain infectious on inanimate objects from 2 h to 9 days, depending on temperature, humidity and the type of material. Ethanol, 2- and 1- propanolare rigorous disinfectants of surfaces and skin, and limit the virus infectivity as much as 5 logs, in just 30 s [<xref rid="B126-pharmaceutics-12-00688" ref-type="bibr">126</xref>]. Additionally, chlorine-based solutions, that are mainly used for surface and wastewater treatments, have exhibited concentration-depended anti-SARS-CoV-2 effects. Indeed, 1:50 and 1:100 dilutions have been proved to limit the viral load by 3 logs [<xref rid="B127-pharmaceutics-12-00688" ref-type="bibr">127</xref>].</p><p>Viral infections account for a significant percentage of food-borne diseases worldwide. The two most prevalent viral enteropathogens are the norovirus (NoV) and rotavirus (RV). Human NoV (HuNoV) does not propagate in cell cultures, but instead, close phylogenetically viral surrogates, like the murine NoV (MNV), are utilized in research for anti-noroviral compounds. In a recent study, the anti-MNV potential of the surfactants SDS (powder), NP-40 (4-nonylphenyl-polyethylene glycol), Triton X-100, and Tween-20 was examined, and found that all surfactants were able to inactivate MNV-1 in a dose-dependent manner [<xref rid="B128-pharmaceutics-12-00688" ref-type="bibr">128</xref>]. Similarly, a mixture consisting of levulinic acid and SDS limited the activity of MNV and hepatitis A virus (HAV) on strawberries. The mean reduction of viral yield only reached 1-log, but levulinic acid/SDS mixture was more efficient compared to water or bleach [<xref rid="B129-pharmaceutics-12-00688" ref-type="bibr">129</xref>]. A recent study, using viral-like particles, consisting of the noroviral capsid proteins only, reported that the cationic surfactant cetyl trimethyl ammonium bromide (CTAB) and the anionic surfactant SDS could disassociate and entrap the viral-like particles in micelles, effectively limiting their infectivity [<xref rid="B130-pharmaceutics-12-00688" ref-type="bibr">130</xref>]. Contrasting results have been reported concerning the most potent hand disinfection method against MNV. Some have proposed that ethanol-based sanitizers are the most efficient anti-MNV sanitization method [<xref rid="B131-pharmaceutics-12-00688" ref-type="bibr">131</xref>], while others have shown that common soaps diluted in water are far superior [<xref rid="B132-pharmaceutics-12-00688" ref-type="bibr">132</xref>,<xref rid="B133-pharmaceutics-12-00688" ref-type="bibr">133</xref>]. Regardless, alcohol-based sanitizers have been shown to completely diminish the infectivity of RV and HAV in less than 30s [<xref rid="B134-pharmaceutics-12-00688" ref-type="bibr">134</xref>]. </p><p>Rhamnolipids have been reported to have antiviral activity against the herpes simplex virus (HSV) types I and II [<xref rid="B135-pharmaceutics-12-00688" ref-type="bibr">135</xref>]. The effect was dose dependent and occurred at concentrations below the critical micelle concentration of the rhamnolipid. One of the first reports on the antiviral activity of SLs was presented by Shah et al. [<xref rid="B136-pharmaceutics-12-00688" ref-type="bibr">136</xref>]. The authors discovered an anti-human immunodeficiency virus (HIV) activity of the tested SLs together with a spermicidal activity comparable with nonoxynol-9. The potential activity of SLs against retrovirus, herpes virus and papillomavirus has been the subject of several patents [<xref rid="B137-pharmaceutics-12-00688" ref-type="bibr">137</xref>,<xref rid="B138-pharmaceutics-12-00688" ref-type="bibr">138</xref>]. Moreover, the report by Gross et al. [<xref rid="B137-pharmaceutics-12-00688" ref-type="bibr">137</xref>] also presented the influence of SLs on the Epstein&#x02013;Barr virus. </p><p><xref rid="pharmaceutics-12-00688-t003" ref-type="table">Table 3</xref> summarizes the known SAAs with the documented anti-viral activity as well as their potential targets and the suggested mechanism(s) of action:</p></sec><sec id="sec6-pharmaceutics-12-00688"><title>6. Anti-Inflammatory Properties </title><p>Balanced inflammatory responses are crucial for survival. They are divided into two broad categories: acute and chronic. Acute inflammatory responses can be triggered by pathogens, chemical irritants or tissue injury and can result in the neutralization of the stimuli and wound tissue repair [<xref rid="B139-pharmaceutics-12-00688" ref-type="bibr">139</xref>]. The main soluble mediators of inflammatory response are interleukins (ILs), chemokines, eicosanoids and histamine, produced by the injured tissue or in situ immunological populations. On the other hand, the duration and magnitude of the inflammatory response is tightly regulated by transforming growth factor-&#x003b2; (TGF-&#x003b2;), which locally suppresses the production of pro-inflammatory molecules, whilst supporting the proliferation of fibroblasts and the production of extracellular matrix proteins, involved in the remodeling of the damaged tissue. In this way, unregulated responses can lead to systemic and chronic inflammation that are strictly correlated with autoimmune disorders, cancer, metabolic and cardiovascular disease, among other pathological conditions [<xref rid="B139-pharmaceutics-12-00688" ref-type="bibr">139</xref>].</p><p>Currently, synthetic surfactants are studied as potential drug candidates for the acute respiratory distress syndrome (ARDS). This is a multifactorial condition, also caused by pulmonary surfactant deficit and prolonged inflammatory responses. Importantly, COVID-19 can lead to ARDS as SARS-CoV-2 can infect and impair the function of type II cells in the lungs, affecting the production of pulmonary surfactants, at the third stage of the infection [<xref rid="B140-pharmaceutics-12-00688" ref-type="bibr">140</xref>]. Current therapeutic approaches include anti-inflammatory agents, vasodilators and surfactant replacement therapy, among others [<xref rid="B141-pharmaceutics-12-00688" ref-type="bibr">141</xref>,<xref rid="B142-pharmaceutics-12-00688" ref-type="bibr">142</xref>]. The most commonly used are porcine lung surfactants. However, major limitations in their use include: (i) the difficulty of isolation and (ii) their limited production, thereby reflecting the inability of high-dose administration. To this end, synthetic SAAs with anti-inflammatory potential are being studied for their use as pulmonary surfactant substitutes in ARDS patients. For instance, CHF5633 is a novel synthetic surfactant, consisting of: (i) analogues of surfactant proteins B (SP-B) and C (SP-C) (both possessing changes in size and amino-acid sequence) and (ii) a 1:1 phospholipid mixture of dipalmitoyl phosphatidyl choline (DPPC) and palmitoyl oleyl phoshatidyl glycerol (POPG). SP-B and SP-C are the lipid-associated protein components of the pulmonary surfactant that protect the alveoli shape during breathing. CHF5633 has been thoroughly examined for its ability to elicit an anti-inflammatory response in naive or activated neonatal or adult monocytes. In each model used, CHF5633 decreased the expression of the inflammatory mediators like tumor necrosis factor-&#x003b1; (TNF-&#x003b1;) and interleukin-1&#x003b2; (IL-1&#x003b2;), but had no effect on the expression levels of interleukin-8, -10, Toll-like receptor 2 (TLR2) and 4 (TLR-4) [<xref rid="B143-pharmaceutics-12-00688" ref-type="bibr">143</xref>,<xref rid="B144-pharmaceutics-12-00688" ref-type="bibr">144</xref>]. Similarly, the activated CD4+T human lymphocytes that were exposed to CHF5633 exhibited higher transcriptional levels of the anti-inflammatory cytokines, interleukin-4 and -10 [<xref rid="B145-pharmaceutics-12-00688" ref-type="bibr">145</xref>]. </p><p>On another note, it was previously shown that synthetic dimyristoyl phosphatidyl glycerol (DMPG) exerted its anti-inflammatory potential by silencing TLR-signaling in lipopolysaccharide (LPS)-challenged alveolar macrophages [<xref rid="B146-pharmaceutics-12-00688" ref-type="bibr">146</xref>]. Moreover, a mixture of DPPC, egg-phosphatidylglycerol (PG), palmitic acid (PA) and SP-CL16(6-28) (a peptide with anti-inflammatory potential) [<xref rid="B147-pharmaceutics-12-00688" ref-type="bibr">147</xref>] dose-dependently limited interleukin inflammatory mediators in LPS-activated human monocytes [<xref rid="B148-pharmaceutics-12-00688" ref-type="bibr">148</xref>]. </p><p>In addition, another synthetic surfactant, a mixture of recombinant surfactant protein (rSP)-C, palmitoyl-phosphatidyl-glycerol (PPG) and DPPC also inhibited the release of IL-1&#x003b2;, in U937 human lymphoma cells, by interfering with the ATP-mediated inflammasome activation, in a dose-dependent manner. The authors suggested that the active constituent of the surfactant was DPPC, which acted as an antagonist on non-canonical nicotinic acetylcholine receptors in immune cells [<xref rid="B149-pharmaceutics-12-00688" ref-type="bibr">149</xref>]. </p><p>Lastly, synthetic galactose-taurine sodium salt has been shown to exhibit surface active properties by halting the pro-inflammatory response in LPS-activated RAW 264.7 macrophages via: (i) the down-regulation of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression levels as well as (ii) the suppression of the activation of nuclear factor-&#x003ba;&#x00392; (NF-&#x003ba;&#x00392;). As a result, the secretion of the inflammatory mediators IL-1&#x003b2;, IL-6 and TNF-&#x003b1; was reduced [<xref rid="B150-pharmaceutics-12-00688" ref-type="bibr">150</xref>]. </p><p>In vivo studies exploring the anti-inflammatory potential of synthetic SAAs are limited. A protein-free synthetic surfactant prepared from DPPC (i.e., hexadecanol and tyloxapol) exhibited anti-inflammatory properties in rats with LPS-induced lung injury. The surfactant-treated rats showed a lower expression of IL-1&#x003b2;, IL-2, TNF-&#x003b1;, interferon-&#x003b3; (IFN-&#x003b3;), monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1&#x003b2; (MIP-1&#x003b2;) (chemokines that recruit monocytes and activate granulocytes, fibroblasts and macrophages in situ, respectively), when compared to the non-treated (control) ones [<xref rid="B151-pharmaceutics-12-00688" ref-type="bibr">151</xref>]. </p><p>Reports on the anti-inflammatory properties of glycolipid biosurfactants are few, but do suggest potential in applications that exploit these properties. Sophorolipids derived from the yeast of <italic>C. bombicola</italic> reduce the lipopolysaccharide-induced expression of inflammatory cytokines [<xref rid="B152-pharmaceutics-12-00688" ref-type="bibr">152</xref>]. Moreover, SLs display anti-inflammatory effects in in vitro models of allergic conditions by down regulating important genes in IgE production (BSAP (Pax5), TLR-2, STAT3 and IL-6) [<xref rid="B153-pharmaceutics-12-00688" ref-type="bibr">153</xref>]. MELs have also been shown to inhibit the secretion of inflammatory mediators (amines such as histamine and serotonin, leukotrienes and cytokines) from mast cells [<xref rid="B154-pharmaceutics-12-00688" ref-type="bibr">154</xref>]. </p><p><xref ref-type="fig" rid="pharmaceutics-12-00688-f002">Figure 2</xref> summarizes the molecular targets of surfactants with a documented anti-inflammatory potential: </p></sec><sec id="sec7-pharmaceutics-12-00688"><title>7. Anti-Cancer Properties</title><p>Cancer is considered a multistage disease with multifactorial aetiology and is associated with high global incidence and mortality rates. Chemotherapy, surgery and radiation are still the most common treatment options for malignant tumors. However, all of them are associated with adverse-side effects, thus indicating the lack of specificity and the need for discovering new anti-tumor agents from various environmental resources [<xref rid="B155-pharmaceutics-12-00688" ref-type="bibr">155</xref>,<xref rid="B156-pharmaceutics-12-00688" ref-type="bibr">156</xref>,<xref rid="B157-pharmaceutics-12-00688" ref-type="bibr">157</xref>]. To these ends, only recently, several studies have indicated the anti-tumor potential of various different SAAs.</p><p>Benzethonium chloride (BCl) is a synthetic quaternary ammonium salt, characterized as a cationic surfactant and is mainly known for its anti-microbial activities [<xref rid="B158-pharmaceutics-12-00688" ref-type="bibr">158</xref>]. However, according to the National Cancer Institute/NIH Developmental Therapeutics Program (NCI/NIH-DTP), BCl was also found to exhibit significant anti-cancer potential against leukemia, lung, colon, melanoma and ovarian cancers [<xref rid="B159-pharmaceutics-12-00688" ref-type="bibr">159</xref>]. In addition, it induced apoptosis in Jurkat T-lymphoma cells, through the release of cytochrome c and the activation of caspases -3 and -9 [<xref rid="B158-pharmaceutics-12-00688" ref-type="bibr">158</xref>]. In another report, BCl inhibited the proliferative activity of human laryngeal (UMSCC23) and tongue (HN12) squamous carcinoma cells, by inducing a terminal unfolded protein response (UPR), which led to the up-regulation of the transcription factor CCAAT-enhancer-binding protein homologous protein (CHOP) and subsequently to CHOP-dependent apoptosis [<xref rid="B160-pharmaceutics-12-00688" ref-type="bibr">160</xref>]. This compound also exhibited a significant anticancer effect, against FaDu, (hypopharyngeal) and C666-1 (nasopharyngeal) squamous cancer cells. Specifically, in FaDu cells, BCl-induced apoptotic death was related to the activation of caspases -2, -8, -9, -3 and the loss of mitochondrial membrane potential (&#x00394;<italic>&#x003a8;</italic>m). Moreover, itsin vivo anti-cancer effect was accompanied by the inhibition of FaDu xenografts in SCID (severe combined immunodeficient) mice [<xref rid="B159-pharmaceutics-12-00688" ref-type="bibr">159</xref>]. </p><p>Finally, another chemical surfactant, the non-ionic NP-40, caused a cytotoxic effect against SK-N-SH human neuroblastoma cells by promoting apoptosis through: (i) the generation of ROS, (ii) the increase in the Bax:Bcl-2 ratio, (iii) the up-regulation of the p53 expression levels and finally (iv) the release of cytochrome c [<xref rid="B161-pharmaceutics-12-00688" ref-type="bibr">161</xref>]. </p><p>Edelfosine (1-<italic>O</italic>-octadecyl-2-<italic>O</italic>-methyl-<italic>rac</italic>-glycero-3-phosphocholine; ET-18-OCH<sub>3</sub>) is a synthetic surface-active alkyl-lysophospholipid which is also considered as a selective anti-tumor agent [<xref rid="B162-pharmaceutics-12-00688" ref-type="bibr">162</xref>]. In a previous study, edelfosine induced apoptosis through loss of &#x00394;<italic>&#x003a8;</italic>m potential and caspase-3 activation in both Jurkat (T-lymphoid leukemia) and HL-60 (acute leukemia) cells [<xref rid="B163-pharmaceutics-12-00688" ref-type="bibr">163</xref>]. Moreover, it was shown to induce apoptosis in MM144, MMIS, MM1R (human multiple myeloma) and T-lymphoid Jurkat/B-lymphoid JY (leukemia) cells. Specifically, it promoted apoptosis in MM144 multiple myeloma cells via the recruitment of the Fas/CD95 death receptor and TRAIL receptors DR4, DR5. In this way, the recruitment of Bid (a linker molecule between death receptor and mitochondria apoptotic pathways) into lipid rafts (membrane microdomains, enriched in cholesterol, sphingolipids and gangliosides) facilitated the Fas/CD95- and mitochondria-mediated apoptotic death [<xref rid="B164-pharmaceutics-12-00688" ref-type="bibr">164</xref>]. A similar anti-cancer mechanism was reported against Jurkat cells [<xref rid="B165-pharmaceutics-12-00688" ref-type="bibr">165</xref>] and CD138+ malignant cells derived from multiple myeloma patients. [<xref rid="B166-pharmaceutics-12-00688" ref-type="bibr">166</xref>]. Additionally, edelfosine was found to enhance the sensitivity of SNU638 and AGS gastric cancer cells, against recombinant human tumor necrosis factor (TNF)-related apoptosis-inducing ligand (rhTRAIL)-induced apoptosis. The underlying anti-cancer mechanism appears to involve the up-regulation and/or translocation of death receptor 5 (DR5) into lipid rafts and the kinase p38-mediated loss of &#x00394;<italic>&#x003a8;</italic>m [<xref rid="B167-pharmaceutics-12-00688" ref-type="bibr">167</xref>]. Moreover, the compound was shown to induce apoptosis in U118 glioblastoma cells through the activation of caspases-3 and -8 and the disruption of &#x00394;&#x003a8;m, followed by caspase-9 activation [<xref rid="B168-pharmaceutics-12-00688" ref-type="bibr">168</xref>]. In addition, H-ras-transformed human breast epithelial cells (MCF10-<italic>ras</italic>) were also led to apoptosis, following edelfosine treatment, viathe inhibition of ERK1/2 and Akt kinases activity and the reduction of nuclear factor-kappa B (NF-&#x003ba;&#x00392;) expression levels, probably through the induction of a cyclooxygenase-2 (COX-2) expression [<xref rid="B169-pharmaceutics-12-00688" ref-type="bibr">169</xref>]. Likewise, edelfosine was able to induce apoptotic death in another two prostate cancer cell lines, LNCaP and VCap, through the differential regulation of p-AKT and activated transcription factor 3 (ATF3), respectively [two known regulators of androgen receptor (AR) activity]. Moreover, the in vivo anti-tumor activity of edelfosine was confirmed in prostate LNCaP [<xref rid="B170-pharmaceutics-12-00688" ref-type="bibr">170</xref>] and glioma C6 [<xref rid="B171-pharmaceutics-12-00688" ref-type="bibr">171</xref>] xenografts as well. Finally, a recent report indicated an in vitro anti-metastatic capacity of edelfosine, against RT112 muscle-invasive urothelial cancer cells, mediated through the inhibition of the small conductance calcium-activated potassium channel 3 (SK3; a metastasis inducer). Similarly, edelfosine inhibited the invasive ability of RT112-derived tumors, in vivo, using a modified chicken chorioallantoic membrane (CAM) model [<xref rid="B172-pharmaceutics-12-00688" ref-type="bibr">172</xref>]. <xref ref-type="fig" rid="pharmaceutics-12-00688-f003">Figure 3</xref> illustrates suggested the anti-cancer mechanisms activated by the different synthetic surfactants. </p><p>The effect of rhamnolipids on the cancer cell lines HL-60, BV-173, SKW-3, and JMSU-1 has been determined for the C10C10 monorhamnolipid R1, and the corresponding C10C10 dirhamnolipid R2 [<xref rid="B173-pharmaceutics-12-00688" ref-type="bibr">173</xref>]. R1 was the more potent of the two and inhibited cellular division at lower concentrations (IC<sub>50</sub>) than R2. The mechanism of inhibition appeared to be the induction of apoptosis. Rahimi et al. [<xref rid="B174-pharmaceutics-12-00688" ref-type="bibr">174</xref>] confirmed the anti-cancer properties of R1 and R2 (on the MCF7 human breast cancer cells) and the lower IC<sub>50</sub> of R1 (25.87 &#x000b5;g/mL) compared to R2 (31.00 &#x000b5;g/mL). Others have also confirmed the anticancer potential of rhamnolipids [<xref rid="B175-pharmaceutics-12-00688" ref-type="bibr">175</xref>].</p><p>Sophorolipids extracted from the yeast strain <italic>Wickerhamiella domercqiae</italic> Y2A isolated from oil-contaminated wastewater were noticed to present anticancer activity as described by Chen et al. [<xref rid="B176-pharmaceutics-12-00688" ref-type="bibr">176</xref>]. SL was tested against four cancer cell lines, H7402 (liver), A549 (lung), HL60 and K562 (leukaemia) and showed a significant inhibitory effect on cell proliferation on all the tested cell lines. What is more, the authors observed a direct dependence of inhibition on the surfactant&#x02019;s concentration, where 0% cell viability was recorded for the sophorolipid concentration above 62.5 &#x000b5;g mL<sup>&#x02212;1</sup>. A cytotoxic effect of lactonic SLs against breast adenocarcinoma lines MDA-MB-231 was described by Ribeiro et al. [<xref rid="B177-pharmaceutics-12-00688" ref-type="bibr">177</xref>]. Moreover, a correlation between a cytotoxic effect and surfactant&#x02019;s critical micelle concentration CMC was observed, in other words, when the surfactant&#x02019;s concentrations were in the range of its CMC, a higher cytotoxic effect was observed. The authors observed a greater anticancer effect of diacetylated lactonic SLs compared to acidic SLs. Similar conclusions were drawn by Shao et al. [<xref rid="B178-pharmaceutics-12-00688" ref-type="bibr">178</xref>] who tested the effects of ten structurally different SLs on two human oesophageal cancer cell lines, KYSE 109 and KYSE 450. They observed the diacetylated lactonic SL to be the most efficient at inhibiting two oesophageal cancer cell lines, while acidic sophorolipids hardly indicated any anticancer activity. SLs have also shown anticancer activities towards the human cervical cancer cell line HeLa, as presented by Nawale et al. [<xref rid="B179-pharmaceutics-12-00688" ref-type="bibr">179</xref>] and Li et al. [<xref rid="B180-pharmaceutics-12-00688" ref-type="bibr">180</xref>] The latter also presented a relationship between the cytotoxicity of diacetylated lactonic SLs of different unsaturation degrees and their carbon chain length. The longer the chain length, the stronger the cytotoxicity of SLs observed. Apart from the aforementioned anticancer activities towards breast, cervical, lung, liver and oesophageal cancer, SLs were also found to show cytotoxic properties against human pancreatic cancer cell lines [<xref rid="B181-pharmaceutics-12-00688" ref-type="bibr">181</xref>] and glioma cell line LN-229 [<xref rid="B182-pharmaceutics-12-00688" ref-type="bibr">182</xref>].</p><p>There are numerous reports on the anti-tumour activity of MELs against various cancer types. In some, the successful treatment was related to the MEL-containing liposomes as summarised by Silva Coelho et al. [<xref rid="B183-pharmaceutics-12-00688" ref-type="bibr">183</xref>]. The anticancer effect of MEL-A and MEL-B on human leukaemia HL-60 cell lines was reported by Isoda et al. [<xref rid="B184-pharmaceutics-12-00688" ref-type="bibr">184</xref>] The surfactants were also found to inhibit the insulin-dependent proliferation of human myelogenous leukaemia cell line K562 through the inhibition of the tyrosine phosphorylation [<xref rid="B185-pharmaceutics-12-00688" ref-type="bibr">185</xref>,<xref rid="B186-pharmaceutics-12-00688" ref-type="bibr">186</xref>]. Zhao et al. [<xref rid="B187-pharmaceutics-12-00688" ref-type="bibr">187</xref>] reported an induction of apoptosis by MELs against mouse melanoma B16 cell lines. The authors [<xref rid="B188-pharmaceutics-12-00688" ref-type="bibr">188</xref>] later showed a MEL-induced differentiation of melanoma B16 cells takes place through a pathway involving protein kinase C&#x003b1; (PKC&#x003b1;). In their latest studies, Bakur et al. [<xref rid="B189-pharmaceutics-12-00688" ref-type="bibr">189</xref>,<xref rid="B190-pharmaceutics-12-00688" ref-type="bibr">190</xref>] presented the use of MELs for synthesizing gold nanoparticles (Au-NPs) and assessed the MEL-AuNPs properties. Based on their findings, the newly synthesized nanoparticles showed potential cytotoxic activity against human liver hepatoma HepG2 cells. Furthermore, the authors evaluated other MEL-containing nanocomposites, MEL@ZnONPs and Ag&#x02013;ZnO/MEL/GA, for their cytotoxic activity against HepG2, and observed a decrease in the viability of cells with increasing concentrations of the nanocomposites.</p></sec><sec id="sec8-pharmaceutics-12-00688"><title>8. Anti-Aging Properties</title><p>Aging is generally considered a complex, multifactorial and time-dependent process that is strictly related to morbidity and mortality among humans [<xref rid="B191-pharmaceutics-12-00688" ref-type="bibr">191</xref>]. Specifically, aging is characterized by a significant decline/deterioration of physiological and anatomical functions at the molecular, cellular and tissue levels [<xref rid="B192-pharmaceutics-12-00688" ref-type="bibr">192</xref>], leading to the impairment of homeostasis and ultimately to death [<xref rid="B193-pharmaceutics-12-00688" ref-type="bibr">193</xref>]. At the cellular level, several mechanisms have been associated with the aging process including: (i) increased levels of oxidative stress, (ii) the dysfunction of the mitochondrial machinery, (iii) telomere attrition and finally (iv) the impairment of DNA repair mechanism [<xref rid="B194-pharmaceutics-12-00688" ref-type="bibr">194</xref>,<xref rid="B195-pharmaceutics-12-00688" ref-type="bibr">195</xref>,<xref rid="B196-pharmaceutics-12-00688" ref-type="bibr">196</xref>], all of which have been correlated to the onset of different age-related diseases such as cancer, diabetes, cardiovascular disorders and neurodegenerative diseases [<xref rid="B197-pharmaceutics-12-00688" ref-type="bibr">197</xref>,<xref rid="B198-pharmaceutics-12-00688" ref-type="bibr">198</xref>,<xref rid="B199-pharmaceutics-12-00688" ref-type="bibr">199</xref>].</p><p>In general, the skin aging process is caused by both intrinsic (chronological aging) and extrinsic factors. It is a rather complex process that is associated with the gradual loss of skin integrity as well as stability, and the decline of its physiological function [<xref rid="B200-pharmaceutics-12-00688" ref-type="bibr">200</xref>,<xref rid="B201-pharmaceutics-12-00688" ref-type="bibr">201</xref>,<xref rid="B202-pharmaceutics-12-00688" ref-type="bibr">202</xref>,<xref rid="B203-pharmaceutics-12-00688" ref-type="bibr">203</xref>]. Its clinical manifestations include alterations of pigmentation/elasticity and the appearance of wrinkles and dryness, among others [<xref rid="B204-pharmaceutics-12-00688" ref-type="bibr">204</xref>,<xref rid="B205-pharmaceutics-12-00688" ref-type="bibr">205</xref>,<xref rid="B206-pharmaceutics-12-00688" ref-type="bibr">206</xref>]. Specifically, among various environmental (extrinsic) causing factors, exposure to UV radiation is considered as the most prominent one. In addition, extrinsic skin aging is also referred as to photo-aging which further depends on the frequency, duration and intensity of exposure to sunlight [<xref rid="B207-pharmaceutics-12-00688" ref-type="bibr">207</xref>]. UV-induced photo-aging is mainly mediated by the up-regulation of several matrix metalloproteinases [MMPs; responsible for the degradation of the extracellular matrix (ECM) components] such as collagen, fibronectin and elastin, that in turn, support the skin architecture at a structural and functional level [<xref rid="B208-pharmaceutics-12-00688" ref-type="bibr">208</xref>,<xref rid="B209-pharmaceutics-12-00688" ref-type="bibr">209</xref>]. In addition, the reduced expression levels of the tissue inhibitor of metalloproteinases (TIMPs) as well as the altered activity of UV-induced ROS, MAPKs and transcription factors [e.g., nuclear factor &#x003ba;B (NF-&#x003ba;&#x00392;) and activator protein 1 (AP-1)] appear as major mediators of the photoaging process [<xref rid="B210-pharmaceutics-12-00688" ref-type="bibr">210</xref>,<xref rid="B211-pharmaceutics-12-00688" ref-type="bibr">211</xref>,<xref rid="B212-pharmaceutics-12-00688" ref-type="bibr">212</xref>]. In this context, anti-aging and anti-photoaging skin products dominate the cosmetic and/or cosmeceutical industry, reflecting the high demand for developing new and more effective products with such functionality [<xref rid="B213-pharmaceutics-12-00688" ref-type="bibr">213</xref>,<xref rid="B214-pharmaceutics-12-00688" ref-type="bibr">214</xref>]. Interestingly, a variety of scientific reports indicate the ability of SAAs as potential molecules capable of preventing and/or ameliorating the symptoms of aging and/or photoaging processes, in different experimental models.</p><p>Different studies have shown the protective activity of synthetic biosurfactants against UV-induced damage by utilizing both in vitro and in vivo experimental models. For instance, chitooligosaccharides (COS; water-soluble derivatives of chitin or chitosan) obtained through chemical or enzymatic hydrolysis [<xref rid="B215-pharmaceutics-12-00688" ref-type="bibr">215</xref>], exerted a significant protective role against UV-irradiated human dermal fibroblasts (HDF). Specifically, 3-5kDa COS were shown to absorb both UV-A and UV-B light, indicating a protective effect against skin photo-damage. At the molecular level, COS inhibited the expression of various MMPs including MMPs-1, -8 and -13 collagenases and MMPs-2 and -9 gelatinases, an effect accompanied by the induction of their negative regulators TIMP-1 and -2. Moreover, COS-treated HDF cells showed an increased expression of different pro-procollagen members, such as I, III and IV, through the negative regulation of the AP-1 signaling pathway members, like c-Jun and c-Fos [<xref rid="B216-pharmaceutics-12-00688" ref-type="bibr">216</xref>]. Similarly, COS exhibited significant photo-protective activity against UV-induced damage in hairless mouse dorsal skin. Following the topical application of COS, an improvement of UV-induced damages of the skin (at the macroscopic and histopathological levels) were documented and shown to be mediated by the increased levels of total collagen as well as collagen I. Moreover, the increased levels of various anti-oxidant enzymes like catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), together with reduced levels of pro-inflammatory cytokines (e.g., TNF-a, IL-1&#x000df; and IL-6), contributed to the photo-protective effect of COS [<xref rid="B217-pharmaceutics-12-00688" ref-type="bibr">217</xref>]. Such results suggest that COS could be used as potential cosmetic agents against the impairment of collagen synthesis in photo-damaged skin. </p><p>Furthermore, a synthetic complex consisting of &#x003ba;-carrageenan and collagen peptides (CP) (&#x003ba;-ca3000 + CP) inhibited UV-induced apoptotic death in HaCaT and MEF cells by (i) blocking the activation of the MAPK signaling pathway, (ii) reducing the MMP-1 expression and (iii) inhibiting ROS production, thus resulting in increased levels of collagen I synthesis [<xref rid="B105-pharmaceutics-12-00688" ref-type="bibr">105</xref>].</p><p>Over the years, the prevention of aging has attracted significant interest among the scientific community. On the other hand, the increased production of ROS has been identified as one of the most prominent determinants of aging, affecting cellular anti-oxidant defense systems and favoring pro-inflammatory and immune dysfunction [<xref rid="B218-pharmaceutics-12-00688" ref-type="bibr">218</xref>,<xref rid="B219-pharmaceutics-12-00688" ref-type="bibr">219</xref>]. To this end, the development and use of anti-oxidant and anti-inflammatory agents appear as a promising strategy against aging and age-related diseases. Interestingly, COS exert significant in vivo anti-aging activity against D-gal induced subacute aging mice by (i) blocking the impairment of kidney and liver functions, (ii) partially mediating an improvement of the anti-oxidant activity (by the means of the increased expression of CAT, GSH-Px, SOD) and furthermore (iii) enhancing the immune function (by the means of an increased expression of serum immunoglobulins IgG and/or IgM) [<xref rid="B220-pharmaceutics-12-00688" ref-type="bibr">220</xref>]. </p><p>Glycolipid biosurfactants have been reported to have potential anti-aging properties that could be exploited in cosmetic formulations. The focus of this research has been on MELs, although any glycolipid displaying anti-oxidant or anti-inflammatory properties has anti-aging potential, with rhamnolipids as the subject of patents for anti-wrinkle and anti-aging products [<xref rid="B221-pharmaceutics-12-00688" ref-type="bibr">221</xref>]. MELs have moisturizing properties comparable to natural skins ceramides [<xref rid="B222-pharmaceutics-12-00688" ref-type="bibr">222</xref>,<xref rid="B223-pharmaceutics-12-00688" ref-type="bibr">223</xref>]. Moreover, the ability of MELs to protect skin cells against oxidative stress [<xref rid="B110-pharmaceutics-12-00688" ref-type="bibr">110</xref>], a property believed to arise from the unsaturated fatty acid chains in MELs, also strongly suggests potential as an anti-aging ingredient.</p><p><xref rid="pharmaceutics-12-00688-t004" ref-type="table">Table 4</xref> summarizes the known SAAs with documented anti-aging/photoaging activity including the suggested mechanism(s) of action:</p></sec><sec sec-type="conclusions" id="sec9-pharmaceutics-12-00688"><title>9. Conclusions</title><p>SAAs are molecules of multifunctional significance given their widespread use in almost every major industrial sector producing consumer products, aiming to optimize their utilization in accordance to their beneficial properties. To this end, SAAs are characterized in the context of their health-promoting properties, while the scientific interest keeps on growing in an attempt to shed light on the underlying molecular mechanism(s) by which they exert such properties. This is of utmost importance as it provides a valid rationale for the selection of better chemical derivatives with enhanced functionality. In this respect, biosurfactants have excellent promise as the replacers of synthetic SAAs as they would find favor with consumers due to their perceived naturalness, lower toxicity and ecotoxicity, higher biodegradability and excellent surface active properties. However, the study of their bioactive properties is relatively new and before they can fully replace synthetic SAAs in bioactive applications, more work is required to fully understand the mechanisms and extent of their efficacy in health-promoting activities.</p></sec></body><back><notes><title>Author Contributions</title><p>Conceptualization, A.P. and M.I.P.; writing&#x02014;original draft preparation, I.A., D.E.K., A.K., K.S., A.G., S.R.E., A.P. and M.I.P.; writing&#x02014;review and editing, I.A., S.R.E., A.P. and M.I.P.; supervision, A.P. and M.I.P.; project administration, A.P. and M.I.P.; funding acquisition, A.G., S.R.E., A.P. and M.I.P. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research and the APC were funded by the European Union Framework Programme for Research and Innovation, Horizon 2020, under Grant Agreement No. 635340 MARISURF.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-12-00688"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schramm</surname><given-names>L.L.</given-names></name><name><surname>Stasiuk</surname><given-names>E.N.</given-names></name><name><surname>Marangoni</surname><given-names>D.G.</given-names></name></person-group><article-title>Surfactants and their applications</article-title><source>Annu. Rep. Prog. Chem. Sect. C Phys.</source><year>2003</year><volume>99</volume><fpage>3</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1039/B208499F</pub-id></element-citation></ref><ref id="B2-pharmaceutics-12-00688"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>J.N.</given-names></name><name><surname>Lyngs&#x000f8;</surname><given-names>J.</given-names></name><name><surname>Zinn</surname><given-names>T.</given-names></name><name><surname>Otzen</surname><given-names>D.E.</given-names></name><name><surname>Pedersen</surname><given-names>J.S.</given-names></name></person-group><article-title>A complete picture of protein unfolding and refolding in surfactants</article-title><source>Chem. Sci.</source><year>2020</year><volume>11</volume><fpage>699</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1039/C9SC04831F</pub-id></element-citation></ref><ref id="B3-pharmaceutics-12-00688"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otzen</surname><given-names>D.E.</given-names></name></person-group><article-title>Biosurfactants and surfactants interacting with membranes and proteins: Same but different?</article-title><source>Biochim. Biophys. Acta-Biomembr.</source><year>2017</year><volume>1859</volume><fpage>639</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2016.09.024</pub-id><?supplied-pmid 27693345?><pub-id pub-id-type="pmid">27693345</pub-id></element-citation></ref><ref id="B4-pharmaceutics-12-00688"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sa&#x00142;ek</surname><given-names>K.</given-names></name><name><surname>Euston</surname><given-names>S.R.</given-names></name></person-group><article-title>Sustainable microbial biosurfactants and bioemulsifiers for commercial exploitation</article-title><source>Process Biochem.</source><year>2019</year><volume>85</volume><fpage>143</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/j.procbio.2019.06.027</pub-id></element-citation></ref><ref id="B5-pharmaceutics-12-00688"><label>5.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hasenhuettl</surname><given-names>G.L.</given-names></name></person-group><article-title>Synthesis and commercial preparation of food emulsifiers</article-title><source>Food Emulsifiers and Their Applications</source><edition>3rd ed.</edition><person-group person-group-type="editor"><name><surname>Hasenhuettl</surname><given-names>G.L.</given-names></name><name><surname>Hartel</surname><given-names>R.</given-names></name></person-group><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2019</year><fpage>11</fpage><lpage>39</lpage></element-citation></ref><ref id="B6-pharmaceutics-12-00688"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>B.G.</given-names></name><name><surname>Schellevis</surname><given-names>F.</given-names></name><name><surname>Stobberingh</surname><given-names>E.</given-names></name><name><surname>Goossens</surname><given-names>H.</given-names></name><name><surname>Pringle</surname><given-names>M.</given-names></name></person-group><article-title>A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance</article-title><source>BMC Infect. Dis.</source><year>2014</year><volume>14</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2334-14-13</pub-id><pub-id pub-id-type="pmid">24405683</pub-id></element-citation></ref><ref id="B7-pharmaceutics-12-00688"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000f8;iby</surname><given-names>N.</given-names></name><name><surname>Bjarnsholt</surname><given-names>T.</given-names></name><name><surname>Givskov</surname><given-names>M.</given-names></name><name><surname>Molin</surname><given-names>S.</given-names></name><name><surname>Ciofu</surname><given-names>O.</given-names></name></person-group><article-title>Antibiotic resistance of bacterial biofilms</article-title><source>Int. J. Antimicrob. Agents</source><year>2010</year><volume>35</volume><fpage>322</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2009.12.011</pub-id><pub-id pub-id-type="pmid">20149602</pub-id></element-citation></ref><ref id="B8-pharmaceutics-12-00688"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Qiao</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Hou</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Fan</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Selective Antimicrobial Activities and Action Mechanism of Micelles Self-Assembled by Cationic Oligomeric Surfactants</article-title><source>ACS Appl. Mater Interfaces</source><year>2016</year><volume>8</volume><fpage>4242</fpage><lpage>4249</lpage><pub-id pub-id-type="doi">10.1021/acsami.5b12688</pub-id><pub-id pub-id-type="pmid">26820390</pub-id></element-citation></ref><ref id="B9-pharmaceutics-12-00688"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaban</surname><given-names>S.M.</given-names></name><name><surname>Abd-Elaal</surname><given-names>A.A.</given-names></name></person-group><article-title>Studying the silver nanoparticles influence on thermodynamic behavior and antimicrobial activities of novel amide Gemini cationic surfactants</article-title><source>Mater. Sci. Eng. C Mater. Biol. Appl.</source><year>2017</year><volume>76</volume><fpage>871</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1016/j.msec.2017.03.185</pub-id><pub-id pub-id-type="pmid">28482602</pub-id></element-citation></ref><ref id="B10-pharmaceutics-12-00688"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kashapov</surname><given-names>R.R.</given-names></name><name><surname>Razuvayeva</surname><given-names>Y.S.</given-names></name><name><surname>Ziganshina</surname><given-names>A.Y.</given-names></name><name><surname>Mukhitova</surname><given-names>R.K.</given-names></name><name><surname>Sapunova</surname><given-names>A.S.</given-names></name><name><surname>Voloshina</surname><given-names>A.D.</given-names></name><name><surname>Zakharova</surname><given-names>L.Y.</given-names></name></person-group><article-title>Self-assembling and biological properties of single-chain dicationic pyridinium-based surfactants</article-title><source>Colloids Surf. B Biointerfaces</source><year>2019</year><volume>175</volume><fpage>351</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2018.12.010</pub-id><pub-id pub-id-type="pmid">30554013</pub-id></element-citation></ref><ref id="B11-pharmaceutics-12-00688"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colomer</surname><given-names>A.</given-names></name><name><surname>Pinazo</surname><given-names>A.</given-names></name><name><surname>Manresa</surname><given-names>M.A.</given-names></name><name><surname>Vinardell</surname><given-names>M.P.</given-names></name><name><surname>Mitjans</surname><given-names>M.</given-names></name><name><surname>Infante</surname><given-names>M.R.</given-names></name><name><surname>P&#x000e9;rez</surname><given-names>L.</given-names></name></person-group><article-title>Cationic surfactants derived from lysine: Effects of their structure and charge type on antimicrobial and hemolytic activities</article-title><source>J. Med. Chem.</source><year>2011</year><volume>54</volume><fpage>989</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1021/jm101315k</pub-id><pub-id pub-id-type="pmid">21229984</pub-id></element-citation></ref><ref id="B12-pharmaceutics-12-00688"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perinelli</surname><given-names>D.R.</given-names></name><name><surname>Petrelli</surname><given-names>D.</given-names></name><name><surname>Vitali</surname><given-names>L.A.</given-names></name><name><surname>Bonacucina</surname><given-names>G.</given-names></name><name><surname>Cespi</surname><given-names>M.</given-names></name><name><surname>Vllasaliu</surname><given-names>D.</given-names></name><name><surname>Giorgioni</surname><given-names>G.</given-names></name><name><surname>Palmieri</surname><given-names>G.F.</given-names></name></person-group><article-title>Quaternary Ammonium Leucine-Based Surfactants: The Effect of a Benzyl Group on Physicochemical Properties and Antimicrobial Activity</article-title><source>Pharmaceutics</source><year>2019</year><volume>11</volume><elocation-id>287</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics11060287</pub-id><?supplied-pmid 31248093?><pub-id pub-id-type="pmid">31248093</pub-id></element-citation></ref><ref id="B13-pharmaceutics-12-00688"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>M.F.</given-names></name><name><surname>Zepeda-Velazquez</surname><given-names>L.</given-names></name><name><surname>Brook</surname><given-names>M.A.</given-names></name></person-group><article-title>Tunable, antibacterial activity of silicone polyether surfactants</article-title><source>Colloids Surf. B Biointerfaces</source><year>2015</year><volume>132</volume><fpage>216</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2015.05.016</pub-id><pub-id pub-id-type="pmid">26057244</pub-id></element-citation></ref><ref id="B14-pharmaceutics-12-00688"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinazo</surname><given-names>A.</given-names></name><name><surname>Petrizelli</surname><given-names>V.</given-names></name><name><surname>Bustelo</surname><given-names>M.</given-names></name><name><surname>Pons</surname><given-names>R.</given-names></name><name><surname>Vinardell</surname><given-names>M.P.</given-names></name><name><surname>Mitjans</surname><given-names>M.</given-names></name><name><surname>Manresa</surname><given-names>A.</given-names></name><name><surname>Perez</surname><given-names>L.</given-names></name></person-group><article-title>New cationic vescicles prepared with double chain surfactants from arginine: Role of the hydrophobic group on the antimicrobial activity and cytotoxicity</article-title><source>Colloids Surf. B Biointerfaces</source><year>2016</year><volume>141</volume><fpage>19</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2016.01.020</pub-id><?supplied-pmid 26820106?><pub-id pub-id-type="pmid">26820106</pub-id></element-citation></ref><ref id="B15-pharmaceutics-12-00688"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>R.</given-names></name><name><surname>Shibata</surname><given-names>M.</given-names></name><name><surname>Koeda</surname><given-names>S.</given-names></name><name><surname>Miyagawa</surname><given-names>A.</given-names></name><name><surname>Yamamura</surname><given-names>H.</given-names></name><name><surname>Mizuno</surname><given-names>T.</given-names></name></person-group><article-title>Development of New Antimicrobial Agents from Cationic PG-surfactants containing oligo-Lys peptides</article-title><source>Bioconjug. Chem.</source><year>2018</year><volume>29</volume><fpage>4072</fpage><lpage>4082</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.8b00693</pub-id><pub-id pub-id-type="pmid">30354128</pub-id></element-citation></ref><ref id="B16-pharmaceutics-12-00688"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x000ed;az De Rienzo</surname><given-names>M.A.</given-names></name><name><surname>Stevenson</surname><given-names>P.</given-names></name><name><surname>Marchant</surname><given-names>R.</given-names></name><name><surname>Banat</surname><given-names>I.M.</given-names></name></person-group><article-title>Antibacterial properties of biosurfactants against selected Gram-positive and-negative bacteria</article-title><source>FEMS Microbiol. Lett.</source><year>2016</year><volume>363</volume><fpage>fnv224</fpage><pub-id pub-id-type="doi">10.1093/femsle/fnv224</pub-id><pub-id pub-id-type="pmid">26598715</pub-id></element-citation></ref><ref id="B17-pharmaceutics-12-00688"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yal&#x000e7;in</surname><given-names>E.</given-names></name><name><surname>Ergene</surname><given-names>A.</given-names></name></person-group><article-title>Screening the antimicrobial activity of biosurfactants produced by microorganisms isolated from refinery wastewaters</article-title><source>J. Appl. Biol. Sci.</source><year>2009</year><volume>3</volume><fpage>163</fpage><lpage>168</lpage></element-citation></ref><ref id="B18-pharmaceutics-12-00688"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Freitas Ferreira</surname><given-names>J.</given-names></name><name><surname>Vieira</surname><given-names>E.A.</given-names></name><name><surname>Nitschke</surname><given-names>M.</given-names></name></person-group><article-title>The antibacterial activity of rhamnolipid biosurfactant is pH dependent</article-title><source>Food Res. Int.</source><year>2019</year><volume>116</volume><fpage>737</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1016/j.foodres.2018.09.005</pub-id><?supplied-pmid 30717003?><pub-id pub-id-type="pmid">30717003</pub-id></element-citation></ref><ref id="B19-pharmaceutics-12-00688"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magalh&#x000e3;es</surname><given-names>L.</given-names></name><name><surname>Nitschke</surname><given-names>M.</given-names></name></person-group><article-title>Antimicrobial activity of rhamnolipids against Listeria monocytogenes and their synergistic interaction with nisin</article-title><source>Food Control</source><year>2013</year><volume>29</volume><fpage>138</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/j.foodcont.2012.06.009</pub-id></element-citation></ref><ref id="B20-pharmaceutics-12-00688"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elshikh</surname><given-names>M.</given-names></name><name><surname>Moya-Ram&#x000ed;rez</surname><given-names>I.</given-names></name><name><surname>Moens</surname><given-names>H.</given-names></name><name><surname>Roelants</surname><given-names>S.L.K.W.</given-names></name><name><surname>Soetaert</surname><given-names>W.</given-names></name><name><surname>Marchant</surname><given-names>R.</given-names></name><name><surname>Banat</surname><given-names>I.M.</given-names></name></person-group><article-title>Rhamnolipids and lactonic sophorolipids: Natural antimicrobial surfactants for oral hygiene</article-title><source>J. Appl. Microbiol.</source><year>2017</year><volume>123</volume><fpage>1111</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1111/jam.13550</pub-id><pub-id pub-id-type="pmid">28766815</pub-id></element-citation></ref><ref id="B21-pharmaceutics-12-00688"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silveira</surname><given-names>V.A.I.</given-names></name><name><surname>Freitas</surname><given-names>C.A.U.Q.</given-names></name><name><surname>Celligoi</surname><given-names>M.A.P.C.</given-names></name></person-group><article-title>Antimicrobial applications of sophorolipid from Candida bombicola: A promising alternative to conventional drugs</article-title><source>J. Appl. Biol. Biotechnol.</source><year>2018</year><volume>6</volume><fpage>87</fpage><lpage>90</lpage></element-citation></ref><ref id="B22-pharmaceutics-12-00688"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Rienzo</surname><given-names>M.A.D.</given-names></name><name><surname>Banat</surname><given-names>I.M.</given-names></name><name><surname>Dolman</surname><given-names>B.</given-names></name><name><surname>Winterburn</surname><given-names>J.</given-names></name><name><surname>Martin</surname><given-names>P.J.</given-names></name></person-group><article-title>Sophorolipid biosurfactants: Possible uses as antibacterial and antibiofilm agent</article-title><source>New Biotechnol.</source><year>2015</year><volume>32</volume><fpage>720</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1016/j.nbt.2015.02.009</pub-id><?supplied-pmid 25738966?><pub-id pub-id-type="pmid">25738966</pub-id></element-citation></ref><ref id="B23-pharmaceutics-12-00688"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceresa</surname><given-names>C.</given-names></name><name><surname>Fracchia</surname><given-names>L.</given-names></name><name><surname>Williams</surname><given-names>M.</given-names></name><name><surname>Banat</surname><given-names>I.M.</given-names></name><name><surname>De Rienzo</surname><given-names>M.D.</given-names></name></person-group><article-title>The effect of sophorolipids against microbial biofilms on medical-grade silicone</article-title><source>J. Biotechnol.</source><year>2020</year><volume>309</volume><fpage>34</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2019.12.019</pub-id><pub-id pub-id-type="pmid">31887325</pub-id></element-citation></ref><ref id="B24-pharmaceutics-12-00688"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valotteau</surname><given-names>C.</given-names></name><name><surname>Banat</surname><given-names>I.M.</given-names></name><name><surname>Mitchell</surname><given-names>C.A.</given-names></name><name><surname>Lydon</surname><given-names>H.</given-names></name><name><surname>Marchant</surname><given-names>R.</given-names></name><name><surname>Babonneau</surname><given-names>F.</given-names></name><name><surname>Pradier</surname><given-names>C.M.</given-names></name><name><surname>Baccile</surname><given-names>N.</given-names></name><name><surname>Humblot</surname><given-names>V.</given-names></name></person-group><article-title>Antibacterial properties of sophorolipid modified gold surfaces against Gram positive and Gram negative pathogens</article-title><source>Colloid Surf. B</source><year>2017</year><volume>157</volume><fpage>325</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2017.05.072</pub-id><?supplied-pmid 28609707?><pub-id pub-id-type="pmid">28609707</pub-id></element-citation></ref><ref id="B25-pharmaceutics-12-00688"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valotteau</surname><given-names>C.</given-names></name><name><surname>Baccile</surname><given-names>N.</given-names></name><name><surname>Humblot</surname><given-names>V.</given-names></name><name><surname>Roelants</surname><given-names>S.</given-names></name><name><surname>Soetaert</surname><given-names>W.</given-names></name><name><surname>Stevens</surname><given-names>C.V.</given-names></name><name><surname>Dufr&#x000ea;ne</surname><given-names>Y.F.</given-names></name></person-group><article-title>Nanoscale antiadhesion properties of sophorolipid-coated surfaces against pathogenic bacteria</article-title><source>Nanoscale Horizons</source><year>2019</year><volume>4</volume><fpage>17</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1039/C9NH00006B</pub-id></element-citation></ref><ref id="B26-pharmaceutics-12-00688"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shu</surname><given-names>Q.</given-names></name><name><surname>Niu</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name></person-group><article-title>Antibacterial activity and mannosylerythritol lipids against vegetative cells and spores of Bacillus cereus</article-title><source>Food Control</source><year>2019</year><volume>106</volume><fpage>106711</fpage><pub-id pub-id-type="doi">10.1016/j.foodcont.2019.106711</pub-id></element-citation></ref><ref id="B27-pharmaceutics-12-00688"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceresa</surname><given-names>C.</given-names></name><name><surname>Hutton</surname><given-names>S.</given-names></name><name><surname>Lajarin-Cuesta</surname><given-names>M.</given-names></name><name><surname>Heaton</surname><given-names>R.</given-names></name><name><surname>Hargreaves</surname><given-names>I.</given-names></name><name><surname>Fracchia</surname><given-names>L.</given-names></name><name><surname>De Rienzo</surname><given-names>M.A.D.</given-names></name></person-group><article-title>Production of Mannosylerythritol Lipids (MELs) to be Used as Antimicrobial Agents Against S. aureus ATCC 6538</article-title><source>Curr. Microbiol.</source><year>2020</year><volume>77</volume><fpage>1373</fpage><lpage>1380</lpage><pub-id pub-id-type="doi">10.1007/s00284-020-01927-2</pub-id><pub-id pub-id-type="pmid">32123984</pub-id></element-citation></ref><ref id="B28-pharmaceutics-12-00688"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janek</surname><given-names>T.</given-names></name><name><surname>Krasowska</surname><given-names>A.</given-names></name><name><surname>Czy&#x0017c;nikowska</surname><given-names>&#x0017b;.</given-names></name><name><surname>&#x00141;ukaszewicz</surname><given-names>M.</given-names></name></person-group><article-title>Trehalose Lipid Biosurfactant Reduces Adhesion of Microbial Pathogens to Polystyrene and Silicone Surfaces: An Experimental and Computational Approach</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><fpage>2441</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.02441</pub-id><pub-id pub-id-type="pmid">30386313</pub-id></element-citation></ref><ref id="B29-pharmaceutics-12-00688"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez-Melc&#x000f3;n</surname><given-names>C.</given-names></name><name><surname>Riesco-Pel&#x000e1;ez</surname><given-names>F.</given-names></name><name><surname>Garc&#x000ed;a-Fern&#x000e1;ndez</surname><given-names>C.</given-names></name><name><surname>Alonso-Calleja</surname><given-names>C.</given-names></name><name><surname>Capita</surname><given-names>R.</given-names></name></person-group><article-title>Susceptibility of Listeria monocytogenesplanktonic cultures and biofilms to sodiumhypochlorite and benzalkoniumchloride</article-title><source>Food Microbiol.</source><year>2019</year><volume>82</volume><fpage>533</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1016/j.fm.2019.03.020</pub-id><pub-id pub-id-type="pmid">31027816</pub-id></element-citation></ref><ref id="B30-pharmaceutics-12-00688"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y.S.</given-names></name><name><surname>Lee</surname><given-names>Y.S.</given-names></name></person-group><article-title>Effect of Sub Minimal Inhibitory Concentration Cetylpyridinium Chloride on Biofilm Formation and Hydropyobicity of Streptococci and Actinomycetes</article-title><source>J. Adv. Microbiol.</source><year>2018</year><volume>9</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.9734/JAMB/2018/39738</pub-id></element-citation></ref><ref id="B31-pharmaceutics-12-00688"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramalingam</surname><given-names>K.</given-names></name><name><surname>Amaechi</surname><given-names>B.T.</given-names></name><name><surname>Ralph</surname><given-names>R.H.</given-names></name><name><surname>Lee</surname><given-names>V.A.</given-names></name></person-group><article-title>Antimicrobial activity of nanoemulsion on cariogenic planktonic and biofilm organisms</article-title><source>Arch. Oral Biol.</source><year>2012</year><volume>57</volume><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.archoralbio.2011.07.001</pub-id><pub-id pub-id-type="pmid">21807359</pub-id></element-citation></ref><ref id="B32-pharmaceutics-12-00688"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>C.</given-names></name><name><surname>Hattori</surname><given-names>Y.</given-names></name><name><surname>Yagi</surname><given-names>S.</given-names></name><name><surname>Murai</surname><given-names>T.</given-names></name><name><surname>Takai</surname><given-names>C.</given-names></name><name><surname>Ogawa</surname><given-names>N.</given-names></name><name><surname>Tanemura</surname><given-names>M.</given-names></name><name><surname>Fuji</surname><given-names>M.</given-names></name><name><surname>Kawashima</surname><given-names>Y.</given-names></name><name><surname>Yamamoto</surname><given-names>H.</given-names></name></person-group><article-title>Optimization of ionic liquid-incorporated PLGA nanoparticles for treatment of biofilm infections</article-title><source>Mater. Sci. Eng. C Mater. Biol. Appl.</source><year>2019</year><volume>97</volume><fpage>78</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.msec.2018.11.079</pub-id><pub-id pub-id-type="pmid">30678968</pub-id></element-citation></ref><ref id="B33-pharmaceutics-12-00688"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz</surname><given-names>A.</given-names></name><name><surname>Pinazo</surname><given-names>A.</given-names></name><name><surname>P&#x000e9;rez</surname><given-names>L.</given-names></name><name><surname>Manresa</surname><given-names>A.</given-names></name><name><surname>Marqu&#x000e9;s</surname><given-names>A.M.</given-names></name></person-group><article-title>Green Catanionic Gemini Surfactant-Lichenysin Mixture: Improved Surface, Antimicrobial, and Physiological Properties</article-title><source>ACS Appl. Mater Interfaces</source><year>2017</year><volume>9</volume><fpage>22121</fpage><lpage>22131</lpage><pub-id pub-id-type="doi">10.1021/acsami.7b03348</pub-id><?supplied-pmid 28636319?><pub-id pub-id-type="pmid">28636319</pub-id></element-citation></ref><ref id="B34-pharmaceutics-12-00688"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ob&#x00142;&#x00105;k</surname><given-names>E.</given-names></name><name><surname>Piecuch</surname><given-names>A.</given-names></name><name><surname>Dworniczek</surname><given-names>E.</given-names></name><name><surname>Olejniczak</surname><given-names>T.</given-names></name></person-group><article-title>The influence of biodegradable gemini surfactants, N,N&#x02019;-bis(1-decyloxy-1-oxopronan-2-yl)-N,N,N&#x02019;,N&#x02019; tetramethylpropane-1,3-diammonium dibromide and N,N&#x02019;-bis(1-dodecyloxy-1-oxopronan-2-yl) N,N,N&#x02019;,N&#x02019;-tetramethylethane-1,2-diammonium dibromide, on fungal biofilm and adhesion</article-title><source>J. Oleo Sci.</source><year>2015</year><volume>64</volume><fpage>527</fpage><lpage>537</lpage><?supplied-pmid 25843277?><pub-id pub-id-type="pmid">25843277</pub-id></element-citation></ref><ref id="B35-pharmaceutics-12-00688"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>E Silva</surname><given-names>S.S.</given-names></name><name><surname>Carvalho</surname><given-names>J.W.P.</given-names></name><name><surname>Aires</surname><given-names>C.P.</given-names></name><name><surname>Nitschke</surname><given-names>M.</given-names></name></person-group><article-title>Disruption of Staphylococcus aureus biofilms using rhamnolipid biosurfactants</article-title><source>J. Dairy Sci.</source><year>2017</year><volume>100</volume><fpage>7864</fpage><lpage>7873</lpage><pub-id pub-id-type="doi">10.3168/jds.2017-13012</pub-id><?supplied-pmid 28822551?><pub-id pub-id-type="pmid">28822551</pub-id></element-citation></ref><ref id="B36-pharmaceutics-12-00688"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aleksic</surname><given-names>I.</given-names></name><name><surname>Petkovic</surname><given-names>M.</given-names></name><name><surname>Jovanovic</surname><given-names>M.</given-names></name><name><surname>Milivojevic</surname><given-names>D.</given-names></name><name><surname>Vasiljevic</surname><given-names>B.</given-names></name><name><surname>Nikodinovic-Runic</surname><given-names>J.</given-names></name><name><surname>Senerovic</surname><given-names>L.</given-names></name></person-group><article-title>Anti-biofilm properties of bacterial di-rhamnolipids and their semi-synthetic amide derivatives</article-title><source>Front. Microbiol.</source><year>2017</year><volume>8</volume><fpage>2454</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2017.02454</pub-id><pub-id pub-id-type="pmid">29276509</pub-id></element-citation></ref><ref id="B37-pharmaceutics-12-00688"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Rienzo</surname><given-names>M.A.D.</given-names></name><name><surname>Martin</surname><given-names>P.J.</given-names></name></person-group><article-title>Effect of mono and di-rhamnolipids on biofilms pre-formed by Bacillus subtilis BBK006</article-title><source>Curr. Microbiol.</source><year>2016</year><volume>73</volume><fpage>183</fpage><pub-id pub-id-type="doi">10.1007/s00284-016-1046-4</pub-id><?supplied-pmid 27113589?><pub-id pub-id-type="pmid">27113589</pub-id></element-citation></ref><ref id="B38-pharmaceutics-12-00688"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Do Valle Gomes</surname><given-names>M.Z.</given-names></name><name><surname>Nitschke</surname><given-names>M.</given-names></name></person-group><article-title>Evaluation of rhamnolipid and surfactin to reduce the adhesion and remove biofilms of individual and mixed cultures of food pathogenic bacteria</article-title><source>Food Control</source><year>2012</year><volume>25</volume><fpage>441</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1016/j.foodcont.2011.11.025</pub-id></element-citation></ref><ref id="B39-pharmaceutics-12-00688"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>N.</given-names></name><name><surname>Pemmaraju</surname><given-names>S.C.</given-names></name><name><surname>Pruthi</surname><given-names>P.A.</given-names></name><name><surname>Cameotra</surname><given-names>S.S.</given-names></name><name><surname>Pruthi</surname><given-names>V.</given-names></name></person-group><article-title>Candida biofilm disrupting ability of di-rhamnolipid (RL-2) produced from Pseudomonas aeruginosa DSVP20</article-title><source>Appl. Biochem. Biotechnol.</source><year>2013</year><volume>169</volume><fpage>2374</fpage><lpage>2391</lpage><pub-id pub-id-type="doi">10.1007/s12010-013-0149-7</pub-id><pub-id pub-id-type="pmid">23446981</pub-id></element-citation></ref><ref id="B40-pharmaceutics-12-00688"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dusane</surname><given-names>D.H.</given-names></name><name><surname>Dam</surname><given-names>S.</given-names></name><name><surname>Nancharaiah</surname><given-names>Y.V.</given-names></name><name><surname>Kumar</surname><given-names>A.R.</given-names></name><name><surname>Venugopalan</surname><given-names>V.P.</given-names></name><name><surname>Zinjarde</surname><given-names>S.S.</given-names></name></person-group><article-title>Disruption of Yarrowia lipolytica biofilms by rhamnolipid biosurfactant</article-title><source>Aquat.Biosyst.</source><year>2012</year><volume>8</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1186/2046-9063-8-17</pub-id><pub-id pub-id-type="pmid">22520865</pub-id></element-citation></ref><ref id="B41-pharmaceutics-12-00688"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurowska</surname><given-names>A.</given-names></name><name><surname>Ghate</surname><given-names>V.</given-names></name><name><surname>Kodoth</surname><given-names>A.</given-names></name><name><surname>Shah</surname><given-names>A.</given-names></name><name><surname>Shah</surname><given-names>A.</given-names></name><name><surname>Vishalakshi</surname><given-names>B.</given-names></name><name><surname>Prakash</surname><given-names>B.</given-names></name><name><surname>Lewis</surname><given-names>S.A.</given-names></name></person-group><article-title>Non-Propellant Foams of Green Nano-Silver and Sulfadiazine: Development and In Vivo Evaluation for Burn Wounds</article-title><source>Pharm. Res.</source><year>2019</year><volume>36</volume><fpage>122</fpage><pub-id pub-id-type="doi">10.1007/s11095-019-2658-8</pub-id><pub-id pub-id-type="pmid">31218556</pub-id></element-citation></ref><ref id="B42-pharmaceutics-12-00688"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Percival</surname><given-names>S.L.</given-names></name><name><surname>Mayer</surname><given-names>D.</given-names></name><name><surname>Salisbury</surname><given-names>A.-M.</given-names></name></person-group><article-title>Efficacy of a surfactant-based wound dressing on biofilm control</article-title><source>Wound Repair Regen.</source><year>2017</year><volume>25</volume><fpage>767</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1111/wrr.12581</pub-id><?supplied-pmid 28857343?><pub-id pub-id-type="pmid">28857343</pub-id></element-citation></ref><ref id="B43-pharmaceutics-12-00688"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salisbury</surname><given-names>A.M.</given-names></name><name><surname>Percival</surname><given-names>S.L.</given-names></name></person-group><article-title>Efficacy of a Surfactant-Based Wound Dressing in the Prevention of Biofilms</article-title><source>Adv. Skin Wound Care</source><year>2018</year><volume>31</volume><fpage>514</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1097/01.ASW.0000544612.28804.34</pub-id><pub-id pub-id-type="pmid">30335643</pub-id></element-citation></ref><ref id="B44-pharmaceutics-12-00688"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palumbo</surname><given-names>F.P.</given-names></name><name><surname>Harding</surname><given-names>K.G.</given-names></name><name><surname>Abbritti</surname><given-names>F.</given-names></name><name><surname>Bradbury</surname><given-names>S.</given-names></name><name><surname>Cech</surname><given-names>J.D.</given-names></name><name><surname>Ivins</surname><given-names>N.</given-names></name><name><surname>Klein</surname><given-names>D.</given-names></name><name><surname>Menzinger</surname><given-names>G.</given-names></name><name><surname>Meuleneire</surname><given-names>F.</given-names></name><name><surname>Seratoni</surname><given-names>S.</given-names></name><etal/></person-group><article-title>New Surfactant-based Dressing Product to Improve Wound Closure Rates of Nonhealing Wounds: A European Multicenter Study Including 1036 Patients</article-title><source>Wounds</source><year>2016</year><volume>28</volume><fpage>233</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">27428718</pub-id></element-citation></ref><ref id="B45-pharmaceutics-12-00688"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Nahhal</surname><given-names>I.M.</given-names></name><name><surname>Elmanama</surname><given-names>A.A.</given-names></name><name><surname>El Ashgar</surname><given-names>N.M.</given-names></name><name><surname>Amara</surname><given-names>N.</given-names></name><name><surname>Selmane</surname><given-names>M.</given-names></name><name><surname>Chehimi</surname><given-names>M.M.</given-names></name></person-group><article-title>Stabilization of nano-structured ZnO particles onto the surface of cotton fibers using different surfactants and their antimicrobial activity</article-title><source>Ultrason. Sonochem.</source><year>2017</year><volume>38</volume><fpage>478</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1016/j.ultsonch.2017.03.050</pub-id><pub-id pub-id-type="pmid">28633850</pub-id></element-citation></ref><ref id="B46-pharmaceutics-12-00688"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benavent</surname><given-names>C.</given-names></name><name><surname>Garc&#x000ed;a-Herrero</surname><given-names>V.</given-names></name><name><surname>Torrado</surname><given-names>C.</given-names></name><name><surname>Torrado-Santiago</surname><given-names>S.</given-names></name></person-group><article-title>Nystatin antifungal micellar systems on endotracheal tubes: Development, characterization and in vitro evaluation</article-title><source>Pharmazie</source><year>2019</year><volume>74</volume><fpage>34</fpage><lpage>38</lpage><?supplied-pmid 30782248?><pub-id pub-id-type="pmid">30782248</pub-id></element-citation></ref><ref id="B47-pharmaceutics-12-00688"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majchrzycka</surname><given-names>K.</given-names></name><name><surname>Okrasa</surname><given-names>M.</given-names></name><name><surname>Szulc</surname><given-names>J.</given-names></name><name><surname>Brycki</surname><given-names>B.</given-names></name><name><surname>Gutarowska</surname><given-names>B.</given-names></name></person-group><article-title>Time-Dependent Antimicrobial Activity of Filtering Nonwovens with Gemini Surfactant-Based Biocides</article-title><source>Molecules</source><year>2017</year><volume>22</volume><elocation-id>1620</elocation-id><pub-id pub-id-type="doi">10.3390/molecules22101620</pub-id><?supplied-pmid 28953259?><pub-id pub-id-type="pmid">28953259</pub-id></element-citation></ref><ref id="B48-pharmaceutics-12-00688"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz</surname><given-names>D.</given-names></name><name><surname>Church</surname><given-names>J.</given-names></name><name><surname>Young</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>K.T.</given-names></name><name><surname>Park</surname><given-names>J.</given-names></name><name><surname>Hwang</surname><given-names>Y.B.</given-names></name><name><surname>Santra</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>W.H.</given-names></name></person-group><article-title>Silica-quaternary ammonium &#x0201c;Fixed-Quat&#x0201d; nanofilm coated fiberglass mesh for water disinfection and harmful algal blooms control</article-title><source>J. Environ. Sci. (China)</source><year>2019</year><volume>82</volume><fpage>213</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/j.jes.2019.03.011</pub-id><?supplied-pmid 31133266?><pub-id pub-id-type="pmid">31133266</pub-id></element-citation></ref><ref id="B49-pharmaceutics-12-00688"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chimote</surname><given-names>G.</given-names></name><name><surname>Banerjee</surname><given-names>R.</given-names></name></person-group><article-title>Evaluation of antitubercular drug-loaded surfactants as inhalable drug-delivery systems for pulmonary tuberculosis</article-title><source>J. Biomed. Mater. Res. A</source><year>2009</year><volume>89</volume><fpage>281</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1002/jbm.a.31959</pub-id><?supplied-pmid 18431766?><pub-id pub-id-type="pmid">18431766</pub-id></element-citation></ref><ref id="B50-pharmaceutics-12-00688"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>C.Y.</given-names></name><name><surname>Sung</surname><given-names>C.T.</given-names></name><name><surname>Aljuffali</surname><given-names>I.A.</given-names></name><name><surname>Chen</surname><given-names>C.H.</given-names></name><name><surname>Hu</surname><given-names>K.Y.</given-names></name><name><surname>Fang</surname><given-names>J.Y.</given-names></name></person-group><article-title>Intravenous anti-MRSA phosphatiosomes mediate enhanced affinity to pulmonary surfactants for effective treatment of infectious pneumonia</article-title><source>Nanomedicine</source><year>2018</year><volume>14</volume><fpage>215</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2017.10.006</pub-id><?supplied-pmid 29128664?><pub-id pub-id-type="pmid">29128664</pub-id></element-citation></ref><ref id="B51-pharmaceutics-12-00688"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Gu</surname><given-names>Y.</given-names></name><name><surname>Tang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name></person-group><article-title>Development of sulconazole-loaded nanoemulsions for enhancement of transdermal permeation and antifungal activity</article-title><source>Int. J. Nanomed.</source><year>2019</year><volume>28</volume><fpage>3955</fpage><lpage>3966</lpage><pub-id pub-id-type="doi">10.2147/IJN.S206657</pub-id></element-citation></ref><ref id="B52-pharmaceutics-12-00688"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>J.</given-names></name><name><surname>Nair</surname><given-names>A.B.</given-names></name><name><surname>Jacob</surname><given-names>S.</given-names></name><name><surname>Patel</surname><given-names>R.K.</given-names></name><name><surname>Shah</surname><given-names>H.</given-names></name><name><surname>Shehata</surname><given-names>T.M.</given-names></name><name><surname>Morsy</surname><given-names>M.A.</given-names></name></person-group><article-title>Nanoemulsion Based Vehicle for Effective Ocular Delivery of Moxifloxacin Using Experimental Design and Pharmacokinetic Study in Rabbits</article-title><source>Pharmaceutics</source><year>2019</year><volume>11</volume><elocation-id>230</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics11050230</pub-id></element-citation></ref><ref id="B53-pharmaceutics-12-00688"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eid</surname><given-names>H.M.</given-names></name><name><surname>Elkomy</surname><given-names>M.H.</given-names></name><name><surname>El Menshawe</surname><given-names>S.F.</given-names></name><name><surname>Salem</surname><given-names>H.F.</given-names></name></person-group><article-title>Development, Optimization, and In Vitro/In Vivo Characterization of Enhanced Lipid Nanoparticles for Ocular Delivery of Ofloxacin: The Influence of Pegylation and Chitosan Coating</article-title><source>AAPS PharmSciTech</source><year>2019</year><volume>20</volume><fpage>183</fpage><pub-id pub-id-type="doi">10.1208/s12249-019-1371-6</pub-id><?supplied-pmid 31054011?><pub-id pub-id-type="pmid">31054011</pub-id></element-citation></ref><ref id="B54-pharmaceutics-12-00688"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziech</surname><given-names>D.</given-names></name><name><surname>Franco</surname><given-names>R.</given-names></name><name><surname>Georgakilas</surname><given-names>A.G.</given-names></name><name><surname>Georgakila</surname><given-names>S.</given-names></name><name><surname>Malamou-Mitsi</surname><given-names>V.</given-names></name><name><surname>Schoneveld</surname><given-names>O.</given-names></name><name><surname>Pappa</surname><given-names>A.</given-names></name><name><surname>Panayiotidis</surname><given-names>M.I.</given-names></name></person-group><article-title>The role of reactive oxygen species and oxidative stress in environmental carcinogenesis and biomarker development</article-title><source>Chem. Biol. Interact.</source><year>2010</year><volume>188</volume><fpage>334</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2010.07.010</pub-id><?supplied-pmid 20637748?><pub-id pub-id-type="pmid">20637748</pub-id></element-citation></ref><ref id="B55-pharmaceutics-12-00688"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanafi</surname><given-names>R.</given-names></name><name><surname>Anestopoulos</surname><given-names>I.</given-names></name><name><surname>Voulgaridou</surname><given-names>G.P.</given-names></name><name><surname>Franco</surname><given-names>R.</given-names></name><name><surname>Georgakilas</surname><given-names>A.G.</given-names></name><name><surname>Ziech</surname><given-names>D.</given-names></name><name><surname>Malamou-Mitsi</surname><given-names>V.</given-names></name><name><surname>Pappa</surname><given-names>A.</given-names></name><name><surname>Panayiotidis</surname><given-names>M.I.</given-names></name></person-group><article-title>Oxidative stress based-biomarkers in oral carcinogenesis: How far have we gone?</article-title><source>Curr. Mol. Med.</source><year>2012</year><volume>12</volume><fpage>698</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.2174/156652412800792598</pub-id><pub-id pub-id-type="pmid">22292437</pub-id></element-citation></ref><ref id="B56-pharmaceutics-12-00688"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finkel</surname><given-names>T.</given-names></name></person-group><article-title>Signal transduction by reactive oxygen species</article-title><source>J. Cell Biol.</source><year>2011</year><volume>194</volume><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1083/jcb.201102095</pub-id><?supplied-pmid 21746850?><pub-id pub-id-type="pmid">21746850</pub-id></element-citation></ref><ref id="B57-pharmaceutics-12-00688"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro-Yepes</surname><given-names>J.</given-names></name><name><surname>Burns</surname><given-names>M.</given-names></name><name><surname>Anandhan</surname><given-names>A.</given-names></name><name><surname>Khalimonchuk</surname><given-names>O.</given-names></name><name><surname>del Razo</surname><given-names>L.M.</given-names></name><name><surname>Quintanilla-Vega</surname><given-names>B.</given-names></name><name><surname>Pappa</surname><given-names>A.</given-names></name><name><surname>Panayiotidis</surname><given-names>M.I.</given-names></name><name><surname>Franco</surname><given-names>R.</given-names></name></person-group><article-title>Oxidative stress, redox signaling, and autophagy: Cell death versus survival</article-title><source>Antioxid. Redox Signal.</source><year>2014</year><volume>21</volume><fpage>66</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1089/ars.2014.5837</pub-id><?supplied-pmid 24483238?><pub-id pub-id-type="pmid">24483238</pub-id></element-citation></ref><ref id="B58-pharmaceutics-12-00688"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziech</surname><given-names>D.</given-names></name><name><surname>Franco</surname><given-names>R.</given-names></name><name><surname>Pappa</surname><given-names>A.</given-names></name><name><surname>Panayiotidis</surname><given-names>M.I.</given-names></name></person-group><article-title>Reactive oxygen species (ROS)-induced genetic and epigenetic alterations in human carcinogenesis</article-title><source>Mutat. Res.</source><year>2011</year><volume>711</volume><fpage>167</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.mrfmmm.2011.02.015</pub-id><pub-id pub-id-type="pmid">21419141</pub-id></element-citation></ref><ref id="B59-pharmaceutics-12-00688"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziech</surname><given-names>D.</given-names></name><name><surname>Anestopoulos</surname><given-names>I.</given-names></name><name><surname>Hanafi</surname><given-names>R.</given-names></name><name><surname>Voulgaridou</surname><given-names>G.-P.</given-names></name><name><surname>Franco</surname><given-names>R.</given-names></name><name><surname>Georgakilas</surname><given-names>A.G.</given-names></name><name><surname>Pappa</surname><given-names>A.</given-names></name><name><surname>Panayiotidis</surname><given-names>M.I.</given-names></name></person-group><article-title>Pleiotrophic effects of natural products in ROS-induced carcinogenesis: The role of plant-derived natural products in oral cancer chemoprevention</article-title><source>Cancer Lett.</source><year>2012</year><volume>327</volume><fpage>16</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2012.02.025</pub-id><?supplied-pmid 22381695?><pub-id pub-id-type="pmid">22381695</pub-id></element-citation></ref><ref id="B60-pharmaceutics-12-00688"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halliwell</surname><given-names>B.</given-names></name></person-group><article-title>Free radicals and antioxidants-quo vadis?</article-title><source>Trends Pharmacol. Sci.</source><year>2011</year><volume>32</volume><fpage>125</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2010.12.002</pub-id><?supplied-pmid 21216018?><pub-id pub-id-type="pmid">21216018</pub-id></element-citation></ref><ref id="B61-pharmaceutics-12-00688"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voulgaridou</surname><given-names>G.-P.</given-names></name><name><surname>Anestopoulos</surname><given-names>I.</given-names></name><name><surname>Franco</surname><given-names>R.</given-names></name><name><surname>Panayiotidis</surname><given-names>M.I.</given-names></name><name><surname>Pappa</surname><given-names>A.</given-names></name></person-group><article-title>DNA damage induced by endogenous aldehydes: Current state of knowledge</article-title><source>Mutat. Res.</source><year>2011</year><volume>711</volume><fpage>13</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.mrfmmm.2011.03.006</pub-id><pub-id pub-id-type="pmid">21419140</pub-id></element-citation></ref><ref id="B62-pharmaceutics-12-00688"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Garcia</surname><given-names>A.</given-names></name><name><surname>Rodriguez-Rocha</surname><given-names>H.</given-names></name><name><surname>Madayiputhiya</surname><given-names>N.</given-names></name><name><surname>Pappa</surname><given-names>A.</given-names></name><name><surname>Panayiotidis</surname><given-names>M.I.</given-names></name><name><surname>Franco</surname><given-names>R.</given-names></name></person-group><article-title>Biomarkers of protein oxidation in human disease</article-title><source>Curr. Mol. Med.</source><year>2012</year><volume>12</volume><fpage>681</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.2174/156652412800792543</pub-id><?supplied-pmid 22292436?><pub-id pub-id-type="pmid">22292436</pub-id></element-citation></ref><ref id="B63-pharmaceutics-12-00688"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alamed</surname><given-names>J.</given-names></name><name><surname>Chaiyasit</surname><given-names>W.</given-names></name><name><surname>McClements</surname><given-names>D.J.</given-names></name><name><surname>Decker</surname><given-names>E.A.</given-names></name></person-group><article-title>Relationships between free radical scavenging and antioxidant activity in foods</article-title><source>J. Agric. Food Chem.</source><year>2009</year><volume>57</volume><fpage>2969</fpage><lpage>2976</lpage><pub-id pub-id-type="doi">10.1021/jf803436c</pub-id><?supplied-pmid 19265447?><pub-id pub-id-type="pmid">19265447</pub-id></element-citation></ref><ref id="B64-pharmaceutics-12-00688"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halliwell</surname><given-names>B.</given-names></name></person-group><article-title>Free radicals and antioxidants: Updating a personal view</article-title><source>Nutr. Rev.</source><year>2012</year><volume>70</volume><fpage>257</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1111/j.1753-4887.2012.00476.x</pub-id><?supplied-pmid 22537212?><pub-id pub-id-type="pmid">22537212</pub-id></element-citation></ref><ref id="B65-pharmaceutics-12-00688"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blunt</surname><given-names>J.W.</given-names></name><name><surname>Copp</surname><given-names>B.R.</given-names></name><name><surname>Munro</surname><given-names>M.H.</given-names></name><name><surname>Northcote</surname><given-names>P.T.</given-names></name><name><surname>Prinsep</surname><given-names>M.R.</given-names></name></person-group><article-title>Marine natural products</article-title><source>Nat. Prod. Rep.</source><year>2006</year><volume>23</volume><fpage>26</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1039/b502792f</pub-id><?supplied-pmid 16453031?><pub-id pub-id-type="pmid">16453031</pub-id></element-citation></ref><ref id="B66-pharmaceutics-12-00688"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balboa</surname><given-names>E.M.</given-names></name><name><surname>Conde</surname><given-names>E.</given-names></name><name><surname>Moure</surname><given-names>A.</given-names></name><name><surname>Falque</surname><given-names>E.</given-names></name><name><surname>Dominguez</surname><given-names>H.</given-names></name></person-group><article-title>In vitro antioxidant properties of crude extracts and compounds from brown algae</article-title><source>Food Chem.</source><year>2013</year><volume>138</volume><fpage>1764</fpage><lpage>1785</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2012.11.026</pub-id><pub-id pub-id-type="pmid">23411309</pub-id></element-citation></ref><ref id="B67-pharmaceutics-12-00688"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngo</surname><given-names>D.H.</given-names></name><name><surname>Kim</surname><given-names>S.K.</given-names></name></person-group><article-title>Antioxidant effects of chitin, chitosan, and their derivatives</article-title><source>Adv. Food Nutr. Res.</source><year>2014</year><volume>73</volume><fpage>15</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">25300540</pub-id></element-citation></ref><ref id="B68-pharmaceutics-12-00688"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luther</surname><given-names>M.</given-names></name><name><surname>Parry</surname><given-names>J.</given-names></name><name><surname>Moore</surname><given-names>J.</given-names></name><name><surname>Meng</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Cheng</surname><given-names>Z.</given-names></name><name><surname>Yu</surname><given-names>L.L.</given-names></name></person-group><article-title>Inhibitory effect of Chardonnay and black raspberry seed extracts on lipid oxidation in fish oil and their radical scavenging and antimicrobial properties</article-title><source>Food Chem.</source><year>2007</year><volume>104</volume><fpage>1065</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2007.01.034</pub-id></element-citation></ref><ref id="B69-pharmaceutics-12-00688"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McClements</surname><given-names>D.J.</given-names></name><name><surname>Decker</surname><given-names>E.A.</given-names></name></person-group><article-title>Lipid oxidation in oil-in-water emulsions: Impact of molecular environment on chemical reactions in heterogeneous food systems</article-title><source>J. Food Sci.</source><year>2006</year><volume>65</volume><fpage>1270</fpage><lpage>1282</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2621.2000.tb10596.x</pub-id></element-citation></ref><ref id="B70-pharmaceutics-12-00688"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McClements</surname><given-names>D.J.</given-names></name><name><surname>Rao</surname><given-names>J.</given-names></name></person-group><article-title>Food-Grade Nanoemulsions: Formulation, Fabrication, Properties, Performance, Biological Fate, and Potential Toxicity</article-title><source>Crit. Rev. Food Sci. Nutr.</source><year>2011</year><volume>51</volume><fpage>285</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1080/10408398.2011.559558</pub-id><pub-id pub-id-type="pmid">21432697</pub-id></element-citation></ref><ref id="B71-pharmaceutics-12-00688"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>B.</given-names></name><name><surname>Kim</surname><given-names>M.J.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name></person-group><article-title>Effects of emulsifier charges on the oxidative stability in oil-in-water emulsions under riboflavin photosensitization</article-title><source>Food Sci. Biotechnol.</source><year>2016</year><volume>25</volume><fpage>1003</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1007/s10068-016-0162-z</pub-id><pub-id pub-id-type="pmid">30263366</pub-id></element-citation></ref><ref id="B72-pharmaceutics-12-00688"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>K.</given-names></name><name><surname>Huang</surname><given-names>S.W.</given-names></name><name><surname>German</surname><given-names>J.B.</given-names></name><name><surname>Tiersch</surname><given-names>B.</given-names></name><name><surname>Hartmann</surname><given-names>J.</given-names></name><name><surname>Frankel</surname><given-names>E.N.</given-names></name></person-group><article-title>Activities of antioxidants are affected by colloidal properties of oil-in-water and water-in-oil emulsions and bulk oils</article-title><source>J. Agric. Food Chem.</source><year>2000</year><volume>48</volume><fpage>4874</fpage><lpage>4882</lpage><pub-id pub-id-type="doi">10.1021/jf991289a</pub-id><?supplied-pmid 11052748?><pub-id pub-id-type="pmid">11052748</pub-id></element-citation></ref><ref id="B73-pharmaceutics-12-00688"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaiyasit</surname><given-names>W.</given-names></name><name><surname>Elias</surname><given-names>R.J.</given-names></name><name><surname>McClements</surname><given-names>D.J.</given-names></name><name><surname>Decker</surname><given-names>E.A.</given-names></name></person-group><article-title>Role of physical structures in bulk oils on lipid oxidation</article-title><source>Crit. Rev. Food Sci. Nutr.</source><year>2007</year><volume>47</volume><fpage>299</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1080/10408390600754248</pub-id><pub-id pub-id-type="pmid">17453926</pub-id></element-citation></ref><ref id="B74-pharmaceutics-12-00688"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J.H.</given-names></name><name><surname>Decker</surname><given-names>E.A.</given-names></name></person-group><article-title>Effects of metal chelator, sodium azide, and superoxide dismutase (SOD) on the oxidative stability in riboflavin photosensitized O/W emulsion systems</article-title><source>J. Agric. FoodChem.</source><year>2011</year><volume>59</volume><fpage>6271</fpage><lpage>6276</lpage><pub-id pub-id-type="doi">10.1021/jf2001537</pub-id></element-citation></ref><ref id="B75-pharmaceutics-12-00688"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McClements</surname><given-names>D.J.</given-names></name><name><surname>Decker</surname><given-names>E.</given-names></name></person-group><article-title>Interfacial Antioxidants: A Review of Natural and Synthetic Emulsifiers and Coemulsifiers That Can Inhibit Lipid Oxidation</article-title><source>J. Agric. Food Chem.</source><year>2018</year><volume>66</volume><fpage>20</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1021/acs.jafc.7b05066</pub-id><?supplied-pmid 29227097?><pub-id pub-id-type="pmid">29227097</pub-id></element-citation></ref><ref id="B76-pharmaceutics-12-00688"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y.E.</given-names></name><name><surname>Wang</surname><given-names>W.D.</given-names></name><name><surname>Chen</surname><given-names>H.W.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name></person-group><article-title>Autoxidation of unsaturated lipids in food emulsion</article-title><source>Crit. Rev. Food Sci.</source><year>2011</year><volume>51</volume><fpage>453</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1080/10408391003672086</pub-id><?supplied-pmid 21491270?><pub-id pub-id-type="pmid">21491270</pub-id></element-citation></ref><ref id="B77-pharmaceutics-12-00688"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silvestre</surname><given-names>M.P.</given-names></name><name><surname>Chaiyasit</surname><given-names>W.</given-names></name><name><surname>Brannan</surname><given-names>R.G.</given-names></name><name><surname>McClements</surname><given-names>D.J.</given-names></name><name><surname>Decker</surname><given-names>E.A.</given-names></name></person-group><article-title>Ability of surfactant headgroup size to alter lipid and antioxidant oxidation in oil-in-water emulsions</article-title><source>J. Agric. Food Chem.</source><year>2000</year><volume>48</volume><fpage>2057</fpage><lpage>2061</lpage><pub-id pub-id-type="doi">10.1021/jf991162l</pub-id><pub-id pub-id-type="pmid">10888498</pub-id></element-citation></ref><ref id="B78-pharmaceutics-12-00688"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaiyasit</surname><given-names>W.</given-names></name><name><surname>Silvestre</surname><given-names>M.P.</given-names></name><name><surname>McClements</surname><given-names>D.J.</given-names></name><name><surname>Decker</surname><given-names>E.A.</given-names></name></person-group><article-title>Ability of surfactant hydrophobic tail group size to alter lipid oxidation in oil-in-water emulsions</article-title><source>J. Agric. Food Chem.</source><year>2000</year><volume>48</volume><fpage>3077</fpage><lpage>3080</lpage><pub-id pub-id-type="doi">10.1021/jf000323e</pub-id><?supplied-pmid 10956071?><pub-id pub-id-type="pmid">10956071</pub-id></element-citation></ref><ref id="B79-pharmaceutics-12-00688"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>T.S.</given-names></name><name><surname>Decker</surname><given-names>E.A.</given-names></name><name><surname>Lee</surname><given-names>J.H.</given-names></name></person-group><article-title>Effects of chlorophyll photosensitization on the oxidative stability in O/W emulsion</article-title><source>Food Chem.</source><year>2012</year><volume>33</volume><fpage>1449</fpage><lpage>1455</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2012.02.033</pub-id></element-citation></ref><ref id="B80-pharmaceutics-12-00688"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J.H.</given-names></name><name><surname>Min</surname><given-names>D.B.</given-names></name></person-group><article-title>Changes of headspace volatiles in milk with riboflavin photosensitization</article-title><source>J. Food Sci.</source><year>2009</year><volume>74</volume><fpage>563</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3841.2009.01295.x</pub-id></element-citation></ref><ref id="B81-pharmaceutics-12-00688"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J.H.</given-names></name><name><surname>Min</surname><given-names>D.B.</given-names></name></person-group><article-title>Analysis of volatile compounds from chlorophyll photosensitized linoleic acid by headspace Solid-phase microextraction (HS-SPME)</article-title><source>Food Sci. Biotechnol.</source><year>2010</year><volume>19</volume><fpage>611</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1007/s10068-010-0086-y</pub-id></element-citation></ref><ref id="B82-pharmaceutics-12-00688"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancuso</surname><given-names>J.R.</given-names></name><name><surname>McClements</surname><given-names>D.J.</given-names></name><name><surname>Decker</surname><given-names>E.A.</given-names></name></person-group><article-title>The effects of surfactant type, pH, and chelators on the oxidation of salmon oil-in-water emulsions</article-title><source>J. Agric. Food Chem.</source><year>1999</year><volume>47</volume><fpage>4112</fpage><lpage>4116</lpage><pub-id pub-id-type="doi">10.1021/jf990203a</pub-id><?supplied-pmid 10552775?><pub-id pub-id-type="pmid">10552775</pub-id></element-citation></ref><ref id="B83-pharmaceutics-12-00688"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uluata</surname><given-names>S.</given-names></name><name><surname>McClements</surname><given-names>D.J.</given-names></name><name><surname>Decker</surname><given-names>E.A.</given-names></name></person-group><article-title>Physical Stability, Autoxidation, and Photosensitized Oxidation of &#x003c9;-3 Oils in Nanoemulsions Prepared with Natural and Synthetic Surfactants</article-title><source>J. Agric. Food Chem.</source><year>2015</year><volume>63</volume><fpage>9333</fpage><lpage>9340</lpage><pub-id pub-id-type="doi">10.1021/acs.jafc.5b03572</pub-id><?supplied-pmid 26452408?><pub-id pub-id-type="pmid">26452408</pub-id></element-citation></ref><ref id="B84-pharmaceutics-12-00688"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berton</surname><given-names>C.</given-names></name><name><surname>Genot</surname><given-names>C.</given-names></name><name><surname>Guilbert</surname><given-names>D.</given-names></name><name><surname>Ropers</surname><given-names>M.H.</given-names></name></person-group><article-title>Effect of lateral heterogeneity in mixed surfactant-stabilized interfaces on the oxidation of unsaturated lipids in oil-in-water emulsions</article-title><source>J. Colloid Interface Sci.</source><year>2012</year><volume>377</volume><fpage>244</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1016/j.jcis.2012.03.084</pub-id><?supplied-pmid 22525896?><pub-id pub-id-type="pmid">22525896</pub-id></element-citation></ref><ref id="B85-pharmaceutics-12-00688"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiszhar</surname><given-names>Z.</given-names></name><name><surname>Czucz</surname><given-names>J.</given-names></name><name><surname>Revesz</surname><given-names>C.</given-names></name><name><surname>Rosivall</surname><given-names>L.</given-names></name><name><surname>Szebeni</surname><given-names>J.</given-names></name><name><surname>Rozsnyay</surname><given-names>Z.</given-names></name></person-group><article-title>Complement activation bypolyethoxylatedpharmaceuticalsurfactants:Cremophor-EL, Tween-80 and Tween-20</article-title><source>Eur. J. Pharm. Sci.</source><year>2012</year><volume>45</volume><fpage>492</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2011.09.016</pub-id><pub-id pub-id-type="pmid">21963457</pub-id></element-citation></ref><ref id="B86-pharmaceutics-12-00688"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Roses</surname><given-names>R.</given-names></name><name><surname>Risco</surname><given-names>E.</given-names></name><name><surname>Vila</surname><given-names>R.</given-names></name><name><surname>Penalver</surname><given-names>P.</given-names></name><name><surname>Canigueral</surname><given-names>S.</given-names></name></person-group><article-title>Antioxidant activity of Tween-20 and Tween-80 evaluated through different in-vitro tests</article-title><source>J. Pharm. Pharmacol.</source><year>2015</year><volume>67</volume><fpage>666</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1111/jphp.12369</pub-id><pub-id pub-id-type="pmid">25556861</pub-id></element-citation></ref><ref id="B87-pharmaceutics-12-00688"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadoqi</surname><given-names>M.</given-names></name><name><surname>Lau-Cam</surname><given-names>C.A.</given-names></name><name><surname>Wu</surname><given-names>S.H.</given-names></name></person-group><article-title>Investigation of the micellar properties of the tocopheryl polyethylene glycolsuccinate surfactants TPGS 400 and TPGS 1000 by steady state fluorometry</article-title><source>J. Colloid Interface Sci.</source><year>2009</year><volume>333</volume><fpage>585</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1016/j.jcis.2009.01.048</pub-id><pub-id pub-id-type="pmid">19232633</pub-id></element-citation></ref><ref id="B88-pharmaceutics-12-00688"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>A.R.</given-names></name><name><surname>Banerjee</surname><given-names>R.</given-names></name></person-group><article-title>Effect of D-a-tocopheryl polyethylene glycol 1000 succinate (TPGS) on surfactant monolayers</article-title><source>Colloid Surf. B Biointerfaces</source><year>2011</year><volume>85</volume><fpage>116</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2011.01.021</pub-id><pub-id pub-id-type="pmid">21398100</pub-id></element-citation></ref><ref id="B89-pharmaceutics-12-00688"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Tan</surname><given-names>S.</given-names></name><name><surname>Otieno</surname><given-names>B.O.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name></person-group><article-title>The applications of Vitamin E TPGS in drug delivery</article-title><source>Eur. J. Pharm. Sci.</source><year>2013</year><volume>49</volume><fpage>175</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2013.02.006</pub-id><pub-id pub-id-type="pmid">23485439</pub-id></element-citation></ref><ref id="B90-pharmaceutics-12-00688"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Constantinides</surname><given-names>P.P.</given-names></name><name><surname>Han</surname><given-names>J.H.</given-names></name><name><surname>Davis</surname><given-names>S.S.</given-names></name></person-group><article-title>Advances in the use of tocols as drug delivery vehicles</article-title><source>Pharm. Res.</source><year>2006</year><volume>23</volume><fpage>243</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1007/s11095-005-9262-9</pub-id><pub-id pub-id-type="pmid">16421666</pub-id></element-citation></ref><ref id="B91-pharmaceutics-12-00688"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varma</surname><given-names>M.V.</given-names></name><name><surname>Panchagnula</surname><given-names>R.</given-names></name></person-group><article-title>Enhanced oral paclitaxel absorption with Vitamin E-TPGS: Effect on solubility and permeability in vitro, in situ and in vivo</article-title><source>Eur. J. Pharm. Sci.</source><year>2005</year><volume>25</volume><fpage>445</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2005.04.003</pub-id><pub-id pub-id-type="pmid">15890503</pub-id></element-citation></ref><ref id="B92-pharmaceutics-12-00688"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dintaman</surname><given-names>J.M.</given-names></name><name><surname>Silverman</surname><given-names>J.A.</given-names></name></person-group><article-title>Inhibition of P-glycoprotein by D-a-tor ocopheryl polyethylene glycol 1000 succinate (TPGS)</article-title><source>Pharm. Res.</source><year>1999</year><volume>16</volume><fpage>1550</fpage><lpage>1556</lpage><pub-id pub-id-type="doi">10.1023/A:1015000503629</pub-id><?supplied-pmid 10554096?><pub-id pub-id-type="pmid">10554096</pub-id></element-citation></ref><ref id="B93-pharmaceutics-12-00688"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mi</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.T.</given-names></name><name><surname>Feng</surname><given-names>S.S.</given-names></name></person-group><article-title>Formulation of Docetaxel byfolic acid-conjugated D-a-tocopheryl polyethylene glycol succinate 2000 (VitaminETPGS(2k)) micelles for targeted and synergistic chemotherapy</article-title><source>Biomaterials</source><year>2011</year><volume>32</volume><fpage>4058</fpage><lpage>4066</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2011.02.022</pub-id><?supplied-pmid 21396707?><pub-id pub-id-type="pmid">21396707</pub-id></element-citation></ref><ref id="B94-pharmaceutics-12-00688"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>A.</given-names></name><name><surname>Trendelenburg</surname><given-names>C.F.</given-names></name><name><surname>Diez-Fernandez</surname><given-names>C.</given-names></name><name><surname>Prieto</surname><given-names>P.</given-names></name><name><surname>Houy</surname><given-names>S.</given-names></name><name><surname>Trommer</surname><given-names>W.E.</given-names></name><name><surname>Cordier</surname><given-names>A.</given-names></name></person-group><article-title>Cyclosporine A-induced oxidative stress in rat hepatocytes</article-title><source>J. Pharmacol. Exp. Ther.</source><year>1997</year><volume>280</volume><fpage>1328</fpage><lpage>1334</lpage><pub-id pub-id-type="pmid">9067320</pub-id></element-citation></ref><ref id="B95-pharmaceutics-12-00688"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahidi</surname><given-names>F.</given-names></name><name><surname>Zhong</surname><given-names>Y.</given-names></name></person-group><article-title>Novel antioxidants in food quality preservation and health promotion</article-title><source>Eur. J. Lipid Sci. Technol.</source><year>2010</year><volume>112</volume><fpage>930</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1002/ejlt.201000044</pub-id></element-citation></ref><ref id="B96-pharmaceutics-12-00688"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marzocchi</surname><given-names>S.</given-names></name><name><surname>Anankanbil</surname><given-names>S.</given-names></name><name><surname>Caboni</surname><given-names>M.F.</given-names></name><name><surname>Guo</surname><given-names>Z.</given-names></name></person-group><article-title>Enzymatic alkylsuccinylation of tyrosol: Synthesis, characterization and property evaluation as a dual-functional antioxidant</article-title><source>Food Chem.</source><year>2018</year><volume>246</volume><fpage>108</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2017.10.142</pub-id><?supplied-pmid 29291828?><pub-id pub-id-type="pmid">29291828</pub-id></element-citation></ref><ref id="B97-pharmaceutics-12-00688"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>A.C.</given-names></name><name><surname>Vestner</surname><given-names>J.</given-names></name><name><surname>Barril</surname><given-names>C.</given-names></name><name><surname>Maury</surname><given-names>C.</given-names></name><name><surname>Prenzler</surname><given-names>P.D.</given-names></name><name><surname>Scollary</surname><given-names>G.R.</given-names></name></person-group><article-title>The influence of stereochemistry of antioxidants and flavanols on oxidation processes in a model wine system: Ascorbic acid, erythorbic acid, (+)-catechin and (-)-epicatechin</article-title><source>J. Agric. Food Chem.</source><year>2009</year><volume>58</volume><fpage>1004</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.1021/jf903233x</pub-id></element-citation></ref><ref id="B98-pharmaceutics-12-00688"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakatsuji</surname><given-names>T.</given-names></name><name><surname>Kao</surname><given-names>M.C.</given-names></name><name><surname>Fang</surname><given-names>J.Y.</given-names></name><name><surname>Zouboulis</surname><given-names>C.C.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Gallo</surname><given-names>R.L.</given-names></name><name><surname>Huang</surname><given-names>C.M.</given-names></name></person-group><article-title>Antimicrobial property of lauric acid against Propionibacterium acnes: Its therapeutic potential for inflammatory acne vulgaris</article-title><source>J. Investig. Dermatol.</source><year>2009</year><volume>129</volume><fpage>2480</fpage><lpage>2488</lpage><pub-id pub-id-type="doi">10.1038/jid.2009.93</pub-id><pub-id pub-id-type="pmid">19387482</pub-id></element-citation></ref><ref id="B99-pharmaceutics-12-00688"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>K.M.</given-names></name><name><surname>Lee</surname><given-names>M.J.</given-names></name><name><surname>Jo</surname><given-names>S.K.</given-names></name><name><surname>Choi</surname><given-names>S.J.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Chang</surname><given-names>P.S.</given-names></name></person-group><article-title>Erythorbyl laurate as a potential food additive with multi-functionalities: Interfacial characteristics and antioxidant activity</article-title><source>Food Chem.</source><year>2017</year><volume>215</volume><fpage>101</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2016.07.174</pub-id><pub-id pub-id-type="pmid">27542455</pub-id></element-citation></ref><ref id="B100-pharmaceutics-12-00688"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ifuku</surname><given-names>S.</given-names></name></person-group><article-title>Chitin and chitosan nanofibers: Preparation and chemical modifications</article-title><source>Molecules</source><year>2014</year><volume>19</volume><fpage>18367</fpage><lpage>18380</lpage><pub-id pub-id-type="doi">10.3390/molecules191118367</pub-id><pub-id pub-id-type="pmid">25393598</pub-id></element-citation></ref><ref id="B101-pharmaceutics-12-00688"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aranaz</surname><given-names>I.</given-names></name><name><surname>Acosta</surname><given-names>N.</given-names></name><name><surname>Civera</surname><given-names>C.</given-names></name><name><surname>Elorza</surname><given-names>B.</given-names></name><name><surname>Mingo</surname><given-names>J.</given-names></name><name><surname>Castro</surname><given-names>C.</given-names></name><name><surname>De los Llanos Gandia</surname><given-names>M.</given-names></name><name><surname>Caballero</surname><given-names>A.H.</given-names></name></person-group><article-title>Cosmetics and Cosmeceutical Applications of Chitin, Chitosan and Their Derivatives</article-title><source>Polymers</source><year>2018</year><volume>10</volume><elocation-id>213</elocation-id><pub-id pub-id-type="doi">10.3390/polym10020213</pub-id></element-citation></ref><ref id="B102-pharmaceutics-12-00688"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luan</surname><given-names>F.</given-names></name><name><surname>Wei</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Tan</surname><given-names>W.</given-names></name><name><surname>Chem</surname><given-names>Y.</given-names></name><name><surname>Dong</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Guo</surname><given-names>Z.</given-names></name></person-group><article-title>Preparation and Characterization of Quaternized Chitosan Derivatives and Assessment of Their Antioxidant Activity</article-title><source>Molecules</source><year>2018</year><volume>23</volume><elocation-id>516</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23030516</pub-id><?supplied-pmid 29495379?><pub-id pub-id-type="pmid">29495379</pub-id></element-citation></ref><ref id="B103-pharmaceutics-12-00688"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maldonado</surname><given-names>O.S.</given-names></name><name><surname>Lucas</surname><given-names>R.</given-names></name><name><surname>Cornelles</surname><given-names>F.</given-names></name><name><surname>Gonzalez</surname><given-names>M.J.</given-names></name><name><surname>Parra</surname><given-names>J.S.</given-names></name><name><surname>Medina</surname><given-names>I.</given-names></name><name><surname>Morales</surname><given-names>J.C.</given-names></name></person-group><article-title>Synthesis and characterization of phenolic antioxidants with surfactant properties: Glucosyl- and glucuronosyl alkyl gallates</article-title><source>Tetrahedron</source><year>2011</year><volume>67</volume><fpage>7268</fpage><lpage>7279</lpage><pub-id pub-id-type="doi">10.1016/j.tet.2011.07.046</pub-id></element-citation></ref><ref id="B104-pharmaceutics-12-00688"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name></person-group><article-title>Preparation and in vitro antioxidant activity of kappa-carrageenan oligosaccharides and their oversulfated, acetylated, and phosphorylated derivatives</article-title><source>Carbohydr. Res.</source><year>2005</year><volume>340</volume><fpage>685</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1016/j.carres.2004.12.026</pub-id><?supplied-pmid 15721341?><pub-id pub-id-type="pmid">15721341</pub-id></element-citation></ref><ref id="B105-pharmaceutics-12-00688"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>S.W.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Guan</surname><given-names>H.S.</given-names></name></person-group><article-title>Protective effects of kappa-ca3000+CP against ultraviolet-induced damage in HaCaT and MEF cells</article-title><source>J. Photochem. Photobiol. B</source><year>2010</year><volume>101</volume><fpage>22</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.jphotobiol.2010.06.007</pub-id><pub-id pub-id-type="pmid">20638296</pub-id></element-citation></ref><ref id="B106-pharmaceutics-12-00688"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haque</surname><given-names>E.</given-names></name><name><surname>Kayalvizhi</surname><given-names>K.</given-names></name><name><surname>Hassan</surname><given-names>S.</given-names></name></person-group><article-title>Biocompatibility, Antioxidant and Anti-Infective Effect of Biosurfactant Produced by Marinobacter litoralis MB15</article-title><source>Int. J. Pharm. Investig.</source><year>2020</year><volume>10</volume><fpage>172</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.5530/ijpi.2020.2.32</pub-id></element-citation></ref><ref id="B107-pharmaceutics-12-00688"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdollahi</surname><given-names>S.</given-names></name><name><surname>Tofighi</surname><given-names>Z.</given-names></name><name><surname>Babaee</surname><given-names>T.</given-names></name><name><surname>Shamsi</surname><given-names>M.</given-names></name><name><surname>Rahimzadeh</surname><given-names>G.</given-names></name><name><surname>Rezvanifar</surname><given-names>H.</given-names></name><name><surname>Saeidi</surname><given-names>E.</given-names></name><name><surname>Mohajeri Amiri</surname><given-names>M.</given-names></name><name><surname>Saffari Ashtiani</surname><given-names>Y.</given-names></name><name><surname>Samadi</surname><given-names>N.</given-names></name></person-group><article-title>Evaluation of Anti-oxidant and Anti-biofilm Activities of Biogenic Surfactants Derived from Bacillus amyloliquefaciens and Pseudomonas aeruginosa</article-title><source>Iran. J. Pharm. Res.</source><year>2020</year><comment>in press</comment></element-citation></ref><ref id="B108-pharmaceutics-12-00688"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Ma</surname><given-names>C.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Bai</surname><given-names>L.</given-names></name><name><surname>Decker</surname><given-names>E.A.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>McClements</surname><given-names>D.J.</given-names></name></person-group><article-title>Fabrication of concentrated fish oil emulsions using dual-channel microfluidization: Impact of droplet concentration on physical properties and lipid oxidation</article-title><source>J. Agric. Food Chem.</source><year>2016</year><volume>64</volume><fpage>9532</fpage><lpage>9541</lpage><pub-id pub-id-type="doi">10.1021/acs.jafc.6b04413</pub-id><?supplied-pmid 27936671?><pub-id pub-id-type="pmid">27936671</pub-id></element-citation></ref><ref id="B109-pharmaceutics-12-00688"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohamed</surname><given-names>S.K.</given-names></name><name><surname>Asif</surname><given-names>M.</given-names></name><name><surname>Nazari</surname><given-names>M.V.</given-names></name><name><surname>Baharetha</surname><given-names>H.M.</given-names></name><name><surname>Mahmood</surname><given-names>S.</given-names></name><name><surname>Yatim</surname><given-names>A.R.M.</given-names></name><name><surname>Majid</surname><given-names>A.S.A.</given-names></name><name><surname>Majid</surname><given-names>A.M.S.A.</given-names></name></person-group><article-title>Antiangiogenic activity of sophorolipids extracted from refined bleached deodorized palm olein</article-title><source>Indian J. Pharmacol.</source><year>2019</year><volume>51</volume><fpage>45</fpage><pub-id pub-id-type="pmid">31031467</pub-id></element-citation></ref><ref id="B110-pharmaceutics-12-00688"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>M.</given-names></name><name><surname>Morita</surname><given-names>T.</given-names></name><name><surname>Fukuoka</surname><given-names>T.</given-names></name><name><surname>Imura</surname><given-names>T.</given-names></name><name><surname>Kitamoto</surname><given-names>D.</given-names></name></person-group><article-title>Glycolipid biosurfactants, mannosylerythritol lipids, show antioxidant and protective effects against H2O2-induced oxidative stress in cultured human skin fibroblasts</article-title><source>J. Oleo Sci.</source><year>2012</year><volume>61</volume><fpage>457</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.5650/jos.61.457</pub-id><pub-id pub-id-type="pmid">22864517</pub-id></element-citation></ref><ref id="B111-pharmaceutics-12-00688"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>J.P.</given-names></name><name><surname>Sasse</surname><given-names>F.</given-names></name><name><surname>Bronstrup</surname><given-names>M.</given-names></name><name><surname>Diez</surname><given-names>J.</given-names></name><name><surname>Meyerhans</surname><given-names>A.</given-names></name></person-group><article-title>Antiviral Drug Discovery: Broad-Spectrum Drugs From Nature</article-title><source>Nat. Prod. Rep.</source><year>2015</year><volume>32</volume><fpage>29</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1039/C4NP00085D</pub-id><pub-id pub-id-type="pmid">25315648</pub-id></element-citation></ref><ref id="B112-pharmaceutics-12-00688"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreiss</surname><given-names>J.</given-names></name><name><surname>Ngugi</surname><given-names>E.</given-names></name><name><surname>Holmes</surname><given-names>K.</given-names></name><name><surname>Ndinya-Achola</surname><given-names>J.</given-names></name><name><surname>Waiyaki</surname><given-names>P.</given-names></name><name><surname>Roberts</surname><given-names>P.L.</given-names></name><name><surname>Ruminjo</surname><given-names>I.</given-names></name><name><surname>Sajabi</surname><given-names>R.</given-names></name><name><surname>Kimata</surname><given-names>J.</given-names></name><name><surname>Fleming</surname><given-names>T.R.</given-names></name><etal/></person-group><article-title>Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes</article-title><source>JAMA</source><year>1992</year><volume>268</volume><fpage>477</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1001/jama.1992.03490040053025</pub-id><?supplied-pmid 1320133?><pub-id pub-id-type="pmid">1320133</pub-id></element-citation></ref><ref id="B113-pharmaceutics-12-00688"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roddy</surname><given-names>R.E.</given-names></name><name><surname>Cordero</surname><given-names>M.</given-names></name><name><surname>Ryan</surname><given-names>K.A.</given-names></name><name><surname>Figueroa</surname><given-names>J.</given-names></name></person-group><article-title>A randomized controlled trial comparing nonoxynol-9 lubricated condoms with silicone lubricated condoms for prophylaxis</article-title><source>Sex Transm. Infect.</source><year>1998</year><volume>74</volume><fpage>116</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1136/sti.74.2.116</pub-id><?supplied-pmid 9634323?><pub-id pub-id-type="pmid">9634323</pub-id></element-citation></ref><ref id="B114-pharmaceutics-12-00688"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leydet</surname><given-names>A.</given-names></name><name><surname>El Hachemi</surname><given-names>H.</given-names></name><name><surname>Boyer</surname><given-names>B.</given-names></name><name><surname>Lamaty</surname><given-names>G.</given-names></name><name><surname>Roque</surname><given-names>J.P.</given-names></name><name><surname>Schols</surname><given-names>D.</given-names></name><name><surname>Snoeck</surname><given-names>R.</given-names></name><name><surname>Andrei</surname><given-names>G.</given-names></name><name><surname>Ikeda</surname><given-names>S.</given-names></name><name><surname>Neyts</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Polyanion inhibitors of human immunodeficiency virus and other viruses. Part 2. Polymerized anionic surfactants derived from amino acids and dipeptides</article-title><source>J. Med. Chem.</source><year>1996</year><volume>39</volume><fpage>1626</fpage><lpage>1634</lpage><pub-id pub-id-type="doi">10.1021/jm950358j</pub-id><?supplied-pmid 8648602?><pub-id pub-id-type="pmid">8648602</pub-id></element-citation></ref><ref id="B115-pharmaceutics-12-00688"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leydet</surname><given-names>A.</given-names></name><name><surname>Barragan</surname><given-names>V.</given-names></name><name><surname>Boyer</surname><given-names>B.</given-names></name><name><surname>Mont&#x000e9;ro</surname><given-names>J.L.</given-names></name><name><surname>Roque</surname><given-names>J.P.</given-names></name><name><surname>Witvrouw</surname><given-names>M.</given-names></name><name><surname>Este</surname><given-names>J.</given-names></name><name><surname>Snoeck</surname><given-names>R.</given-names></name><name><surname>Andrei</surname><given-names>G.</given-names></name><name><surname>De Clercq</surname><given-names>E.</given-names></name></person-group><article-title>Polyanion inhibitors of human immunodeficiency virus and other viruses. 5. Telomerized anionic surfactants derived from amino acids</article-title><source>J. Med. Chem.</source><year>1997</year><volume>40</volume><fpage>342</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1021/jm960493b</pub-id><pub-id pub-id-type="pmid">9022800</pub-id></element-citation></ref><ref id="B116-pharmaceutics-12-00688"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howett</surname><given-names>M.K.</given-names></name><name><surname>Neely</surname><given-names>E.B.</given-names></name><name><surname>Christensen</surname><given-names>N.D.</given-names></name><name><surname>Wigdahl</surname><given-names>B.</given-names></name><name><surname>Krebs</surname><given-names>F.C.</given-names></name><name><surname>Malamud</surname><given-names>D.</given-names></name><name><surname>Patrick</surname><given-names>S.D.</given-names></name><name><surname>Pickel</surname><given-names>M.D.</given-names></name><name><surname>Welsh</surname><given-names>P.A.</given-names></name><name><surname>Reed</surname><given-names>C.A.</given-names></name><etal/></person-group><article-title>A broad-spectrum microbicide with virucidal activity against sexually transmitted viruses</article-title><source>Antimicrob. Agents Chemother.</source><year>1999</year><volume>43</volume><fpage>314</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1128/AAC.43.2.314</pub-id><pub-id pub-id-type="pmid">9925525</pub-id></element-citation></ref><ref id="B117-pharmaceutics-12-00688"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piret</surname><given-names>J.</given-names></name><name><surname>D&#x000e9;sormeaux</surname><given-names>A.</given-names></name><name><surname>Bergeron</surname><given-names>M.G.</given-names></name></person-group><article-title>Sodium lauryl sulfate, a microbicide effective against enveloped and nonenveloped viruses</article-title><source>Curr. Drug Targets</source><year>2002</year><volume>3</volume><fpage>17</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.2174/1389450023348037</pub-id><pub-id pub-id-type="pmid">11899262</pub-id></element-citation></ref><ref id="B118-pharmaceutics-12-00688"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>A.</given-names></name><name><surname>Longson</surname><given-names>M.</given-names></name></person-group><article-title>Virucidal activity of chlorhexidine on strains of Herpesvirus hominis, poliovirus, and adenovirus</article-title><source>J. Clin. Pathol.</source><year>1972</year><volume>25</volume><fpage>76</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1136/jcp.25.1.76</pub-id><pub-id pub-id-type="pmid">4335578</pub-id></element-citation></ref><ref id="B119-pharmaceutics-12-00688"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenabian</surname><given-names>M.A.</given-names></name><name><surname>Auvert</surname><given-names>B.</given-names></name><name><surname>Sa&#x000ef;di</surname><given-names>H.</given-names></name><name><surname>Lissouba</surname><given-names>P.</given-names></name><name><surname>Matta</surname><given-names>M.</given-names></name><name><surname>B&#x000e9;lec</surname><given-names>L.</given-names></name></person-group><article-title>Potent in vitro inactivation of both free and cell-associated CCR5- and CXCR4-tropic HIV-1 by common commercial soap bars from South Africa</article-title><source>J. Acquir. Immune Defic. Syndr.</source><year>2010</year><volume>54</volume><fpage>340</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1097/QAI.0b013e3181e3dbf6</pub-id><pub-id pub-id-type="pmid">20517160</pub-id></element-citation></ref><ref id="B120-pharmaceutics-12-00688"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alkhatib</surname><given-names>M.H.</given-names></name><name><surname>Aly</surname><given-names>M.M.</given-names></name><name><surname>Rahbeni</surname><given-names>R.A.</given-names></name><name><surname>Balamash</surname><given-names>K.S.</given-names></name></person-group><article-title>Antimicrobial Activity of Biocompatible Microemulsions Against Aspergillus niger and Herpes Simplex Virus Type 2</article-title><source>Jundishapur J. Microbiol.</source><year>2016</year><volume>9</volume><fpage>e37437</fpage><pub-id pub-id-type="doi">10.5812/jjm.37437</pub-id><pub-id pub-id-type="pmid">27800146</pub-id></element-citation></ref><ref id="B121-pharmaceutics-12-00688"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chepurnov</surname><given-names>A.A.</given-names></name><name><surname>Bakulina</surname><given-names>L.F.</given-names></name><name><surname>Dadaeva</surname><given-names>A.A.</given-names></name><name><surname>Ustinova</surname><given-names>E.N.</given-names></name><name><surname>Chepurnova</surname><given-names>T.S.</given-names></name><name><surname>Baker</surname><given-names>J.R.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Inactivation of Ebola virus with a surfactant nanoemulsion</article-title><source>Acta Trop.</source><year>2003</year><volume>87</volume><fpage>315</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1016/S0001-706X(03)00120-7</pub-id><pub-id pub-id-type="pmid">12875924</pub-id></element-citation></ref><ref id="B122-pharmaceutics-12-00688"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jefferson</surname><given-names>T.</given-names></name><name><surname>Jones</surname><given-names>M.A.</given-names></name><name><surname>Doshi</surname><given-names>P.</given-names></name><name><surname>Del Mar</surname><given-names>C.B.</given-names></name><name><surname>Hama</surname><given-names>R.</given-names></name><name><surname>Thompson</surname><given-names>M.J.</given-names></name><name><surname>Spencer</surname><given-names>E.A.</given-names></name><name><surname>Onakpoya</surname><given-names>I.</given-names></name><name><surname>Mahtani</surname><given-names>K.R.</given-names></name><name><surname>Nunan</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children</article-title><source>Cochrane Database Syst. Rev.</source><year>2014</year><volume>4</volume><fpage>CD008965</fpage><pub-id pub-id-type="doi">10.1590/1516-3180.20141324T2</pub-id></element-citation></ref><ref id="B123-pharmaceutics-12-00688"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greatorex</surname><given-names>J.S.</given-names></name><name><surname>Digard</surname><given-names>P.</given-names></name><name><surname>Curran</surname><given-names>M.D.</given-names></name><name><surname>Moynihan</surname><given-names>R.</given-names></name><name><surname>Wensley</surname><given-names>H.</given-names></name><name><surname>Wreghitt</surname><given-names>T.</given-names></name><name><surname>Varsani</surname><given-names>H.</given-names></name><name><surname>Garcia</surname><given-names>F.</given-names></name><name><surname>Enstone</surname><given-names>J.</given-names></name><name><surname>Nguyen-Van-Tam</surname><given-names>J.S.</given-names></name></person-group><article-title>Survival of influenza A(H1N1) on Materials Found in Households: Implications for Infection Control</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e27932</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0027932</pub-id><?supplied-pmid 22132172?><pub-id pub-id-type="pmid">22132172</pub-id></element-citation></ref><ref id="B124-pharmaceutics-12-00688"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Botequim</surname><given-names>D.</given-names></name><name><surname>Maia</surname><given-names>J.</given-names></name><name><surname>Lino</surname><given-names>M.M.</given-names></name><name><surname>Lopes</surname><given-names>L.M.</given-names></name><name><surname>Simoes</surname><given-names>P.N.</given-names></name><name><surname>IIharco</surname><given-names>L.M.</given-names></name><name><surname>Ferreira</surname><given-names>L.</given-names></name></person-group><article-title>Nanoparticles and surfaces presenting antifungal, antibacterial and antiviral properties</article-title><source>Langmuir</source><year>2012</year><volume>28</volume><fpage>7646</fpage><lpage>7656</lpage><pub-id pub-id-type="doi">10.1021/la300948n</pub-id><?supplied-pmid 22545667?><pub-id pub-id-type="pmid">22545667</pub-id></element-citation></ref><ref id="B125-pharmaceutics-12-00688"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donovan</surname><given-names>B.W.</given-names></name><name><surname>Reuter</surname><given-names>J.D.</given-names></name><name><surname>Cao</surname><given-names>Z.</given-names></name><name><surname>Myc</surname><given-names>A.</given-names></name><name><surname>Johnson</surname><given-names>K.J.</given-names></name><name><surname>Baker</surname><given-names>J.R.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Prevention of murine influenza A virus pneumonitis by surfactant nano-emulsions</article-title><source>Antivir. Chem. Chemother.</source><year>2000</year><volume>11</volume><fpage>41</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1177/095632020001100104</pub-id><?supplied-pmid 10693653?><pub-id pub-id-type="pmid">10693653</pub-id></element-citation></ref><ref id="B126-pharmaceutics-12-00688"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kampf</surname><given-names>G.</given-names></name><name><surname>Todt</surname><given-names>D.</given-names></name><name><surname>Pfaender</surname><given-names>S.</given-names></name><name><surname>Steinmann</surname><given-names>E.</given-names></name></person-group><article-title>Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents</article-title><source>J. Hosp. Infect.</source><year>2020</year><volume>104</volume><fpage>246</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1016/j.jhin.2020.01.022</pub-id><?supplied-pmid 32035997?><pub-id pub-id-type="pmid">32035997</pub-id></element-citation></ref><ref id="B127-pharmaceutics-12-00688"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cimolai</surname><given-names>N.</given-names></name></person-group><article-title>Environmental and Decontamination Issues for Human Coronaviruses and Their Potential Surrogates</article-title><source>J. Med.Virol.</source><year>2020</year><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1002/jmv.26170</pub-id><pub-id pub-id-type="pmid">31502247</pub-id></element-citation></ref><ref id="B128-pharmaceutics-12-00688"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Predmore</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>Enhanced removal of a human norovirus surrogate from fresh vegetables and fruits by a combination of surfactants and sanitizers</article-title><source>Appl. Environ. Microbiol.</source><year>2011</year><volume>77</volume><fpage>4829</fpage><lpage>4838</lpage><pub-id pub-id-type="doi">10.1128/AEM.00174-11</pub-id><pub-id pub-id-type="pmid">21622782</pub-id></element-citation></ref><ref id="B129-pharmaceutics-12-00688"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Zuber</surname><given-names>S.</given-names></name><name><surname>Cantergiani</surname><given-names>F.</given-names></name><name><surname>Butot</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Stroheker</surname><given-names>T.</given-names></name><name><surname>Devlieghere</surname><given-names>F.</given-names></name><name><surname>Lima</surname><given-names>A.</given-names></name><name><surname>Piantini</surname><given-names>U.</given-names></name><name><surname>Uyttendaele</surname><given-names>M.</given-names></name></person-group><article-title>Inactivation of viruses and bacteria on strawberries using a levulinic acid plus sodium dodecyl sulfate based sanitizer, taking sensorial and chemical food safety aspects into account</article-title><source>Int. J. Food Microbiol.</source><year>2017</year><volume>257</volume><fpage>176</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.ijfoodmicro.2017.06.023</pub-id><pub-id pub-id-type="pmid">28668727</pub-id></element-citation></ref><ref id="B130-pharmaceutics-12-00688"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertens</surname><given-names>B.S.</given-names></name><name><surname>Velev</surname><given-names>O.D.</given-names></name></person-group><article-title>Characterization and control of surfactant-mediated Norovirus interactions</article-title><source>Soft Matter</source><year>2015</year><volume>11</volume><fpage>8621</fpage><lpage>8631</lpage><pub-id pub-id-type="doi">10.1039/C5SM01778E</pub-id><pub-id pub-id-type="pmid">26378627</pub-id></element-citation></ref><ref id="B131-pharmaceutics-12-00688"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinmann</surname><given-names>J.</given-names></name><name><surname>Paulmann</surname><given-names>D.</given-names></name><name><surname>Becker</surname><given-names>B.</given-names></name><name><surname>Bischoff</surname><given-names>B.</given-names></name><name><surname>Steinmann</surname><given-names>E.</given-names></name><name><surname>Steinmann</surname><given-names>J.</given-names></name></person-group><article-title>Comparison of virucidal activity of alcohol-based hand sanitizers versus antimicrobial hand soaps in vitro and in vivo</article-title><source>J. Hosp. Infect.</source><year>2012</year><volume>82</volume><fpage>277</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.jhin.2012.08.005</pub-id><pub-id pub-id-type="pmid">23009803</pub-id></element-citation></ref><ref id="B132-pharmaceutics-12-00688"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lages</surname><given-names>S.L.</given-names></name><name><surname>Ramakrishnan</surname><given-names>M.A.</given-names></name><name><surname>Goyal</surname><given-names>S.M.</given-names></name></person-group><article-title>In-vivo efficacy of hand sanitisers against feline calicivirus: A surrogate for norovirus</article-title><source>J. Hosp. Infect.</source><year>2008</year><volume>68</volume><fpage>159</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.jhin.2007.11.018</pub-id><pub-id pub-id-type="pmid">18207605</pub-id></element-citation></ref><ref id="B133-pharmaceutics-12-00688"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Yuen</surname><given-names>Y.</given-names></name><name><surname>Hsiao</surname><given-names>H.M.</given-names></name><name><surname>Jaykus</surname><given-names>L.A.</given-names></name><name><surname>Moe</surname><given-names>C.</given-names></name></person-group><article-title>Effectiveness of liquid soap and hand sanitizer against Norwalk virus on contaminated hands</article-title><source>Appl. Environ. Microbiol.</source><year>2009</year><volume>76</volume><fpage>394</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1128/AEM.01729-09</pub-id><pub-id pub-id-type="pmid">19933337</pub-id></element-citation></ref><ref id="B134-pharmaceutics-12-00688"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuladhar</surname><given-names>E.</given-names></name><name><surname>Hazeleger</surname><given-names>W.C.</given-names></name><name><surname>Koopmans</surname><given-names>M.</given-names></name><name><surname>Zwietering</surname><given-names>M.H.</given-names></name><name><surname>Duizer</surname><given-names>E.</given-names></name><name><surname>Beumer</surname><given-names>R.R.</given-names></name></person-group><article-title>Reducing viral contamination from finger pads: Handwashing is more effective than alcohol-based hand disinfectants</article-title><source>J. Hosp. Infect.</source><year>2015</year><volume>90</volume><fpage>226</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.jhin.2015.02.019</pub-id><?supplied-pmid 25936671?><pub-id pub-id-type="pmid">25936671</pub-id></element-citation></ref><ref id="B135-pharmaceutics-12-00688"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Remichkova</surname><given-names>M.</given-names></name><name><surname>Galabova</surname><given-names>D.</given-names></name><name><surname>Roeva</surname><given-names>I.</given-names></name><name><surname>Karpenko</surname><given-names>E.</given-names></name><name><surname>Shulga</surname><given-names>A.</given-names></name><name><surname>Galabov</surname><given-names>A.S.</given-names></name></person-group><article-title>Anti-herpesvirus activities of Pseudomonas sp. S-17 rhamnolipid and its complex with alginate</article-title><source>Z. Naturforsch. C</source><year>2008</year><volume>63</volume><fpage>75</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1515/znc-2008-1-214</pub-id><?supplied-pmid 18386492?><pub-id pub-id-type="pmid">18386492</pub-id></element-citation></ref><ref id="B136-pharmaceutics-12-00688"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>V.</given-names></name><name><surname>Doncel</surname><given-names>G.F.</given-names></name><name><surname>Seyoum</surname><given-names>T.</given-names></name><name><surname>Eaton</surname><given-names>K.M.</given-names></name><name><surname>Zalenskaya</surname><given-names>I.</given-names></name><name><surname>Hagver</surname><given-names>R.</given-names></name><name><surname>Azim</surname><given-names>A.</given-names></name><name><surname>Gross</surname><given-names>R.</given-names></name></person-group><article-title>Sophorolipids, microbial glycolipids with anti-human immunodeficiency virus and sperm-immobilizing activities</article-title><source>Antimicrob. Agents Chemother.</source><year>2005</year><volume>49</volume><fpage>4093</fpage><lpage>4100</lpage><pub-id pub-id-type="doi">10.1128/AAC.49.10.4093-4100.2005</pub-id><?supplied-pmid 16189085?><pub-id pub-id-type="pmid">16189085</pub-id></element-citation></ref><ref id="B137-pharmaceutics-12-00688"><label>137.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name><surname>Gross</surname><given-names>R.A.</given-names></name><name><surname>Shah</surname><given-names>V.</given-names></name></person-group><article-title>Anti-Herpes Virus Properties of various Forms of Sophorolipids</article-title><source>Patent</source><patent>WO2007130738 A1</patent><volume>0738 A1</volume><day>15</day><month>11</month><year>2007</year></element-citation></ref><ref id="B138-pharmaceutics-12-00688"><label>138.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name><surname>Gross</surname><given-names>R.A.</given-names></name><name><surname>Shah</surname><given-names>V.</given-names></name><name><surname>Doncel</surname><given-names>G.</given-names></name></person-group><article-title>Virucidal Properties of Various Forms of Sophorolipids</article-title><source>Patent</source><patent>US8648055:B2</patent><day>11</day><month>2</month><year>2014</year></element-citation></ref><ref id="B139-pharmaceutics-12-00688"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernando</surname><given-names>I.P.S.</given-names></name><name><surname>Nah</surname><given-names>J.W.</given-names></name><name><surname>Jeon</surname><given-names>Y.J.</given-names></name></person-group><article-title>Potential anti-inflammatory natural products from marine algae</article-title><source>Environ. Toxicol. Pharmacol.</source><year>2016</year><volume>48</volume><fpage>22</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.etap.2016.09.023</pub-id><pub-id pub-id-type="pmid">27716532</pub-id></element-citation></ref><ref id="B140-pharmaceutics-12-00688"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>R.J.</given-names></name></person-group><article-title>Thoughts on the alveolar phase of COVID-19</article-title><source>AJP Lung Cell. Mol. Phys.</source><year>2020</year><volume>319</volume><fpage>L115</fpage><lpage>L120</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00126.2020</pub-id></element-citation></ref><ref id="B141-pharmaceutics-12-00688"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hite</surname><given-names>R.D.</given-names></name><name><surname>Morris</surname><given-names>P.E.</given-names></name></person-group><article-title>Acute respiratory distress syndrome: Pharmacological treatment options in development</article-title><source>Drugs</source><year>2001</year><volume>61</volume><fpage>897</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.2165/00003495-200161070-00001</pub-id><?supplied-pmid 11434447?><pub-id pub-id-type="pmid">11434447</pub-id></element-citation></ref><ref id="B142-pharmaceutics-12-00688"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alessandri</surname><given-names>F.</given-names></name><name><surname>Pugliese</surname><given-names>F.</given-names></name><name><surname>Ranieri</surname><given-names>V.M.</given-names></name></person-group><article-title>The Role of Rescue Therapies in the Treatment of Severe ARDS</article-title><source>Respir. Care</source><year>2018</year><volume>63</volume><fpage>92</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.4187/respcare.05752</pub-id><pub-id pub-id-type="pmid">29066591</pub-id></element-citation></ref><ref id="B143-pharmaceutics-12-00688"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glaser</surname><given-names>K.</given-names></name><name><surname>Fehrholz</surname><given-names>M.</given-names></name><name><surname>Papsdorf</surname><given-names>M.</given-names></name><name><surname>Curstedt</surname><given-names>T.</given-names></name><name><surname>Kunzmann</surname><given-names>S.</given-names></name><name><surname>Speer</surname><given-names>C.P.</given-names></name></person-group><article-title>The new generation synthetic reconstituted surfactant CHF5633 suppresses LPS-induced cytokine responses in human neonatal monocytes</article-title><source>Cytokine</source><year>2016</year><volume>86</volume><fpage>119</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2016.08.004</pub-id><pub-id pub-id-type="pmid">27505451</pub-id></element-citation></ref><ref id="B144-pharmaceutics-12-00688"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glaser</surname><given-names>K.</given-names></name><name><surname>Fehrholz</surname><given-names>M.</given-names></name><name><surname>Curstedt</surname><given-names>T.</given-names></name><name><surname>Kunzmann</surname><given-names>S.</given-names></name><name><surname>Speer</surname><given-names>C.P.</given-names></name></person-group><article-title>Effects of the New Generation Synthetic Reconstituted Surfactant CHF5633 on Pro- and Anti-Inflammatory Cytokine Expression in Native and LPS-Stimulated Adult CD14+ Monocytes</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0146898</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0146898</pub-id><?supplied-pmid 26790130?><pub-id pub-id-type="pmid">26790130</pub-id></element-citation></ref><ref id="B145-pharmaceutics-12-00688"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fehrholz</surname><given-names>M.</given-names></name><name><surname>Glaser</surname><given-names>K.</given-names></name><name><surname>Seidenspinner</surname><given-names>S.</given-names></name><name><surname>Ottensmeier</surname><given-names>B.</given-names></name><name><surname>Curstedt</surname><given-names>T.</given-names></name><name><surname>Speer</surname><given-names>C.P.</given-names></name><name><surname>Kunzmann</surname><given-names>S.</given-names></name></person-group><article-title>Impact of the New Generation Reconstituted Surfactant CHF5633 on Human CD4+ Lymphocytes</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0153578</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0153578</pub-id><?supplied-pmid 27077658?><pub-id pub-id-type="pmid">27077658</pub-id></element-citation></ref><ref id="B146-pharmaceutics-12-00688"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuronuma</surname><given-names>K.</given-names></name><name><surname>Mitsuzawa</surname><given-names>H.</given-names></name><name><surname>Takeda</surname><given-names>K.</given-names></name><name><surname>Nishitani</surname><given-names>C.</given-names></name><name><surname>Chan</surname><given-names>E.D.</given-names></name><name><surname>Kuroki</surname><given-names>Y.</given-names></name><name><surname>Nakamura</surname><given-names>M.</given-names></name><name><surname>Voelker</surname><given-names>D.R.</given-names></name></person-group><article-title>Anionic pulmonary surfactant phospholipids inhibit inflammatory responses from alveolar macrophages and U937 cells by binding the lipopolysaccharide-interacting proteins CD14 and MD-2</article-title><source>J. Biol. Chem.</source><year>2009</year><volume>284</volume><fpage>25488</fpage><lpage>25500</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.040832</pub-id><pub-id pub-id-type="pmid">19584052</pub-id></element-citation></ref><ref id="B147-pharmaceutics-12-00688"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otsubo</surname><given-names>E.</given-names></name><name><surname>Irimajiri</surname><given-names>K.</given-names></name><name><surname>Takei</surname><given-names>T.</given-names></name><name><surname>Nomura</surname><given-names>M.</given-names></name></person-group><article-title>Characterization of synthetic lung surfactant activity against proinflammatory cytokines in human monocytes</article-title><source>Biol. Pharm. Bull.</source><year>2002</year><volume>25</volume><fpage>312</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1248/bpb.25.312</pub-id><?supplied-pmid 11913524?><pub-id pub-id-type="pmid">11913524</pub-id></element-citation></ref><ref id="B148-pharmaceutics-12-00688"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wemh&#x000f6;ner</surname><given-names>A.</given-names></name><name><surname>R&#x000fc;diger</surname><given-names>M.</given-names></name><name><surname>Gortner</surname><given-names>L.</given-names></name></person-group><article-title>Inflammatory cytokine mRNA in monocytes is modified by a recombinant (SP-C)-based surfactant and porcine surfactant</article-title><source>Methods Find Exp. Clin. Pharmacol.</source><year>2009</year><volume>31</volume><fpage>317</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1358/mf.2009.31.5.1386592</pub-id><pub-id pub-id-type="pmid">19649338</pub-id></element-citation></ref><ref id="B149-pharmaceutics-12-00688"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Backhaus</surname><given-names>S.</given-names></name><name><surname>Zakrzewicz</surname><given-names>A.</given-names></name><name><surname>Richter</surname><given-names>K.</given-names></name><name><surname>Damm</surname><given-names>J.</given-names></name><name><surname>Wilker</surname><given-names>S.</given-names></name><name><surname>Fuchs-Moll</surname><given-names>G.</given-names></name><name><surname>K&#x000fc;llmar</surname><given-names>M.</given-names></name><name><surname>Hecker</surname><given-names>A.</given-names></name><name><surname>Manzini</surname><given-names>I.</given-names></name><name><surname>Ruppert</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Surfactant inhibits ATP-induced release of interleukin-1&#x003b2; via nicotinic acetylcholine receptors</article-title><source>J. Lipid. Res.</source><year>2017</year><volume>58</volume><fpage>1055</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1194/jlr.M071506</pub-id><pub-id pub-id-type="pmid">28404637</pub-id></element-citation></ref><ref id="B150-pharmaceutics-12-00688"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>N.</given-names></name><name><surname>Chang</surname><given-names>K.J.</given-names></name><name><surname>Park</surname><given-names>S.Y.</given-names></name><name><surname>Um</surname><given-names>J.H.</given-names></name><name><surname>Han</surname><given-names>E.J.</given-names></name><name><surname>Lee</surname><given-names>W.</given-names></name><name><surname>Kim</surname><given-names>E.A.</given-names></name><name><surname>Oh</surname><given-names>J.Y.</given-names></name><name><surname>Kim</surname><given-names>S.H.</given-names></name><name><surname>Jeon</surname><given-names>Y.J.</given-names></name><etal/></person-group><article-title>Anti-inflammatory Effects of Galactose-Taurine Sodium Salt in LPS-Activated RAW 264.7 Cells</article-title><source>Adv. Exp. Med. Biol.</source><year>2017</year><volume>975</volume><fpage>943</fpage><lpage>953</lpage><pub-id pub-id-type="pmid">28849513</pub-id></element-citation></ref><ref id="B151-pharmaceutics-12-00688"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mittal</surname><given-names>N.</given-names></name><name><surname>Sanyal</surname><given-names>S.N.</given-names></name></person-group><article-title>In vivo effect of surfactant on inflammatory cytokines during endotoxin-induced lung injury in rodents</article-title><source>J. Immunotoxicol.</source><year>2011</year><volume>8</volume><fpage>274</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.3109/1547691X.2011.591294</pub-id><pub-id pub-id-type="pmid">21767135</pub-id></element-citation></ref><ref id="B152-pharmaceutics-12-00688"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeng</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>K.T.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Jin</surname><given-names>L.</given-names></name><name><surname>Kim</surname><given-names>K.S.</given-names></name><name><surname>Kim</surname><given-names>Y.H.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Park</surname><given-names>J.H.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Kong</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A novel microbial technique for producing high-quality sophorolipids from horse oil suitable for cosmetic applications</article-title><source>Microb. Biotechnol.</source><year>2018</year><volume>11</volume><fpage>917</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.1111/1751-7915.13297</pub-id><pub-id pub-id-type="pmid">30022625</pub-id></element-citation></ref><ref id="B153-pharmaceutics-12-00688"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagler</surname><given-names>M.</given-names></name><name><surname>Smith-Norowitz</surname><given-names>T.A.</given-names></name><name><surname>Chice</surname><given-names>S.</given-names></name><name><surname>Wallner</surname><given-names>S.R.</given-names></name><name><surname>Viterbo</surname><given-names>D.</given-names></name><name><surname>Mueller</surname><given-names>C.M.</given-names></name><name><surname>Gross</surname><given-names>R.</given-names></name><name><surname>Nowakowski</surname><given-names>M.</given-names></name><name><surname>Schulze</surname><given-names>R.</given-names></name><name><surname>Zenilman</surname><given-names>M.E.</given-names></name><etal/></person-group><article-title>Sophorolipids decrease IgE production in U266 cells by downregulation of BSAP (Pax5), TLR-2, STAT3 and IL-6</article-title><source>J. Allergy Clin. Immun.</source><year>2007</year><volume>119</volume><fpage>S263</fpage><pub-id pub-id-type="doi">10.1016/j.jaci.2006.12.399</pub-id></element-citation></ref><ref id="B154-pharmaceutics-12-00688"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morita</surname><given-names>Y.</given-names></name><name><surname>Tadokoro</surname><given-names>S.</given-names></name><name><surname>Sasai</surname><given-names>M.</given-names></name><name><surname>Kitamoto</surname><given-names>D.</given-names></name><name><surname>Hirashima</surname><given-names>N.</given-names></name></person-group><article-title>Biosurfactant mannosyl-erythritol lipid inhibits secretion of inflammatory mediators from RBL-2H3 cells</article-title><source>BBA Gen. Subj.</source><year>2011</year><volume>1810</volume><fpage>1302</fpage><lpage>1308</lpage><pub-id pub-id-type="doi">10.1016/j.bbagen.2011.07.002</pub-id><?supplied-pmid 21777658?><pub-id pub-id-type="pmid">21777658</pub-id></element-citation></ref><ref id="B155-pharmaceutics-12-00688"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassanpour</surname><given-names>S.H.</given-names></name><name><surname>Dehghani</surname><given-names>M.</given-names></name></person-group><article-title>Review of cancer from perspective of molecular</article-title><source>J. Cancer Res. Pract.</source><year>2017</year><volume>4</volume><fpage>127</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.jcrpr.2017.07.001</pub-id></element-citation></ref><ref id="B156-pharmaceutics-12-00688"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guti&#x000e9;rrez-Rodr&#x000ed;guez</surname><given-names>A.G.</given-names></name><name><surname>Ju&#x000e1;rez-Portilla</surname><given-names>C.</given-names></name><name><surname>Olivares-Ba&#x000f1;uelos</surname><given-names>T.</given-names></name><name><surname>Zepeda</surname><given-names>R.C.</given-names></name></person-group><article-title>Anticancer activity of seaweeds</article-title><source>Drug Discov. Today</source><year>2018</year><volume>23</volume><fpage>434</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2017.10.019</pub-id><?supplied-pmid 29107095?><pub-id pub-id-type="pmid">29107095</pub-id></element-citation></ref><ref id="B157-pharmaceutics-12-00688"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abd El-Hack</surname><given-names>M.E.</given-names></name><name><surname>Abdelnour</surname><given-names>S.</given-names></name><name><surname>Alagawany</surname><given-names>M.</given-names></name><name><surname>Abdo</surname><given-names>M.</given-names></name><name><surname>Sakr</surname><given-names>M.A.</given-names></name><name><surname>Khafaga</surname><given-names>A.F.</given-names></name><name><surname>Gebriel</surname><given-names>M.G.</given-names></name></person-group><article-title>Microalgae in modern cancer therapy: Current knowledge</article-title><source>Biomed. Pharmacother.</source><year>2019</year><volume>111</volume><fpage>42</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.12.069</pub-id><?supplied-pmid 30576933?><pub-id pub-id-type="pmid">30576933</pub-id></element-citation></ref><ref id="B158-pharmaceutics-12-00688"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enomoto</surname><given-names>R.</given-names></name><name><surname>Suzuki</surname><given-names>C.</given-names></name><name><surname>Ohno</surname><given-names>M.</given-names></name><name><surname>Ohasi</surname><given-names>T.</given-names></name><name><surname>Futagami</surname><given-names>R.</given-names></name><name><surname>Ishikawa</surname><given-names>K.</given-names></name><name><surname>Komae</surname><given-names>M.</given-names></name><name><surname>Nishino</surname><given-names>T.</given-names></name><name><surname>Konishi</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>E.</given-names></name></person-group><article-title>Cationic Surfactants Induce Apoptosis in Normal and Cancer Cells</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2007</year><volume>1095</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1196/annals.1397.001</pub-id></element-citation></ref><ref id="B159-pharmaceutics-12-00688"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yip</surname><given-names>K.W.</given-names></name><name><surname>Mao</surname><given-names>X.</given-names></name><name><surname>Au</surname><given-names>P.Y.B.</given-names></name><name><surname>Hedley</surname><given-names>D.W.</given-names></name><name><surname>Chow</surname><given-names>S.</given-names></name><name><surname>Dalili</surname><given-names>S.</given-names></name><name><surname>Mocanu</surname><given-names>J.D.</given-names></name><name><surname>Bastianutto</surname><given-names>C.</given-names></name><name><surname>Schimmer</surname><given-names>A.</given-names></name><name><surname>Liu</surname><given-names>F.F.</given-names></name></person-group><article-title>Benzethonium Chloride: A Novel Anticancer Agent Identified by Using a Cell-Based Small-Molecule Screen</article-title><source>Clin. Cancer Res.</source><year>2006</year><volume>12</volume><fpage>5557</fpage><lpage>5569</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-0536</pub-id><pub-id pub-id-type="pmid">17000693</pub-id></element-citation></ref><ref id="B160-pharmaceutics-12-00688"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rayess</surname><given-names>H.M.</given-names></name><name><surname>Xi</surname><given-names>Y.</given-names></name><name><surname>Garshott</surname><given-names>D.M.</given-names></name><name><surname>Brownell</surname><given-names>A.L.</given-names></name><name><surname>Yoo</surname><given-names>G.H.</given-names></name><name><surname>Callaghan</surname><given-names>M.U.</given-names></name><name><surname>Fribley</surname><given-names>A.M.</given-names></name></person-group><article-title>Benzethonium chloride activates ER stress and reduces proliferation in HNSCC</article-title><source>Oral Oncol.</source><year>2018</year><volume>76</volume><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2017.11.018</pub-id><pub-id pub-id-type="pmid">29290283</pub-id></element-citation></ref><ref id="B161-pharmaceutics-12-00688"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zerin</surname><given-names>T.</given-names></name><name><surname>Song</surname><given-names>H.</given-names></name><name><surname>Gil</surname><given-names>H.</given-names></name><name><surname>Hong</surname><given-names>S.</given-names></name></person-group><article-title>Surfactant 4-nonylphenyl-polyethylene glycol stimulates reactive oxygen species generation and apoptosis in human neuroblastoma cells</article-title><source>J. Environ. Sci.</source><year>2017</year><volume>53</volume><fpage>262</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/j.jes.2016.04.011</pub-id><?supplied-pmid 28372750?><pub-id pub-id-type="pmid">28372750</pub-id></element-citation></ref><ref id="B162-pharmaceutics-12-00688"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busto</surname><given-names>J.V.</given-names></name><name><surname>Sot</surname><given-names>J.</given-names></name><name><surname>Go&#x000f1;i</surname><given-names>F.M.</given-names></name><name><surname>Mollinedo</surname><given-names>F.</given-names></name><name><surname>Alonso</surname><given-names>A.</given-names></name></person-group><article-title>Surface-active properties of the anti-tumor ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (edelfosine)</article-title><source>Biochim. Biophys. Acta</source><year>2007</year><volume>1768</volume><fpage>1855</fpage><lpage>1860</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2007.04.025</pub-id><?supplied-pmid 17543274?><pub-id pub-id-type="pmid">17543274</pub-id></element-citation></ref><ref id="B163-pharmaceutics-12-00688"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gajate</surname><given-names>C.</given-names></name><name><surname>Santos-Beneit</surname><given-names>A.M.</given-names></name><name><surname>Macho</surname><given-names>A.</given-names></name><name><surname>Lazaro</surname><given-names>M.d.</given-names></name><name><surname>Hernandez-De Rojas</surname><given-names>A.</given-names></name><name><surname>Modolell</surname><given-names>M.</given-names></name><name><surname>Munoz</surname><given-names>E.</given-names></name><name><surname>Mollinedo</surname><given-names>F.</given-names></name></person-group><article-title>Involvement of mitochondria and caspase-3 in ET-18-OCH3-induced apoptosis of human leukemic cells</article-title><source>Int. J. Cancer</source><year>2000</year><volume>86</volume><fpage>208</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(20000415)86:2&#x0003c;208::AID-IJC10&#x0003e;3.0.CO;2-E</pub-id><pub-id pub-id-type="pmid">10738248</pub-id></element-citation></ref><ref id="B164-pharmaceutics-12-00688"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gajate</surname><given-names>C.</given-names></name><name><surname>Mollinedo</surname><given-names>F.</given-names></name></person-group><article-title>Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts</article-title><source>Blood</source><year>2007</year><volume>109</volume><fpage>711</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-04-016824</pub-id><pub-id pub-id-type="pmid">17003375</pub-id></element-citation></ref><ref id="B165-pharmaceutics-12-00688"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gajate</surname><given-names>C.</given-names></name><name><surname>del Canto-Ja&#x000f1;ez</surname><given-names>E.</given-names></name><name><surname>Acu&#x000f1;a</surname><given-names>A.U.</given-names></name><name><surname>Amat-Guerri</surname><given-names>F.</given-names></name><name><surname>Geijo</surname><given-names>E.</given-names></name><name><surname>Santos-Beneit</surname><given-names>A.M.</given-names></name><name><surname>Veldman</surname><given-names>R.J.</given-names></name><name><surname>Mollinedo</surname><given-names>F.</given-names></name></person-group><article-title>Intracellular Triggering of Fas Aggregation and Recruitment of Apoptotic Molecules into Fas-enriched Rafts in Selective Tumor Cell Apoptosis</article-title><source>J. Exp. Med.</source><year>2004</year><volume>200</volume><fpage>353</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1084/jem.20040213</pub-id><pub-id pub-id-type="pmid">15289504</pub-id></element-citation></ref><ref id="B166-pharmaceutics-12-00688"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mollinedo</surname><given-names>F.</given-names></name><name><surname>de la Iglesia-Vicente</surname><given-names>J.</given-names></name><name><surname>Gajate</surname><given-names>C.</given-names></name><name><surname>Estella-Hermoso de Mendoza</surname><given-names>A.</given-names></name><name><surname>Villa-Pulgarin</surname><given-names>J.A.</given-names></name><name><surname>Campanero</surname><given-names>M.A.</given-names></name><name><surname>Blanco-Prieto</surname><given-names>M.J.</given-names></name></person-group><article-title>Lipid raft-targeted therapy in multiple myeloma</article-title><source>Oncogene</source><year>2010</year><volume>29</volume><fpage>3748</fpage><lpage>3757</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.131</pub-id><?supplied-pmid 20418917?><pub-id pub-id-type="pmid">20418917</pub-id></element-citation></ref><ref id="B167-pharmaceutics-12-00688"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>S.C.</given-names></name><name><surname>Parajuli</surname><given-names>K.R.</given-names></name><name><surname>Han</surname><given-names>S.I.</given-names></name></person-group><article-title>The alkyllysophospholipidedelfosine enhances TRAIL-mediated apoptosis in gastric cancer cells through death receptor 5 and the mitochondrial pathway</article-title><source>Tumor Biol.</source><year>2016</year><volume>37</volume><fpage>6205</fpage><lpage>6216</lpage><pub-id pub-id-type="doi">10.1007/s13277-015-4485-9</pub-id></element-citation></ref><ref id="B168-pharmaceutics-12-00688"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melo-Lima</surname><given-names>S.</given-names></name><name><surname>Lopes</surname><given-names>M.C.</given-names></name><name><surname>Mollinedo</surname><given-names>F.</given-names></name></person-group><article-title>ERK1/2 acts as a switch between necrotic and apoptotic cell death in ether phospholipid edelfosine-treated glioblastoma cells</article-title><source>Pharmacol. Res.</source><year>2015</year><volume>95&#x02013;96</volume><fpage>2</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2015.02.007</pub-id><?supplied-pmid 25749008?><pub-id pub-id-type="pmid">25749008</pub-id></element-citation></ref><ref id="B169-pharmaceutics-12-00688"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Na</surname><given-names>H.K.</given-names></name><name><surname>Surh</surname><given-names>Y.J.</given-names></name></person-group><article-title>The antitumor ether lipid edelfosine (ET-18-O-CH3) induces apoptosis in H-ras transformed human breast epithelial cells: By blocking ERK1/2 and p38 mitogen- activated protein kinases as potential targets</article-title><source>Asia Pac. J. Clin. Nutr.</source><year>2008</year><volume>17</volume><fpage>204</fpage><lpage>207</lpage><?supplied-pmid 18296338?><pub-id pub-id-type="pmid">18296338</pub-id></element-citation></ref><ref id="B170-pharmaceutics-12-00688"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Udayakumar</surname><given-names>T.S.</given-names></name><name><surname>Stoyanova</surname><given-names>R.</given-names></name><name><surname>Shareef</surname><given-names>M.M.</given-names></name><name><surname>Mu</surname><given-names>Z.</given-names></name><name><surname>Philip</surname><given-names>S.</given-names></name><name><surname>Burnstein</surname><given-names>K.L.</given-names></name><name><surname>Pollack</surname><given-names>A.</given-names></name></person-group><article-title>Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity</article-title><source>Mol. Cancer Ther.</source><year>2016</year><volume>15</volume><fpage>1353</fpage><lpage>1363</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-15-0332</pub-id><pub-id pub-id-type="pmid">26944919</pub-id></element-citation></ref><ref id="B171-pharmaceutics-12-00688"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Estella-Hermoso de Mendoza</surname><given-names>A.</given-names></name><name><surname>Pr&#x000e9;at</surname><given-names>V.</given-names></name><name><surname>Mollinedo</surname><given-names>F.</given-names></name><name><surname>Blanco-Prieto</surname><given-names>M.J.</given-names></name></person-group><article-title>In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma</article-title><source>J. Control. Release</source><year>2011</year><volume>156</volume><fpage>421</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2011.07.030</pub-id><pub-id pub-id-type="pmid">21821074</pub-id></element-citation></ref><ref id="B172-pharmaceutics-12-00688"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinestel</surname><given-names>K.</given-names></name><name><surname>Eder</surname><given-names>S.</given-names></name><name><surname>Ehinger</surname><given-names>K.</given-names></name><name><surname>Schneider</surname><given-names>J.</given-names></name><name><surname>Genze</surname><given-names>F.</given-names></name><name><surname>Winkler</surname><given-names>E.</given-names></name><name><surname>Wardelmann</surname><given-names>E.</given-names></name><name><surname>Schrader</surname><given-names>A.J.</given-names></name><name><surname>Steinestel</surname><given-names>J.</given-names></name></person-group><article-title>The small conductance calcium-activated potassium channel 3 (SK3) is a molecular target for Edelfosine to reduce the invasive potential of urothelial carcinoma cells</article-title><source>Tumor Biol.</source><year>2016</year><volume>37</volume><fpage>6275</fpage><lpage>6283</lpage><pub-id pub-id-type="doi">10.1007/s13277-015-4509-5</pub-id></element-citation></ref><ref id="B173-pharmaceutics-12-00688"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christova</surname><given-names>N.</given-names></name><name><surname>Tuleva</surname><given-names>B.</given-names></name><name><surname>Kril</surname><given-names>A.</given-names></name><name><surname>Georgieva</surname><given-names>M.</given-names></name><name><surname>Konstantinov</surname><given-names>S.</given-names></name><name><surname>Terziyski</surname><given-names>I.</given-names></name><name><surname>Nikolova</surname><given-names>B.</given-names></name><name><surname>Stoineva</surname><given-names>I.</given-names></name></person-group><article-title>Chemical structure and in vitro antitumor activity of rhamnolipids from Pseudomonas aeruginosa BN10</article-title><source>Appl. Biochem. Biotechnol.</source><year>2013</year><volume>170</volume><fpage>676</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1007/s12010-013-0225-z</pub-id><pub-id pub-id-type="pmid">23604971</pub-id></element-citation></ref><ref id="B174-pharmaceutics-12-00688"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahimi</surname><given-names>K.</given-names></name><name><surname>Lotfabad</surname><given-names>T.B.</given-names></name><name><surname>Jabeen</surname><given-names>F.</given-names></name><name><surname>Ganji</surname><given-names>S.M.</given-names></name></person-group><article-title>Cytotoxic effects of mono-and di-rhamnolipids from Pseudomonas aeruginosa MR01 on MCF-7 human breast cancer cells</article-title><source>Colloid Surf. B</source><year>2019</year><volume>181</volume><fpage>943</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2019.06.058</pub-id></element-citation></ref><ref id="B175-pharmaceutics-12-00688"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thanomsub</surname><given-names>B.</given-names></name><name><surname>Pumeechockchai</surname><given-names>W.</given-names></name><name><surname>Limtrakul</surname><given-names>A.</given-names></name><name><surname>Arunrattiyakorn</surname><given-names>P.</given-names></name><name><surname>Petchleelaha</surname><given-names>W.</given-names></name><name><surname>Nitoda</surname><given-names>T.</given-names></name><name><surname>Kanzaki</surname><given-names>H.</given-names></name></person-group><article-title>Chemical structures and biological activities of rhamnolipids produced by Pseudomonas aeruginosa B189 isolated from milk factory waste</article-title><source>Bioresour. Technol.</source><year>2015</year><volume>97</volume><fpage>2457</fpage><lpage>2461</lpage><pub-id pub-id-type="doi">10.1016/j.biortech.2005.10.029</pub-id><?supplied-pmid 16697639?><pub-id pub-id-type="pmid">16697639</pub-id></element-citation></ref><ref id="B176-pharmaceutics-12-00688"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Song</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Qu</surname><given-names>Y.</given-names></name></person-group><article-title>Production, structure elucidation and anticancer properties of sophorolipid from Wickerhamiella domercqiae</article-title><source>Enzyme Microb. Technol.</source><year>2006</year><volume>39</volume><fpage>501</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/j.enzmictec.2005.12.022</pub-id></element-citation></ref><ref id="B177-pharmaceutics-12-00688"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>I.A.</given-names></name><name><surname>Faustino</surname><given-names>C.M.</given-names></name><name><surname>Guerreiro</surname><given-names>P.S.</given-names></name><name><surname>Frade</surname><given-names>R.F.</given-names></name><name><surname>Bronze</surname><given-names>M.R.</given-names></name><name><surname>Castro</surname><given-names>M.F.</given-names></name><name><surname>Ribeiro</surname><given-names>M.H.</given-names></name></person-group><article-title>Development of novel sophorolipids with improved cytotoxic activity toward MDA-MB-231 breast cancer cells</article-title><source>J. Mol. Recognit.</source><year>2015</year><volume>28</volume><fpage>155</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1002/jmr.2403</pub-id><?supplied-pmid 25647712?><pub-id pub-id-type="pmid">25647712</pub-id></element-citation></ref><ref id="B178-pharmaceutics-12-00688"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>L.</given-names></name><name><surname>Song</surname><given-names>X.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Qu</surname><given-names>Y.</given-names></name></person-group><article-title>Bioactivities of sophorolipid with different structures against human esophageal cancer cells</article-title><source>J. Surg. Res.</source><year>2012</year><volume>173</volume><fpage>286</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1016/j.jss.2010.09.013</pub-id><pub-id pub-id-type="pmid">21035135</pub-id></element-citation></ref><ref id="B179-pharmaceutics-12-00688"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nawale</surname><given-names>L.</given-names></name><name><surname>Dubey</surname><given-names>P.</given-names></name><name><surname>Chaudhari</surname><given-names>B.</given-names></name><name><surname>Sarkar</surname><given-names>D.</given-names></name><name><surname>Prabhune</surname><given-names>A.</given-names></name></person-group><article-title>Anti-proliferative effect of novel primary cetyl alcohol derived sophorolipids against human cervical cancer cells HeLa</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0174241</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0174241</pub-id><pub-id pub-id-type="pmid">28419101</pub-id></element-citation></ref><ref id="B180-pharmaceutics-12-00688"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Guo</surname><given-names>W.</given-names></name><name><surname>Ma</surname><given-names>X.J.</given-names></name><name><surname>Li</surname><given-names>J.S.</given-names></name><name><surname>Song</surname><given-names>X.</given-names></name></person-group><article-title>In vitro and in vivo anticancer activity of sophorolipids to human cervical cancer</article-title><source>Appl. Biochem. Biotechnol.</source><year>2017</year><volume>181</volume><fpage>1372</fpage><lpage>1387</lpage><pub-id pub-id-type="doi">10.1007/s12010-016-2290-6</pub-id><pub-id pub-id-type="pmid">27796874</pub-id></element-citation></ref><ref id="B181-pharmaceutics-12-00688"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>S.L.</given-names></name><name><surname>Wallner</surname><given-names>S.R.</given-names></name><name><surname>Bowne</surname><given-names>W.B.</given-names></name><name><surname>Hagler</surname><given-names>M.D.</given-names></name><name><surname>Zenilman</surname><given-names>M.E.</given-names></name><name><surname>Gross</surname><given-names>R.</given-names></name><name><surname>Bluth</surname><given-names>M.H.</given-names></name></person-group><article-title>Sophorolipids and their derivatives are lethal against human pancreatic cancer cells</article-title><source>J. Surg. Res.</source><year>2008</year><volume>148</volume><fpage>77</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.jss.2008.03.005</pub-id><pub-id pub-id-type="pmid">18570934</pub-id></element-citation></ref><ref id="B182-pharmaceutics-12-00688"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi-Navare</surname><given-names>K.</given-names></name><name><surname>Shiras</surname><given-names>A.</given-names></name><name><surname>Prabhune</surname><given-names>A.</given-names></name></person-group><article-title>Differentiation-inducing ability of sophorolipids of oleic and linoleic acids using a glioma cell line</article-title><source>Biotechnol. J.</source><year>2011</year><volume>6</volume><fpage>509</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1002/biot.201000345</pub-id><pub-id pub-id-type="pmid">21381203</pub-id></element-citation></ref><ref id="B183-pharmaceutics-12-00688"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coelho</surname><given-names>A.L.S.</given-names></name><name><surname>Feuser</surname><given-names>P.E.</given-names></name><name><surname>Carciofi</surname><given-names>B.A.M.</given-names></name><name><surname>de Andrade</surname><given-names>C.J.</given-names></name><name><surname>de Oliveira</surname><given-names>D.</given-names></name></person-group><article-title>Mannosylerythritol lipids: Antimicrobial and biomedical properties</article-title><source>Appl. Microbiol. Biot.</source><year>2020</year><volume>104</volume><fpage>2297</fpage><lpage>2318</lpage><pub-id pub-id-type="doi">10.1007/s00253-020-10354-z</pub-id></element-citation></ref><ref id="B184-pharmaceutics-12-00688"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isoda</surname><given-names>H.</given-names></name><name><surname>Kitamoto</surname><given-names>D.</given-names></name><name><surname>Shinmoto</surname><given-names>H.</given-names></name><name><surname>Matsumura</surname><given-names>M.</given-names></name><name><surname>Nakahara</surname><given-names>T.</given-names></name></person-group><article-title>Microbial extracellular glycolipid induction of differentiation and inhibition of the protein kinase C activity of human promyelocytic leukemia cell line HL-60</article-title><source>Biosci. Biotechnol. Biochem.</source><year>1997</year><volume>61</volume><fpage>609</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1271/bbb.61.609</pub-id><pub-id pub-id-type="pmid">9145519</pub-id></element-citation></ref><ref id="B185-pharmaceutics-12-00688"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isoda</surname><given-names>H.</given-names></name><name><surname>Nakahara</surname><given-names>T.</given-names></name></person-group><article-title>Mannosylerythritol lipid induces granulocytic differentiation and inhibits the tyrosine phosphorylation of human myelogenous leukemia cell line K562</article-title><source>Cytotechnology</source><year>1997</year><volume>25</volume><fpage>191</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1023/A:1007982909932</pub-id><?supplied-pmid 22358891?><pub-id pub-id-type="pmid">22358891</pub-id></element-citation></ref><ref id="B186-pharmaceutics-12-00688"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Govindarajan</surname><given-names>M.</given-names></name></person-group><article-title>Amphiphilic glycoconjugates as potential anticancer chemotherapeutics</article-title><source>Eur. J. Med. Chem.</source><year>2018</year><volume>143</volume><fpage>1208</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2017.10.015</pub-id><?supplied-pmid 29126728?><pub-id pub-id-type="pmid">29126728</pub-id></element-citation></ref><ref id="B187-pharmaceutics-12-00688"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Wakamatsu</surname><given-names>Y.</given-names></name><name><surname>Shibahara</surname><given-names>M.</given-names></name><name><surname>Nomura</surname><given-names>N.</given-names></name><name><surname>Geltinger</surname><given-names>C.</given-names></name><name><surname>Nakahara</surname><given-names>T.</given-names></name><name><surname>Murata</surname><given-names>T.</given-names></name><name><surname>Yokoyama</surname><given-names>K.K.</given-names></name></person-group><article-title>Mannosylerythritol lipid is a potent inducer of apoptosis and differentiation of mouse melanoma cells in culture</article-title><source>Cancer Res.</source><year>1999</year><volume>59</volume><fpage>482</fpage><lpage>486</lpage><?supplied-pmid 9927066?><pub-id pub-id-type="pmid">9927066</pub-id></element-citation></ref><ref id="B188-pharmaceutics-12-00688"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Murata</surname><given-names>T.</given-names></name><name><surname>Ohno</surname><given-names>S.</given-names></name><name><surname>Day</surname><given-names>N.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Nomura</surname><given-names>N.</given-names></name><name><surname>Nakahara</surname><given-names>T.</given-names></name><name><surname>Yokoyama</surname><given-names>K.K.</given-names></name></person-group><article-title>Protein kinase C&#x003b1; plays a critical role in mannosylerythritol lipid-induced differentiation of melanoma B16 Cells</article-title><source>J. Biol. Chem.</source><year>2001</year><volume>276</volume><fpage>39903</fpage><lpage>39910</lpage><pub-id pub-id-type="doi">10.1074/jbc.M010281200</pub-id><?supplied-pmid 11546757?><pub-id pub-id-type="pmid">11546757</pub-id></element-citation></ref><ref id="B189-pharmaceutics-12-00688"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakur</surname><given-names>A.</given-names></name><name><surname>Niu</surname><given-names>Y.</given-names></name><name><surname>Kuang</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name></person-group><article-title>Synthesis of gold nanoparticles derived from mannosylerythritol lipid and evaluation of their bioactivities</article-title><source>AMB Express</source><year>2019</year><volume>9</volume><fpage>62</fpage><pub-id pub-id-type="doi">10.1186/s13568-019-0785-6</pub-id><pub-id pub-id-type="pmid">31065818</pub-id></element-citation></ref><ref id="B190-pharmaceutics-12-00688"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakur</surname><given-names>A.</given-names></name><name><surname>Elshaarani</surname><given-names>T.</given-names></name><name><surname>Niu</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name></person-group><article-title>Comparative study of antidiabetic, bactericidal, and antitumor activities of MEL@AgNPs, MEL@ZnONPs, and Ag&#x02013;ZnO/MEL/GA nanocomposites prepared by using MEL and gum arabic</article-title><source>RSC Adv.</source><year>2019</year><volume>9</volume><fpage>9745</fpage><lpage>9754</lpage><pub-id pub-id-type="doi">10.1039/C9RA00344D</pub-id></element-citation></ref><ref id="B191-pharmaceutics-12-00688"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>R.</given-names></name><name><surname>Samoski</surname><given-names>E.A.</given-names></name><name><surname>Acar</surname><given-names>M.</given-names></name></person-group><article-title>The Systems Biology of Single-Cell Aging</article-title><source>iScience</source><year>2018</year><volume>7</volume><fpage>154</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.isci.2018.08.023</pub-id><?supplied-pmid 30267677?><pub-id pub-id-type="pmid">30267677</pub-id></element-citation></ref><ref id="B192-pharmaceutics-12-00688"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campisi</surname><given-names>J.</given-names></name></person-group><article-title>Aging, cellular senescence, and cancer</article-title><source>Annu. Rev. Physiol.</source><year>2013</year><volume>75</volume><fpage>685</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1146/annurev-physiol-030212-183653</pub-id><?supplied-pmid 23140366?><pub-id pub-id-type="pmid">23140366</pub-id></element-citation></ref><ref id="B193-pharmaceutics-12-00688"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>A.</given-names></name><name><surname>Tollefsbol</surname><given-names>T.</given-names></name></person-group><article-title>Telomeres and telomerase: Basic science implications for aging</article-title><source>J. Am. Geriatr. Soc.</source><year>2001</year><volume>49</volume><fpage>1105</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1046/j.1532-5415.2001.49217.x</pub-id><?supplied-pmid 11555075?><pub-id pub-id-type="pmid">11555075</pub-id></element-citation></ref><ref id="B194-pharmaceutics-12-00688"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahin</surname><given-names>E.</given-names></name><name><surname>Depinho</surname><given-names>R.A.</given-names></name></person-group><article-title>Linking functional decline of telomeres, mitochondria and stem cells during ageing</article-title><source>Nature</source><year>2010</year><volume>464</volume><fpage>520</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1038/nature08982</pub-id><?supplied-pmid 20336134?><pub-id pub-id-type="pmid">20336134</pub-id></element-citation></ref><ref id="B195-pharmaceutics-12-00688"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Otin</surname><given-names>C.</given-names></name><name><surname>Blasco</surname><given-names>M.A.</given-names></name><name><surname>Partridge</surname><given-names>L.</given-names></name><name><surname>Serrano</surname><given-names>M.</given-names></name><name><surname>Kroemer</surname><given-names>G.</given-names></name></person-group><article-title>The hallmarks of aging</article-title><source>Cell</source><year>2013</year><volume>153</volume><fpage>1194</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.05.039</pub-id><?supplied-pmid 23746838?><pub-id pub-id-type="pmid">23746838</pub-id></element-citation></ref><ref id="B196-pharmaceutics-12-00688"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riera</surname><given-names>C.E.</given-names></name><name><surname>Merkwirth</surname><given-names>C.</given-names></name><name><surname>De Magalhaes Filho</surname><given-names>C.D.</given-names></name><name><surname>Dillin</surname><given-names>A.</given-names></name></person-group><article-title>Signaling networks determining life span</article-title><source>Annu. Rev. Biochem.</source><year>2016</year><volume>85</volume><fpage>35</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-060815-014451</pub-id><pub-id pub-id-type="pmid">27294438</pub-id></element-citation></ref><ref id="B197-pharmaceutics-12-00688"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>C.W.</given-names></name><name><surname>Chen</surname><given-names>Y.C.</given-names></name><name><surname>Hsieh</surname><given-names>W.L.</given-names></name><name><surname>Chiou</surname><given-names>S.H.</given-names></name><name><surname>Kao</surname><given-names>C.L.</given-names></name></person-group><article-title>Ageing and neurodegenerative diseases</article-title><source>Ageing Res. Rev.</source><year>2010</year><volume>9</volume><fpage>S36</fpage><lpage>S46</lpage><pub-id pub-id-type="doi">10.1016/j.arr.2010.08.006</pub-id><pub-id pub-id-type="pmid">20732460</pub-id></element-citation></ref><ref id="B198-pharmaceutics-12-00688"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kyriakakis</surname><given-names>E.</given-names></name><name><surname>Princz</surname><given-names>A.</given-names></name><name><surname>Tavernarakis</surname><given-names>N.</given-names></name></person-group><article-title>Stress responses during ageing: Molecular pathways regulating protein homeostasis</article-title><source>Methods Mol. Biol.</source><year>2015</year><volume>1292</volume><fpage>215</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">25804759</pub-id></element-citation></ref><ref id="B199-pharmaceutics-12-00688"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Almeida</surname><given-names>A.J.P.O.</given-names></name><name><surname>Ribeiro</surname><given-names>T.P.</given-names></name><name><surname>de Medeiros</surname><given-names>I.A.</given-names></name></person-group><article-title>Aging: Molecular pathways and implications on the cardiovascular system</article-title><source>Oxid. Med. Cell Longev.</source><year>2017</year><volume>2017</volume><fpage>7941563</fpage><pub-id pub-id-type="doi">10.1155/2017/7941563</pub-id><pub-id pub-id-type="pmid">28874954</pub-id></element-citation></ref><ref id="B200-pharmaceutics-12-00688"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farage</surname><given-names>M.A.</given-names></name><name><surname>Miller</surname><given-names>K.W.</given-names></name><name><surname>Elsner</surname><given-names>P.</given-names></name><name><surname>Maibach</surname><given-names>H.I.</given-names></name></person-group><article-title>Functional and physiological characteristics of the aging skin</article-title><source>Aging Clin. Exp. Res.</source><year>2008</year><volume>20</volume><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1007/BF03324769</pub-id><pub-id pub-id-type="pmid">18594185</pub-id></element-citation></ref><ref id="B201-pharmaceutics-12-00688"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganceviciene</surname><given-names>R.</given-names></name><name><surname>Liakou</surname><given-names>A.I.</given-names></name><name><surname>Theodoridis</surname><given-names>A.</given-names></name><name><surname>Markantonaki</surname><given-names>E.</given-names></name><name><surname>Zouboulis</surname><given-names>C.C.</given-names></name></person-group><article-title>Skin anti-aging strategies</article-title><source>Dermatoendocrinology</source><year>2012</year><volume>4</volume><fpage>308</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.4161/derm.22804</pub-id></element-citation></ref><ref id="B202-pharmaceutics-12-00688"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farage</surname><given-names>M.A.</given-names></name><name><surname>Miller</surname><given-names>K.W.</given-names></name><name><surname>Elsner</surname><given-names>P.</given-names></name><name><surname>Mailbach</surname><given-names>H.I.</given-names></name></person-group><article-title>Characteristics of the skin aging</article-title><source>Adv. Wound Care (New Rochelle)</source><year>2013</year><volume>2</volume><fpage>5</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1089/wound.2011.0356</pub-id><pub-id pub-id-type="pmid">24527317</pub-id></element-citation></ref><ref id="B203-pharmaceutics-12-00688"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weihermann</surname><given-names>A.C.</given-names></name><name><surname>Lorencini</surname><given-names>M.</given-names></name><name><surname>Brohem</surname><given-names>C.A.</given-names></name><name><surname>de Carvalho</surname><given-names>C.M.</given-names></name></person-group><article-title>Elastin structure and its involvement in skin photoageing</article-title><source>Int. J. Cosmet. Sci.</source><year>2017</year><volume>39</volume><fpage>241</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1111/ics.12372</pub-id><?supplied-pmid 27731897?><pub-id pub-id-type="pmid">27731897</pub-id></element-citation></ref><ref id="B204-pharmaceutics-12-00688"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>G.</given-names></name></person-group><article-title>Molecular mechanisms of skin ageing</article-title><source>Mech. Ageing Dev.</source><year>2002</year><volume>123</volume><fpage>801</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1016/S0047-6374(01)00425-0</pub-id><pub-id pub-id-type="pmid">11869737</pub-id></element-citation></ref><ref id="B205-pharmaceutics-12-00688"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kammeyer</surname><given-names>A.</given-names></name><name><surname>Luiten</surname><given-names>R.M.</given-names></name></person-group><article-title>Oxidation events and skin aging</article-title><source>Ageing Res. Rev.</source><year>2015</year><volume>21</volume><fpage>16</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.arr.2015.01.001</pub-id><?supplied-pmid 25653189?><pub-id pub-id-type="pmid">25653189</pub-id></element-citation></ref><ref id="B206-pharmaceutics-12-00688"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaikul</surname><given-names>P.</given-names></name><name><surname>Khat-Udomkiri</surname><given-names>N.</given-names></name><name><surname>Iangthnarat</surname><given-names>K.</given-names></name><name><surname>Manosroi</surname><given-names>J.</given-names></name><name><surname>Manosroi</surname><given-names>A.</given-names></name></person-group><article-title>Characteristics and in vitro anti-skin aging activity of gallic acid loaded in cationic CTABniosome</article-title><source>Eur. J. Pharm. Sci.</source><year>2019</year><volume>131</volume><fpage>39</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2019.02.008</pub-id><pub-id pub-id-type="pmid">30735821</pub-id></element-citation></ref><ref id="B207-pharmaceutics-12-00688"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortonne</surname><given-names>J.P.</given-names></name></person-group><article-title>Photoprotective properties of skin melanin</article-title><source>Br. J. Dermatol.</source><year>2002</year><volume>61</volume><fpage>7</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2133.146.s61.3.x</pub-id></element-citation></ref><ref id="B208-pharmaceutics-12-00688"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quan</surname><given-names>T.</given-names></name><name><surname>Qin</surname><given-names>Z.</given-names></name><name><surname>Xia</surname><given-names>W.</given-names></name><name><surname>Shao</surname><given-names>Y.</given-names></name><name><surname>Voorhees</surname><given-names>J.J.</given-names></name><name><surname>Fisher</surname><given-names>G.J.</given-names></name></person-group><article-title>Matrix-degrading metalloproteinases in photoaging</article-title><source>J. Investig. Dermatol. Symp. Proc.</source><year>2009</year><volume>14</volume><fpage>20</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/jidsymp.2009.8</pub-id></element-citation></ref><ref id="B209-pharmaceutics-12-00688"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pittayapruek</surname><given-names>P.</given-names></name><name><surname>Meephansan</surname><given-names>I.</given-names></name><name><surname>Prapapan</surname><given-names>O.</given-names></name><name><surname>Komine</surname><given-names>M.</given-names></name><name><surname>Ohtsuki</surname><given-names>M.</given-names></name></person-group><article-title>Role of matrix metalloproteinases in photoaging and photocarcinogenesis</article-title><source>Int. J. Mol. Sci.</source><year>2016</year><volume>17</volume><elocation-id>868</elocation-id><pub-id pub-id-type="doi">10.3390/ijms17060868</pub-id></element-citation></ref><ref id="B210-pharmaceutics-12-00688"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>M.C.</given-names></name><name><surname>Young</surname><given-names>D.A.</given-names></name><name><surname>Waters</surname><given-names>J.G.</given-names></name><name><surname>Rowan</surname><given-names>A.D.</given-names></name><name><surname>Chantry</surname><given-names>A.</given-names></name><name><surname>Edwards</surname><given-names>D.R.</given-names></name><name><surname>Clark</surname><given-names>I.M.</given-names></name></person-group><article-title>The comparative role of activator protein 1 and Smad factors in the regulation of Timp-1 and MMP-1 gene expression by transforming growth factor-beta 1</article-title><source>J. Biol. Chem.</source><year>2003</year><volume>278</volume><fpage>10304</fpage><lpage>10313</lpage><pub-id pub-id-type="doi">10.1074/jbc.M212334200</pub-id><pub-id pub-id-type="pmid">12525489</pub-id></element-citation></ref><ref id="B211-pharmaceutics-12-00688"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sardy</surname><given-names>M.</given-names></name></person-group><article-title>Role of matrix metalloproteinases in skin ageing</article-title><source>Connect. Tissue Res.</source><year>2009</year><volume>50</volume><fpage>132</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1080/03008200802585622</pub-id><pub-id pub-id-type="pmid">19296304</pub-id></element-citation></ref><ref id="B212-pharmaceutics-12-00688"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>K.C.</given-names></name><name><surname>Fan</surname><given-names>P.C.</given-names></name><name><surname>Tsai</surname><given-names>S.Y.</given-names></name><name><surname>Shih</surname><given-names>I.C.</given-names></name><name><surname>Chiang</surname><given-names>H.M.</given-names></name></person-group><article-title>Ixora parviflora protects against UVB-induced photoaging by inhibiting the expression of MMPs, MAP kinases and COX-2 and by promoting type I procollagen synthesis</article-title><source>Evid. Based Complement Altern. Med.</source><year>2012</year><volume>2012</volume><fpage>417346</fpage><pub-id pub-id-type="doi">10.1155/2012/417346</pub-id></element-citation></ref><ref id="B213-pharmaceutics-12-00688"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poon</surname><given-names>F.</given-names></name><name><surname>Kang</surname><given-names>S.</given-names></name><name><surname>Chien</surname><given-names>A.I.</given-names></name></person-group><article-title>Mechanisms and treatments of photoaging</article-title><source>Photodermatol. Photoimmunol. Photomed.</source><year>2015</year><volume>31</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1111/phpp.12145</pub-id><?supplied-pmid 25351668?><pub-id pub-id-type="pmid">25351668</pub-id></element-citation></ref><ref id="B214-pharmaceutics-12-00688"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corinaldsesi</surname><given-names>C.</given-names></name><name><surname>Barone</surname><given-names>G.</given-names></name><name><surname>Marcellini</surname><given-names>F.</given-names></name><name><surname>Dell&#x02019;Anno</surname><given-names>A.</given-names></name><name><surname>Danovaro</surname><given-names>R.</given-names></name></person-group><article-title>Marine microbial-derived molecules and their potential use in cosmeceutical and cosmetic products</article-title><source>Mar. Drugs</source><year>2017</year><volume>15</volume><elocation-id>118</elocation-id><pub-id pub-id-type="doi">10.3390/md15040118</pub-id><?supplied-pmid 28417932?><pub-id pub-id-type="pmid">28417932</pub-id></element-citation></ref><ref id="B215-pharmaceutics-12-00688"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.K.</given-names></name><name><surname>Rajapakse</surname><given-names>N.</given-names></name></person-group><article-title>Enzymatic production and biological activities of chitosan oligosaccharides (COS): A review</article-title><source>Carbohydr. Polym.</source><year>2005</year><volume>62</volume><fpage>357</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2005.08.012</pub-id></element-citation></ref><ref id="B216-pharmaceutics-12-00688"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.A.</given-names></name><name><surname>Ahn</surname><given-names>B.N.</given-names></name><name><surname>Kong</surname><given-names>C.S.</given-names></name><name><surname>Park</surname><given-names>S.H.</given-names></name><name><surname>Park</surname><given-names>B.J.</given-names></name><name><surname>Kim</surname><given-names>S.K.</given-names></name></person-group><article-title>Antiphotoaging effect of chitoligosaccharides on human dermal fibroblasts</article-title><source>Photodermatol. Photoimmunol. Photomed.</source><year>2012</year><volume>28</volume><fpage>299</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1111/phpp.12004</pub-id><pub-id pub-id-type="pmid">23126291</pub-id></element-citation></ref><ref id="B217-pharmaceutics-12-00688"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Deursen</surname><given-names>J.M.</given-names></name></person-group><article-title>The role of senescent cells in aging</article-title><source>Nature</source><year>2014</year><volume>509</volume><fpage>439</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1038/nature13193</pub-id><pub-id pub-id-type="pmid">24848057</pub-id></element-citation></ref><ref id="B218-pharmaceutics-12-00688"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>I.</given-names></name><name><surname>Osaki</surname><given-names>T.</given-names></name><name><surname>Ifuku</surname><given-names>S.</given-names></name><name><surname>Saimoto</surname><given-names>H.</given-names></name><name><surname>Takamori</surname><given-names>Y.</given-names></name><name><surname>Kurozumi</surname><given-names>S.</given-names></name><name><surname>Inagawa</surname><given-names>T.</given-names></name><name><surname>Azuma</surname><given-names>K.</given-names></name><name><surname>Tsuka</surname><given-names>T.</given-names></name><name><surname>Okamoto</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Evaluation of the effects of chitin nanofibrils on skin function using skin models</article-title><source>Carbohydr. Polym.</source><year>2014</year><volume>101</volume><fpage>464</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2013.09.074</pub-id><pub-id pub-id-type="pmid">24299799</pub-id></element-citation></ref><ref id="B219-pharmaceutics-12-00688"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schieber</surname><given-names>M.</given-names></name><name><surname>Chandel</surname><given-names>N.S.</given-names></name></person-group><article-title>ROS function in redox signaling and oxidative stress</article-title><source>Curr. Biol.</source><year>2014</year><volume>24</volume><fpage>453</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2014.03.034</pub-id><?supplied-pmid 24845678?><pub-id pub-id-type="pmid">24845678</pub-id></element-citation></ref><ref id="B220-pharmaceutics-12-00688"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>S.Z.</given-names></name><name><surname>Li</surname><given-names>J.C.</given-names></name><name><surname>Li</surname><given-names>S.D.</given-names></name><name><surname>Liao</surname><given-names>M.N.</given-names></name><name><surname>Li</surname><given-names>C.P.</given-names></name><name><surname>Zheng</surname><given-names>P.J.</given-names></name><name><surname>Guo</surname><given-names>M.H.</given-names></name><name><surname>Tan</surname><given-names>W.X.</given-names></name><name><surname>Zheng</surname><given-names>Z.H.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name></person-group><article-title>Anti-aging effect of chitosan oligosaccharide on d-galactose-induced subacute aging in mice</article-title><source>Mar. Drugs</source><year>2018</year><volume>16</volume><elocation-id>181</elocation-id><pub-id pub-id-type="doi">10.3390/md16060181</pub-id><?supplied-pmid 29794973?><pub-id pub-id-type="pmid">29794973</pub-id></element-citation></ref><ref id="B221-pharmaceutics-12-00688"><label>221.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name><surname>Piljac</surname><given-names>T.</given-names></name><name><surname>Piljac</surname><given-names>G.</given-names></name></person-group><article-title>Use of Rhamnolipids in Wound Healing, Treating Burn Shock, Atherosclerosis, Organ Transplants, Depression, Schizophrenia and Cosmetics</article-title><source>Patent</source><patent>WO1999043334 A1</patent><day>2</day><month>9</month><year>1999</year></element-citation></ref><ref id="B222-pharmaceutics-12-00688"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitamoto</surname><given-names>D.</given-names></name><name><surname>Morita</surname><given-names>T.</given-names></name><name><surname>Fukuoka</surname><given-names>T.</given-names></name><name><surname>Konishi</surname><given-names>M.A.</given-names></name><name><surname>Imura</surname><given-names>T.</given-names></name></person-group><article-title>Self-assembling properties of glycolipid biosurfactants and their potential applications</article-title><source>Curr. Opin. Colloid</source><year>2009</year><volume>14</volume><fpage>315</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.cocis.2009.05.009</pub-id></element-citation></ref><ref id="B223-pharmaceutics-12-00688"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>S.</given-names></name><name><surname>Morita</surname><given-names>T.</given-names></name><name><surname>Fukuoka</surname><given-names>T.</given-names></name><name><surname>Imura</surname><given-names>T.</given-names></name><name><surname>Yanagidani</surname><given-names>S.</given-names></name><name><surname>Sogabe</surname><given-names>A.</given-names></name><name><surname>Kitamoto</surname><given-names>D.</given-names></name><name><surname>Kitagawa</surname><given-names>M.</given-names></name></person-group><article-title>The moisturizing effects of glycolipid biosurfactants, mannosylerythritol lipids, on human skin</article-title><source>J. Oleo Sci.</source><year>2012</year><volume>61</volume><fpage>407</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.5650/jos.61.407</pub-id><pub-id pub-id-type="pmid">22790172</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="pharmaceutics-12-00688-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Representative structures of synthetic and biosurfactants. (<bold>i</bold>) Anionic synthetic surface-active agent (SAA) sodium dodecyl sulphate (SDS); (<bold>ii</bold>) cationic synthetic SAA cetyltrimethyl ammonium bromide (CTAB); (<bold>iii</bold>) non-ionic synthetic SAA Tween 20 (polyoxyethylene sorbitan monolaurate) (Tween 40 = monopalmitate; Tween 60 = monostearate; Tween 80 = monooleate, the sum of alkyl chains a, b, c and d is 20 for all Tweens); (<bold>iv</bold>) Monorhamnolipid R1 with two C10 alkanoate chains; (<bold>v</bold>) Dirhamnolipid R2 with two C10 alkanoate chains; (<bold>vi</bold>) Acetylated lactonic sophorolipid; (<bold>vii</bold>) Acetylated acidic sophorolipid; (<bold>viii</bold>) Mannositylerithritol lipid (the length of the alkyl chains, n, can be between 6 and 10). For mannosityl erithritol lipid (MEL), A, R<sub>1</sub> and R<sub>2</sub> are acetyl groups; MEL B, R<sub>1</sub> = acetyl, R<sub>2</sub> = H; MEL C, R<sub>1</sub> = H, R<sub>2</sub> = acetyl.</p></caption><graphic xlink:href="pharmaceutics-12-00688-g001"/></fig><fig id="pharmaceutics-12-00688-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Anti-inflammatory activity of SAAs. Synthetic and biosurfactants exert potent anti-inflammatory effects by manipulating crucial cell signaling events. Specifically, S-DMPG treatments were shown to inhibit TLR-4 signaling, while a synthetic mixture comprised of recombinant surfactant protein (rSP)-C, palmitoyl phosphatidyl glycerol, and dipalmitoyl phosphatidyl choline (DPPC) exerted anti-inflammatory actions by reducing inflammasome signaling. Furthermore, CHF5633, SLS, Venticute and S-SF treatments significantly decreased the production of inflammatory mediators via unknown mechanisms. Synthetic mixture*: synthetic surfactant composed of recombinant surfactant protein (rSP)-C, palmitoyl phosphatidyl glycerol, and dipalmitoyl phosphatidyl choline (DPPC); SLS**: SP-CL16(6-28) and synthetic phospholipid mixture; S-SF mixture***: synthetic surfactant comprised of dipalmitoyl phosphohatidyl choline (DPPC), hexadecanol and tyloxapol. Abbreviations: G-T: synthetic galactose-taurine sodium; S-DMPG: synthetic-dimyristyl phosphatidyl glycerol; P2X7: P2X purinoceptor 7;nAchR: nicotinic acetylcholine receptor; TLR: Toll-like receptor; IL: interleukin; IL-1R: interleukin-1 receptor; MyD88: myeloid differentiation primary response 88; TRIF: toll/interleukin-1 receptor-like protein (TIR)-domain-containing adaptor-inducing interferon-&#x003b2;; &#x003a4;RAM: TRIF-related adaptor molecule; IRAK: IL-1 receptor associated kinase; TRAF: tumor necrosis factor receptor-associated factor; TAB1/2: tumor growth factor-&#x003b2; (TGF-&#x003b2;)-activated kinase 1; TAK: TGF-&#x003b2; activated kinase 1; IKK: I&#x003ba;&#x00392; kinase; MKK: mitogen activated protein (MAP) kinase; NF-&#x003ba;&#x00392;: nuclear factor &#x003ba;&#x00392;; &#x00395;RK: extracellular signal activated kinase; JNK: c-Jun N-terminal kinase; AP-1: activator protein-1.</p></caption><graphic xlink:href="pharmaceutics-12-00688-g002"/></fig><fig id="pharmaceutics-12-00688-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Anti-cancer activity of the synthetic SAs. Synthetic surfactants demonstrate significant anti-cancer activity through the activation of both intrinsic (BCL, Edelfosine, NP-40) and extrinsic apoptotic pathways (BCL, Edelfosine), unfolded protein response-mediated cell death (Edelfosine) and the suppression of the MAPK/ERK and Akt/PI3K signaling pathways (Edelfosine). Additionally, the synthetic SAAs Edelfosine was shown to inhibit the migration of cancer cells by suppressing the small conductance calcium-activated potassium channel 3 (SK3) activity. Abbreviations: RTK: receptor tyrosine kinase; PI3K: phosphatidylinositol-3-Kinase; MAPK: mitogen-activated protein kinase; ERK: extracellular signal-regulated kinase; MEK: MAPK/ERK kinase; PIP<sub>2</sub>: phosphatidylinositol 4,5-bisphosphate; PIP<sub>3</sub>: phosphatidylinositol (3,4,5)-trisphosphate; NF-kB: nuclear factor kappa-light-chain-enhancer of activated B cells; FOXO3a: forkhead box O3a; GSK3&#x003b2;: glycogen synthase kinase 3 beta; UPR-mediated cell death: unfolded protein response-mediated cell death; BiP: binding immunoglobulin protein; PERK:protein kinase R-like endoplasmic reticulum kinase; eIF2a: eukaryotic translation initiation factor 2a; ATF4: activating transcription factor 4; CHOP: CCAAT-enhancer-binding protein homologous protein; PARP: poly (ADP-ribose) polymerase; Bid: BH3-interacting domain death agonist; tBid: truncated Bid; Bcl-2: B-cell lymphoma 2; BCL-XL: B-cell lymphoma-extra-large; BAX: BCL2 associated X; BAK: BCL2-antagonist/killer; ROS: reactive oxygen species; Smac/DIABLO: second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI; IAPs: inhibitors of apoptosis proteins; Apaf-1: apoptotic protease activating factor 1; SK3: small conductance calcium-activated potassium channel 3 (SK3); Orai1: ORAI calcium release-activated calcium modulator 1.</p></caption><graphic xlink:href="pharmaceutics-12-00688-g003"/></fig><table-wrap id="pharmaceutics-12-00688-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceutics-12-00688-t001_Table 1</object-id><label>Table 1</label><caption><p>Anti-microbial actions of the synthetic and biosurfactant SAAs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Polymer</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pathogen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MIC</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MBIC</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hexameric with amide moieties (PAHB)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>E. coli</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.93 &#x003bc;&#x0039c;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B8-pharmaceutics-12-00688" ref-type="bibr">8</xref>]</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Alkylbenzyldimethylammonium chlorides (BAC) analogues</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. aureus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.6&#x02013;10.6 &#x003bc;&#x0039c;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B12-pharmaceutics-12-00688" ref-type="bibr">12</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>E. faecalis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.5&#x02013;10.6 &#x003bc;&#x0039c;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>E. coli</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27.9&#x02013;123.7 &#x003bc;&#x0039c;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>P.aeruginosa</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">223.1&#x02013;247.5 &#x003bc;&#x0039c;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.9&#x02013;123.7 &#x003bc;&#x0039c;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Clorexhidine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. anginosus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.97&#x02013;3.91 &#x003bc;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.63&#x02013;31.25 &#x003bc;g/mL</td><td rowspan="16" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B30-pharmaceutics-12-00688" ref-type="bibr">30</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. constellatus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.97&#x02013;3.91 &#x003bc;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.81&#x02013;31.25 &#x003bc;g/mL</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. gordonii</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.95&#x02013;7.81 &#x003bc;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.81&#x02013;31.25 &#x003bc;g/mL</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. mitis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.95&#x02013;15.63 &#x003bc;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.91&#x02013;31.25 &#x003bc;g/mL</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. mutans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.12&#x02013;0.97 &#x003bc;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.63&#x02013;31.25 &#x003bc;g/mL</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. oralis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.97&#x02013;7.81 &#x003bc;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.91&#x02013;15.63 &#x003bc;g/mL</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. salivarius</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.48&#x02013;3.91 &#x003bc;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.95&#x02013;15.63 &#x003bc;g/mL</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. sanguinis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.95&#x02013;3.91 &#x003bc;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.81&#x02013;31.25 &#x003bc;g/mL</td></tr><tr><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Cetylpyridium chloride</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. anginosus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.12&#x02013;1.95 &#x003bc;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.91&#x02013;15.63 &#x003bc;g/mL</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. constellatus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.06&#x02013;0.48 &#x003bc;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.91&#x02013;31.25 &#x003bc;g/mL</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. gordonii</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.12&#x02013;0.97 &#x003bc;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.91&#x02013;31.25 &#x003bc;g/mL</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. mitis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.12&#x02013;0.97 &#x003bc;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.91&#x02013;31.25 &#x003bc;g/mL</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. mutans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.06&#x02013;0.48 &#x003bc;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.91&#x02013;31.25 &#x003bc;g/mL</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. oralis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.12&#x02013;1.95 &#x003bc;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.91&#x02013;31.25 &#x003bc;g/mL</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. salivarius</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.06&#x02013;0.48 &#x003bc;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.91&#x02013;15.63 &#x003bc;g/mL</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. sanguinis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.12&#x02013;0.48 &#x003bc;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.91&#x02013;31.25 &#x003bc;g/mL</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Peptide gemini (PG)surfactants</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>E. coli</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8&#x02013;512 &#x003bc;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B15-pharmaceutics-12-00688" ref-type="bibr">15</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. typhimurium</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8&#x02013;512 &#x003bc;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. aureus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4&#x02013;512&#x003bc;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>B. subtilis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4&#x02013;512 &#x003bc;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="12" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Na-lauroyl-arginine methyle ester-derived cationic double-chain surfactants (LANHC<sub>x</sub>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>M. luteus</italic><break/>ATCC 9341</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17&#x02013;243 &#x003bc;&#x0039c;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td rowspan="12" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B14-pharmaceutics-12-00688" ref-type="bibr">14</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>B. subtilis</italic><break/>ATCC9341</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19&#x02013;486 &#x003bc;&#x0039c;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>S. aureus</italic><break/>ATCC29213</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17&#x02013;486 &#x003bc;&#x0039c;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>S. epiermidis</italic><break/>ATCC12228</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17&#x02013;510 &#x003bc;&#x0039c;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>P. aeruginosa</italic><break/>ATCC27853</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68&#x02013;78 &#x003bc;&#x0039c;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>E. coli</italic><break/>ATCC25922</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38&#x02013;269 &#x003bc;&#x0039c;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>K. pneumonea</italic><break/>ATCC 13883</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78 &#x003bc;&#x0039c;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>C. albicans</italic><break/>ATCC10231</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19&#x02013;243 &#x003bc;&#x0039c;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35&#x02013;436 &#x003bc;&#x0039c;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>P. aeruginosa</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">218&#x02013;459 &#x003bc;&#x0039c;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>K. pneumonieae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">218&#x02013;459 &#x003bc;&#x0039c;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>E. coli</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">166&#x02013;331 &#x003bc;&#x0039c;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Gemini alanine-derived ammonium salts (bromides and chlorides)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. cerevisiae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40&#x02013;1200 &#x003bc;&#x0039c;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B34-pharmaceutics-12-00688" ref-type="bibr">34</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C.albicans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80&#x02013;1200 &#x003bc;&#x0039c;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Rhodotorulamucilaginosa</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10&#x02013;1200 &#x003bc;&#x0039c;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="22" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Rhamnolipid (RL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>P. aeruginosa PAO1</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B16-pharmaceutics-12-00688" ref-type="bibr">16</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>E. coli NCTC10418</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>B. subtilis NCTC10400</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5% (<italic>w</italic>/<italic>v</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. aureus ATCC9144</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5% (<italic>w</italic>/<italic>v</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>E. coli</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12&#x02013;16 mg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B17-pharmaceutics-12-00688" ref-type="bibr">17</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>P. aeruginosa</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8&#x02013;12 mg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. aureus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16&#x02013;24 mg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>B. cereus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12&#x02013;16 mg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>K. pneomoniae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16&#x02013;24 mg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8&#x02013;12 mg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. krusei</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12&#x02013;16 mg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>L. monocytogenes</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78.1&#x02013; &#x0003e;2500 &#x000b5;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B19-pharmaceutics-12-00688" ref-type="bibr">19</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>B. cereus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pH 5 no growth<break/>pH 6 no growth<break/>pH 7 19.5 &#x000b5;g/mL<break/>pH 8 78.1 &#x000b5;g/mL<break/>pH 9 156.2 &#x000b5;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B18-pharmaceutics-12-00688" ref-type="bibr">18</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>L. moncytogenes</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pH 5 no growth<break/>pH 6 19.5 &#x000b5;g/mL<break/>pH 7 156.2 &#x000b5;g/mL<break/>pH 8 &#x0003e; 2500 &#x000b5;g/mL<break/>pH 9 &#x0003e;2500 &#x000b5;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. aureus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pH 5 9.8 &#x000b5;g/mL<break/>pH 6 39.1 &#x000b5;g/mL<break/>pH 7 &#x0003e; 2500 &#x000b5;g/mL<break/>pH 8 &#x0003e; 2500 &#x000b5;g/mL<break/>pH 9 &#x0003e; 2500 &#x000b5;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>E. coli</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pH 5 &#x0003e; 2500 &#x000b5; g/mL<break/>pH 6 &#x0003e; 2500 &#x000b5;g/mL<break/>pH 7 &#x0003e; 2500 &#x000b5;g/mL<break/>pH 8 &#x0003e; 2500 &#x000b5;g/mL<break/>pH 9 &#x0003e; 2500 &#x000b5;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. enterica</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pH 5 &#x0003e; 2500 &#x000b5;g/mL<break/>pH 6 &#x0003e; 2500 &#x000b5;g/mL<break/>pH 7 &#x0003e; 2500 &#x000b5;g/mL<break/>pH 8 &#x0003e; 2500 &#x000b5;g/mL<break/>pH 9 &#x0003e; 2500 &#x000b5;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. mutans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mixed RL 390 mg/mL<break/>MonoRL 780 mg/mL<break/>diRL 390 mg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B20-pharmaceutics-12-00688" ref-type="bibr">20</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. oralis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mixed RL 97.5 mg/mL<break/>monoRL 780 mg/mL<break/>diRL 780 mg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. sanguinis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mixed RL 97.5 mg/mL<break/>monoRL 780 mg/mL<break/>diRL 390 mg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>A. naeslundii</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mixed RL 195 mg/mL<break/>monoRL 1560 mg/mL<break/>diRL 780 mg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>N. mucosa</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mixed RL 390 mg/mL<break/>monoRL 780 mg/mL<break/>diRL 390 mg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MELs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>B. Cereus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.25 mg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-pharmaceutics-12-00688" ref-type="bibr">26</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>MIC: minimum inhibitory concentration; MBIC: minimum biofilm inhibitory concentration; NA: non-applicable.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pharmaceutics-12-00688-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceutics-12-00688-t002_Table 2</object-id><label>Table 2</label><caption><p>Anti-oxidant activity of SAAs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SAAs</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Assay</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism of Action</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SDS (anionic) <break/>Tween-20 (non-ionic)<break/>CTAB (cationic) surfactants, O/W emulsions</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipid hydroperoxides</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; lipid oxidation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B71-pharmaceutics-12-00688" ref-type="bibr">71</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SDS (anionic) <break/>Tween-80 (non-ionic) surfactants, O/W emulsions</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Propanal/hydroperoxides</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; lipid oxidation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B83-pharmaceutics-12-00688" ref-type="bibr">83</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tween-20 (non-ionic)<break/>Tween-20 (non-ionic/Span-20 (co-surfactant) mixture, O/W emulsions</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">oxygen uptake, conjugated dienes (CD) and formation of volatile compounds</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; lipid oxidation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B84-pharmaceutics-12-00688" ref-type="bibr">84</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tween-20/Tween-80<break/>(non-ionic) surfactants</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DCFH-DA / Flow Cytometry</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; ROS productionin PMA/H<sub>2</sub>O<sub>2</sub>-treated human neutrophils</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B86-pharmaceutics-12-00688" ref-type="bibr">86</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">D-&#x003b1;-Tocopheryl polyethylene glycol 1000 succinate (TPGS/Vitamin E TPGS)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TBARS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; ROS production</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B94-pharmaceutics-12-00688" ref-type="bibr">94</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alkyl succinylatedtyrosol synthetic amphiphilic lipids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPPH radical scavenging, TBARS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; formation of DPPH radicals<break/>&#x02193; lipid oxidation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B96-pharmaceutics-12-00688" ref-type="bibr">96</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erythorbyl laurate (6-O-lauroyl-erythorbic acid),</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TBARS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; lipid oxidation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B99-pharmaceutics-12-00688" ref-type="bibr">99</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">single N-quaternized (QCS) and double N-diquaternized (DQCS) chitosan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPPH, hydroxyl, superoxide radicals, reducing power</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; formation of DPPH, hydroxyl and superoxide radicals<break/>&#x02191; reducing power</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B102-pharmaceutics-12-00688" ref-type="bibr">102</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glucosyl- and glucuronosyl alkyl gallates derivatives</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPPH, FRAP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; formation of DPPH,<break/>&#x02191; rates of reduction of Fe<sup>3+</sup> to Fe<sup>2+</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B103-pharmaceutics-12-00688" ref-type="bibr">103</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003ba;-carrageenan oligosaccharides,<break/>oversulfated (SD)<break/>low acetylated (LAD)<break/>high acetylated (HAD) <break/>phosphorylated (PD) <break/>&#x003ba;-carrageenans</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPPH, superoxide anion, hydroxyl radical scavenging activity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; formation of DPPH, superoxide and hydroxyl radicals </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B104-pharmaceutics-12-00688" ref-type="bibr">104</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003ba;-ca3000 + CP complex<break/>(&#x003ba;-carrageenan 3kD+ collagen peptides)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DCFH-DA/FlowCytometry</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; ROS production<break/>Protection of HaCaT abd MEF cells from UV-induced cell death</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B105-pharmaceutics-12-00688" ref-type="bibr">105</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Rhamnolipids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPPH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; formation of DPPH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B106-pharmaceutics-12-00688" ref-type="bibr">106</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPPH, FRAP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; formation of DPPH,<break/>&#x02191; rates of reduction of Fe3+ to Fe2+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B107-pharmaceutics-12-00688" ref-type="bibr">107</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TBARS, Lipid hydroperoxides </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; lipid oxidation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B108-pharmaceutics-12-00688" ref-type="bibr">108</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sophorolipids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPPH, FRAP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; formation of DPPH,<break/>&#x02191; rates of reduction of Fe3+ to Fe2+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B109-pharmaceutics-12-00688" ref-type="bibr">109</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MELs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPPH, superoxide anion scavenging activity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; formation of DPPHand superoxide radicals </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B110-pharmaceutics-12-00688" ref-type="bibr">110</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>SDS: sodium dodecyl sulfate; CTAB: cetyl trimethyl ammonium bromide; O/W: oil in water; ROS: reactive oxygen species; PMA: phorbol myristate acetate; CP: collagen peptide; MELs: mannosylerythritol lipids; DCFH-DA: dichloro-dihydro-fluorescein diacetate; TBARS: thiobarbituric acid reactive substances; FRAP: ferric reducing antioxidant power; DPPH: 2,2-dipheny;-1-picrylhydrazyl; &#x02191;: increased; &#x02193; decreased.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pharmaceutics-12-00688-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceutics-12-00688-t003_Table 3</object-id><label>Table 3</label><caption><p>Anti-viral activity of SAAs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SAA</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism of Action</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Viral Target </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Experimental Model</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SDS/SLS (anionic surfactant)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Membrane disruption and capsid denaturation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV 1 and 2, HPV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">various cell lines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B116-pharmaceutics-12-00688" ref-type="bibr">116</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Membrane disruption and capsid denaturation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV 1 and 2, HPV </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">various cell lines</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B117-pharmaceutics-12-00688" ref-type="bibr">117</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vivo (hairless mice)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SDS (anionic surfactant),levulinic acid and sodium hypochlorite</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Undefined</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MNV, HAV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B129-pharmaceutics-12-00688" ref-type="bibr">129</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CTAB (cationic surfactant),<break/>SDS (anionic surfactant)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Particle disassociation and entrapment in micelles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MNV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vivo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B130-pharmaceutics-12-00688" ref-type="bibr">130</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tween-20 (non-ionic surfactant),<break/>Triton X-100 (non-ionic surfactant) <break/>NP-40 (non-ionic surfactant)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Capsid denaturation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MNV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RAW 264.7 murine macrophages</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B128-pharmaceutics-12-00688" ref-type="bibr">128</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chlorhexidine (cationic surfactant)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Membrane disruption</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Herpes virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hep-2 and RK<sub>13</sub> cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B118-pharmaceutics-12-00688" ref-type="bibr">118</xref>] </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">African soap bars diluted in water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Undefined</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell-free HIV-1, HIV-1 infected lymphocytes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">human PBMCs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B119-pharmaceutics-12-00688" ref-type="bibr">119</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Common soaps</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Undefined</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MNV-1, HuNoV GI.4 and GII.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vivo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B134-pharmaceutics-12-00688" ref-type="bibr">134</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Micro-emulsion of Tween-80 (non-ionic surfactant and emulsifier), Span-20 (co-surfactant), ethanol, oil, isopropyl myristate (IPM), and distilled water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Undefined</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">vero cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B120-pharmaceutics-12-00688" ref-type="bibr">120</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nano-emulsion ATB </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Undefined</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell culture medium and surfaces</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">vero cells </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B121-pharmaceutics-12-00688" ref-type="bibr">121</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nano-emulsion of soybean oil, tributyl phosphate AND Triton X-100 (non-ionic surfactant)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited infectivity <break/>in animals</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine influenza A virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vivo (CD-1 mice)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B125-pharmaceutics-12-00688" ref-type="bibr">125</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanoparticles coated with DDAB (cationic surfactant)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Structural damage and inactivation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H1N1 influenza strain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDCK cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B124-pharmaceutics-12-00688" ref-type="bibr">124</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rhamnolipid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not defined</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV 1 and 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDBK cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B135-pharmaceutics-12-00688" ref-type="bibr">135</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sophorolipid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Membrane disruption</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cell-free HIV inactivation model</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B136-pharmaceutics-12-00688" ref-type="bibr">136</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>SLS: sodium lauryl sulfate; HIV: human immunodeficiency virus; HPV: human papilloma virus; HSV: herpes simplex virus; MNV: murine norovirus; HAV: hepatitis A virus; RK: rabbit kidney; HuNoV: human norovirus; DDAB: didodecyl dimethyl ammonium bromide; MDBK: Madin-Darby bovine kidney; PBMCs: peripheral blood mononuclear cells; MDCK: Madin&#x02013;Darby canine kidney.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pharmaceutics-12-00688-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceutics-12-00688-t004_Table 4</object-id><label>Table 4</label><caption><p>Anti-aging/photoaging activity of SAAs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SAA</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Experimental<break/> Model</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism(s) of Action</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chito-oligosaccharides<break/>3-5kDa (COS)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UV-A/B-irradiated human dermal fibroblasts (HDF)()UV-A/B-irradiated hairless BALB/c mice<break/>D-gal induced subacute aging mice (Kunming mice)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; MMP-1/8/13<break/>&#x02193; MMP-2/9<break/>&#x02193;AP-1, c-Jun, c-Fos<break/>&#x02191; TIMP-1/2<break/>&#x02191; procollagen I-III-IV<break/>Improvement of macroscopic and histopathological features<break/>&#x02191; total collagen and collagen I<break/>&#x02191;CAT, SOD, GSH-Px&#x02193;TNF-a, IL-1&#x003b2;, IL-6<break/>Improvement of kidney and liver function<break/>&#x02193;ALT, AST, ALP, UA, CREA<break/>&#x02191; CAT, GSH-Px, SOD<break/>&#x02191;IgG/IgM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B215-pharmaceutics-12-00688" ref-type="bibr">215</xref>,<xref rid="B216-pharmaceutics-12-00688" ref-type="bibr">216</xref>,<xref rid="B217-pharmaceutics-12-00688" ref-type="bibr">217</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003ba;-ca3000 + CP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UV-A/B-irradiated HaCaT and MEF cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; UV-induced apoptotic death<break/>Inhibition of MAPK pathway and ROS production<break/>&#x02193; MMP-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B105-pharmaceutics-12-00688" ref-type="bibr">105</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>ALT: alanine transaminase; AST: aspartate transaminase; ALP: alkaline phosphatase; UA: uric acid; CREA: creatinine; &#x02191; increased; &#x02193; decreased.</p></fn></table-wrap-foot></table-wrap></floats-group></article>